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Bone metastasis is one of the major clinical concerns that causes skeletal related 
malignancies and increased mortality. Bone is one of the preferred sites for met-
astatic prostate cancer. The metastatic prostate cancer cells interact with bone 
cells (osteoblasts and osteoclasts) resulting in an imbalance in the bone homeo-
stasis leading to increased activation of osteoblasts over osteoclasts. Our prelim-
inary data indicated a non-tyrosine kinase receptor Neuropilin 2 (NRP2) is ex-
pressed in osteoclasts induced by metastatic prostate cancer cells and acts as a 
negative regulator of osteoclast differentiation and function. We hypothesize that 
prostate cancer -induced NRP2 expression in osteoclasts is necessary for low 
osteolytic activity and thus favors an osteoblastic lesion in prostate cancer bone 
metastasis.  
 
Early experimentation discussed in my first section of my thesis demonstrated an 
increase in NRP2 expression in osteoclasts induced by RANKL and M-CSF and 
in PC3 and LNCaP C4-2B conditioned media (CM). TRAP staining and activity 
confirmed the differentiation of osteoclasts under these conditions. Interestingly, 
depletion of NRP2 and treatment with either in RANKL and M-CSF or LNCaP 
C4-2B CM exhibited a drastic increase in osteoclast differentiation and function. 
 
 
An increase in expression of osteoclastic genes following NRP2 depletion in 
RANKL and M-CSF and LNCaP C4-2B CM was also detected. However, NRP2-
depleted osteoclast precursors when treated with PC3 CM showed no change in 
osteoclastogenesis. It is important to note that LNCaP C4-2B promotes mixed 
bone lesions, which inclines more toward osteoblastic lesion, while PC3 pro-
motes predominantly osteoclastic bone lesions. These findings therefore advo-
cate a role of NRP2 in inhibiting osteoclastic activity in PCa bone metastasis with 
mixed lesions and that osteolytic PCa evades NRP2 inhibition.  
 
In the second section of my dissertation, we elucidated the molecular mecha-
nisms through which NRP2 regulates osteoclast differentiation and function in 
normal bone and in LNCaP C4-2B CM. Our studies suggest that NRP2 regulates 
the expression and translocation of NFATC1 which is a crucial osteoclastic tran-
scription factor. Additionally, NRP2 controls NF-κB in the normal bone. These da-
ta imply that NRP2 restricts the translocation of critical transcription factors to 
regulate osteoclasts in prostate cancer bone metastasis. 
 
The last part of my dissertation addressed how PC3 CM-induced OCs escapes 
the inhibition of NRP2. Presence of GM-CSF resulted in a delay in the differentia-
tion and fusion of osteoclasts in RANKL and M-CSF and LNCaP C4-2B CM. It 
can be deduced that secretion of GM-CSF by PC3 CM may regulate the differen-
tiation and fusion of osteoclasts and thereby escapes the regulation of NRP2.  
 
 
Altogether, we report that NRP2 functions as a negative regulator of osteoclasts 
in prostate cancer bone metastasis but is rendered ineffective in osteolytic le-
sions.  Hence, an insight into the regulation of NRP2 in osteoclasts can aid in the 
development of new and effective therapeutic strategies for the treatment of 
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CHAPTER 1A: Introduction to prostate cancer 
Prostate cancer is the most common disease occurring in American men follow-
ing skin cancer. It affects 1 in every 7 men and 99% of the patients with prostate 
cancer are above the age of 50 years. Apart from age, factors such as family his-
tory, smoking, chemical exposure, obesity, geography and ethnicity increase the 
risk of prostate cancer. African American men are more prone to prostate cancer 
than the white American men1,2. As prostate cancer is mostly a slow-growing dis-
ease with exceptions of some cases where it is highly aggressive, no symptoms 
are observed until it reaches an advanced stage.  In 2018, nearly 164, 690 new 
prostate cancer cases are estimated by American cancer society3.  Most of the 
men diagnosed with prostate cancer do not die of the disease rather die of other 
causes with a majority of the cases still undetected. 
In the early stages of prostate cancer when it is confined to the prostate gland, it 
can be treated with excellent chances for survival. Nearly 85% of American men 
are diagnosed with early-stage prostate cancer and with timely medical interven-
tion, these patients can be treated with successful survival outcomes4. As pros-
tate cancer is slow growing, many patients are safely followed by active surveil-
lance or watchful waiting5,6. Active surveillance is a strategy used in which men 
with early stage prostate cancer undergo careful monitoring and serial prostate 
biopsies and the criteria for enrollment in AS include: clinical stage T1 or T2a; 
Gleason pathological score < 6 in the biopsy specimen with no Gleason pattern 
4; 3 or fewer positive biopsies cores (minimum of 12 cores sampled), and no 
core with >50% involvement with cancer1. Other treatment strategies include a 
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combination of surgery, radiation, hormonal or chemotherapy7. In this context, 
understanding of Gleason grading is essential for the better judgement of the 
stage of prostate cancer and aid in deciding the treatment strategy. Based on the 
appearance of the cells under a microscope, a urologist grades the prostate can-
cer patient biopsies ranging from 1 to 5. Gleason grade 1 being well differentiat-
ed associated with favorable prognosis and 5 being the least differentiated which 
is correlated with poor prognosis. The final Gleason score is calculated by the 
sum of the grade of the primary tumor and the second number will be the pattern 
of the highest grade8. The Gleason score ranges from 2 to 10. Prostate cancer 
biopsy with highest score is more aggressive and have poor prognosis.   
 Prostate cancer is known to be advanced when it spreads beyond the prostate 
and its surrounding area into the nearby tissues, lymph nodes, bones, or other 
parts of the body.  Nearly 10-20% of patients with newly diagnosed prostate can-
cer have advanced prostate cancer7,9. In patients diagnosed with localized pros-
tate cancer, advanced prostate cancer will develop in nearly 40% men after they 
were initially treated for the localized disease7. Most prostate cancer–related 
deaths are due to the advanced stage of the disease, which results from a com-
bination of lymphatic, hematogenous, or contiguous local spread9,10. Advanced-
stage prostate cancer is detected more frequently in African Americans with a 
higher Gleason grade compared to white Americans11. Patients diagnosed with 
advanced or stage IV prostate cancer can be broadly divided into two groups. 
Patients who present with locally confined to the pelvis, but involving adjacent 
organs or lymph nodes have localized stage IV prostate cancer. Patients with 
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prostate cancer that has spread to distant organs, most commonly to the spine, 
ribs, pelvis and other bones have metastatic stage IV prostate cancer. In local-
ized stage IV prostate cancer, patients are treated with radiation therapy and 
immediate hormonal therapy with successful 5 year-survival from the initiation of 
treatment without evidence of cancer progression or development of a distant 
metastatic disease11,12.  
Prostate cancer that has spread to distant organs and bones is treatable, but not 
curable with current standard therapies13. Androgen deprivation therapy (ADT) 
through either medical or surgical castration has been the standard treatment of 
metastatic prostate cancer for many years. As the growth of prostate epithelial 
cells requires physiological levels of androgen for its functioning, most of the pa-
tients with advanced prostate cancer usually can be controlled with ADT for a pe-
riod of time13-15. Despite a good initial response to ADT, remissions last on aver-
age 2-3 years, eventually progressing into castration-resistant prostate cancer 
(CRPC) with no further benefit from ADT. Patients with CRPC have a worse 
prognosis and translate into a survival time of 16–18 months on an average from 
the beginning of progression14,15. These patients show a metastatic progression 
of the disease (Fig 1.1). Docetaxel or cabazitaxel in combination with prednisone 
is the first-line chemotherapy regimen for metastatic CRPC patients (mCRPC). 
However, chemotherapy is not well tolerated by all CRPC patients, who were of-
ten elderly men with limited bone marrow reserve and concurrent medical condi-
tions16. Hence, the treatment strategy for mCRPC remains a significant clinical 
challenge.  
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Figure 1.1: Graphical illustration of Progression of Prostate cancer. 
Obtained from Prostate cancer: Clinical update by James L. Gulley 
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CHAPTER 1B: Prostate cancer bone metastasis 
In nearly 90% of mCRPC patients, the progression of metastatic lesions in bone 
is often the initial manifestation resulting in a significant increase in mortality and 
morbidity6,14,16,17. Metastatic prostate cancer progresses to the bone through a 
series of events. It starts with the dissemination of tumor cells from the primary 
site followed by invasion through the vasculature to reach circulation. Once in the 
circulation, they migrate across the sinusoidal wall in the bone marrow cavity and 
home to the bone.  After localization in the bone, the tumor cells may remain 
dormant to overcome the harsh and challenging bone microenvironment, or un-
der favorable conditions, they release growth factors to interact with the bone 
and deregulate bone microenvironment resulting in overt micrometastasis (Fig 
1.2). These patients are symptomatic and are at high risk of developing skeletal-
related events (SREs) which includes pathological fractures, spinal cord com-
pression, bone pain, decreased hematopoiesis resulting in anemia and malignant 
hypercalcemia leading to reduced quality of life and detriment of overall survival. 
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Figure 1.2: Progression of Prostate cancer from primary tumor to the 
metastatic site, bone.  
Obtained from https://prostatecancerinfolink.net/2011/03/23/12283/. 
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Bone cells and Bone remodeling 
Bone is a dynamic tissue that undergoes continuous remodeling to maintain its 
strength, stiffness, and integrity. In a healthy adult bone, bone remodeling is 
achieved by the functions of three types of bone cells: osteoblasts, osteoclasts, 
and osteocytes. Osteoblasts originate from mesenchymal stem cells present in 
the bone marrow. These cells differentiate and mature to mineralize the bone ex-
tracellular matrix by depositing calcium hydroxyapatite crystals18-20. This function 
of osteoblasts provides rigidity and strength to the bone. Osteoblasts are recruit-
ed to the site of resorption pits, injury or damage where they build and lay new 
bone to restore the integrity of the bone. Osteoclasts are bone-resorbing cells 
derived from hematopoietic stem cells. They release enzymes that can degrade 
the bone thereby forming a resorption pit. During bone remodeling, osteoclast 
removes the mineralized bone following which osteoblast lay down new bone 
matrix which subsequently becomes mineralized. This process occurs at discrete 
sites named basic multicellular units (BMUs). Molecularly, osteoblasts and cells 
such as stromal cells, chondrocytes, megakaryocytes, B cells, synoviocytes acti-
vated CD4+ and CD8+ T cells and macrophages in bone matrix release receptor 
activator of nuclear factor kb ligand (RANKL) which then binds to RANK receptor 
on osteoclastic precursors and activate osteoclast for bone resorption. Osteo-
clast activation is negatively regulated by the release of osteoblastic osteopro-
tegerin (OPG) which inhibits the binding of RANKL to RANK receptor18-20. The 
RANKL/RANK/OPG axis thereby orchestrates the bone remodeling and main-
tains bone homeostasis (Fig 1.3).  
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Figure 1.3: Homeostasis in healthy bone. 
Obtained from Tilg H et. al. Gut, inflammation and osteoporosis: basic and clinical concepts. 
Gut. 2008 May;57(5):684-94. 
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 In addition to these cells, mature osteoblast cells become trapped in the newly 
formed bone matrix and become star-shaped osteocytes. These cells form net-
work with each other for exchange of nutrients. Osteocytes are terminally differ-
entiated osteoblasts that are no longer involved in active bone formation, and 
have become entrapped within the lacuna embedded deep in the bone ma-
trix produced by them20. They are abundant in the bone matrix making up to 90% 
of all the bone cells and are long-lived than osteoblasts and osteoclasts. They 
are first cells to detect and respond to mechanical strain in the bone by com-
municating with surface osteoblasts and osteoclasts via a complex network of 
neuron-like processes referred to as canaliculi. Osteocytes play central role in 
bone remodeling by integrating both hormonal and mechanical signals to regu-
late bone mass. They undergo apoptosis to release apoptotic bodies containing 
RANKL to recruit osteoclasts to the site of resorption to either remodel or remove 
damaged bone area. Osteocytes also regulate osteoblast signaling by the re-
lease of sclerostin, which is an inhibitor of Wnt signaling in osteoblasts.  In addi-
tion, osteocytes are critically important for bone mineralization, by regulating 
phosphate metabolism through release of FGF23 (Fig1.4)21. 
Apart from bone cells, the bone microenvironment includes myeloid and immune 
cells, platelets, bone marrow endothelial and hematopoietic cells and bone mar-
row-derived mesenchymal stem cells. Together, the interaction between osteo-
clasts, osteocytes, osteoblasts and the bone microenvironment maintains the 
physiology of healthy bone. However, this tightly regulated bone homeostasis is 
entirely skewed when metastatic prostate cancer cells invade bone. In bone me-
 
11 | P a g e  
 
tastasis, the invading cancer cells aberrantly stimulate the activity of osteoblasts 
and osteoclasts leading to deregulation of bone homeostasis and disrupting the 
process of bone remodeling. 
  
 




Figure 1.4: Bone remodeling. 
Obtained from Pierre J. MARIE. Bone remodeling: a social network of cells. 
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As this study focuses on osteoclasts, a detailed description of osteoclasts in 
general follows.   
Osteoclasts 
Origin: Osteoclasts are giant, multinucleated cells which remain to be one of the 
most complex and fascinating cells in vertebrates. These cells are short-lived and 
modest in numbers yet are uniquely endowed with the capability to degrade the 
complex organic and inorganic bone matrices. Osteoclasts originate from the 
hematopoietic stem cells present in bone marrow which also are common pro-
genitors for lymphoid as well as myeloid lineage. Osteoclasts are derived from 
the myeloid lineage by the commitment of hematopoietic stem cells into common 
myeloid progenitors (Lin-c-kit+sca1-Fms+) which then give rise to Macro-
phage/Dendritic cell precursors (MDP) which are identified as 
CX3CR1+CD117+Lin−. These MDPs in the presence of M-CSF differentiate into 
monocytes (CD31-Ly-6C-cFMS+Rank+), myeloid blasts (CD31+Ly-
6C+cFMS+Rank+) and common Dendritic cell precursor (Lin-cKitlo Flt3+cFMS+). 
Monocytes are known precursors of macrophages, dendritic cells, and osteo-
clasts. Further, macrophages in the presence of RANKL and M-CSF can form 
osteoclasts. Immature dendritic cells that arise from common Dendritic cell pre-
cursors can also trans-differentiate into osteoclasts in the presence of IL-1, TNF, 
and IL-10. Myeloid blasts are the early stage Ly-6C+ monocytes which on stimu-
lation with M-CSF and RANKL become polykaryotic osteoclasts. However, these 
myeloid blasts can also retain the characteristics of Ly-6C- monocytes22-25 (Fig 
1.5). 
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Figure 1.5: Origin of osteoclasts. 
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Commitment: The differentiation of hematopoietic stem cells into bone-resorbing 
osteoclasts involves a sequential activation of various signaling factors released 
by osteoblasts and surrounding cells in the bone environment. The first wave of 
signaling includes M-CSF (Macrophage- colony stimulation factor), CSF1r/ c-Fms 
(receptor for M-CSF) and transcription factor PU.126-28. M-CSF is expressed 
mainly by endothelial cells followed by osteoblasts, stromal fibroblasts, activated 
T-lymphocytes and cells of the epithelium26-28. In response to M-CSF, the hema-
topoietic stem cells commit to myeloid lineage which then proceeds to become 
monocytes or macrophage colony-forming units (CFU-M). Monocytes are the 
common precursors of macrophages and osteoclasts. PU.1 is the first signaling 
molecule known to influence the commitment and differentiation of myeloid pre-
cursors to osteoclast lineage26-28. During the stage of commitment, PU.1 binds to 
the promoter site of Csf1r as well as ITGAM and promote their transcription 
which is intrinsic to osteoclast biology. PU.1 deficient mice die at birth and show 
signs of osteopetrosis. The absence of PU.1 causes an arrest in the normal dif-
ferentiation of myeloid precursors to osteoclasts and macrophages suggesting 
that PU.1 is a central player in the commitment and differentiation of 
osteoclasts26-29 (Fig 1.6). 
Activation of M-CSF is vital for the proliferation and survival of the monocytes. In 
fact, CSF1-deficient osteopetrotic mice (Csf1op/Csf1op) showed severe osteo-
petrosis and a range of hematologic abnormalities in the peripheral blood, bone 
marrow, and spleen along with growth retardation, reduced macrophage densi-
ties, defect in male and female reproductive functions and failure of tooth erup-
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tion. Administration of M-CSF corrected several developmental disorders entirely 
in CSF1-deficient osteopetrotic mice while partial restoration of macrophage 
densities in liver, adrenal, spleen, and large intestine was observed. However, 
presence of residual osteopetrosis caused a tremendous delay in the resorption 
of trabecular bone in the sub epiphyseal region of the long bone along with par-
tial normalization of hematological abnormalities in the bone marrow, peripheral 
blood and spleen suggesting the effects of M-CSF on osteoblasts and osteo-
clasts in these mice26,27,29.   
During the early myeloid differentiation, M-CSF along with other growth factors 
such as IL-1 and IL-3 produce mononuclear progenitors. Following the initial my-
eloid commitment and differentiation into monocytes, M-CSF signaling regulates 
proliferation, survival, and differentiation of monocytes to macrophages and os-
teoclasts. Molecularly, binding of M-CSF with c-Fms/ CSF-1R (Colony Stimulat-
ing Factor 1 Receptor) initiates a signaling cascade which stimulates PI3K/Akt 
pathway which in turn activates GSK3 and the FOXO family of transcription fac-
tors. Once active, GSK3 promotes the proteasomal degradation of cyclin D1 
causing cell cycle arrest in G1 phase. FOXO proteins inhibit the transcription of 
cyclin D1 while increasing the cell cycle inhibitors, p27 and p13026,27. Further, M-
CSF induces the expression of MAPK phosphate-1 (MKP-1) which then 
dephosphorylates ERK leading to its inactivation. This signaling results in the de-
crease in monocyte proliferation to enable the differentiation of monocytes into 
osteoclasts. M-CSF also regulates the proliferation of pre-osteoclasts via the 
ubiquitination, endocytosis and subsequent degradation of c-Fms, c-Src, and c-
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Cbl26. Microphthalmia-associated transcription factor (MITF) is activated as result 
of M-CSF signaling stimulation which in turn binds to Bcl-2 promoter to regulate 
its protein expression in monocytes.  Contrary to the effect of M-CSF signaling on 
proliferation of monocytes, reports by Zhou et al. suggest that PI3K mediates the 
suppression of p27 to promote proliferation of M-CSF-induced monocytes. M-
CSF also induces the expression of RANK receptor which is one of the key play-
ers involved in the differentiation of monocytes to osteoclasts (Fig 1.6) 26,27,29. 
Interactions between PU.1 and MITF are critical for the osteolysis biology. MITF 
mi/mi mice have severe osteopetrosis and inactivate essential osteoclastic fac-
tors such as Tartrate-resistant acid phosphatase (TRAP) and carbonic anhydrase 
2 (CA-II). These mice also contain abundant macrophages, which imply that 
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Figure 1.6: M-CSF signaling in Osteoclastic precursors. 
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Migration and Targeting: The recruitment of osteoclast precursors to the bone 
surface lined with RANKL releasing osteoblasts is a crucial step for osteoclast 
differentiation. Osteoclast precursors are recruited to the site of resorption by 
chemotaxis and chemoattractants that are responsible for this function are re-
leased by mature osteoblasts as well as the bone matrix itself. Many chemokines 
govern the chemotaxis of the monocytic osteoclast precursors. One of the well-
characterized chemokines in the regulation of osteoclast precursors’ migration is 
CXCL12/ SDF-1 (stromal cell-derived factor-1)31,32. CXCL12 is expressed by 
stromal cells in the perivascular regions in the bone marrow cavity. The chemo-
kine receptor CXCR4 is widely expressed on nearly all of the hematopoietic cells 
including osteoclast precursors. CXCL12 promotes chemotactic recruitment, de-
velopment, and survival of osteoclast precursors that express CXCR431,32. Sec-
ondary to this, another chemokine belonging to the same family as CXCL12, 
CX3CL1 is expressed by osteoblasts, and its cognate receptor CX3CR1 is pref-
erentially expressed on osteoclast precursors. CX3CL1 was indicated to play a 
crucial role in the recruitment of osteoclast precursors into the bone marrow cavi-
ty and in the firm adhesion on the bone surface32. Discussion leading to a hy-
pothesis by Noble et al. and Heino et al. suggested that the dying osteocytes 
embedded in the bone matrix release RANKL in the form of apoptotic bodies to 
attract the osteoclast precursors to their location for degradation and healthy os-
teocytes downregulate the resorption (Fig 1.7). 
Sphingosine-1-phosphate (S1P) is lipid mediator present in all the cell types in 
the e bone and enriched in blood and is known a critical regulator of osteoclast 
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precursor migration31. Osteoclast precursors express S1PR1 and S1PR2 on its 
surface, and the migration and targeting of these cells are dynamically regulated 
by S1P. S1PR1 and S1PR2 function in opposing directions in the migration of 
osteoclast precursors. S1PR1 promotes chemotaxis of pre-osteoclasts into blood 
circulation where S1P levels are high while S1PR2 induces chemorepulsion. 
S1PR2 require high concentrations of S1P to conduct chemo repulsion. Once 
activated, it negatively regulates S1PR1 function and induces chemotaxis in the 
opposite direction of S1P gradient  where S1P levels are low which is key to di-
rect osteoclast precursors into the bone marrow cavity (from the blood vessel 
where S1P levels are high) and to the site of resorption.  After the entry into bone 
marrow, S1PR1 is reactivated, and the osteoclast precursors required for resorp-
tion remain while the rest are returned to the blood vessels by S1P gradient (Fig 
1.7)31. This mechanism of chemoattraction and chemorepulsion is a checkpoint 
for controlling osteoclastogenesis as it determines the number of osteoclasts 
precursors that are necessary for the degradation of bone matrix. 
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Figure 1.7: Mechanism of Osteoclastic Precursors Migration and Tar-
geting. 
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Differentiation:  The function of RANKL-RANK-OPG axis tightly regulates the 
differentiation of myeloid precursors into polykaryon, bone-resorbing osteoclasts. 
RANKL (receptor activator of nuclear factor-κB transcription factor ligand) is the 
most potent osteoclastogenic cytokine expressed widely on the surface of osteo-
blasts, stromal cells, chondrocytes, megakaryocytes, B cells, synoviocytes acti-
vated CD4+ and CD8+ T cells and macrophages. RANKL binds to its receptor, 
RANK present on the surface of monocytes and immature dendritic cells to initi-
ate signaling cascade leading to osteoclast differentiation and activation22,33,34. 
Downstream of RANK, TNF receptor-associated factor (TRAF) proteins such as 
TRAF2, TRAF3, TRAF5, and TRAF6 are activated. Of all the TRAFs, mice lack-
ing TRAF6 has a defect in osteoclast differentiation and function which implies 
that TRAF6 is a major mediator of osteoclast formation. Activation of RANK by 
RANKL leads to recruitment of TRAF2 AND TRAF5 to the RANK-RANKL com-
plex, and the subsequent binding of TRAF6 leads to the phosphorylation of 
TAK1, a member of MAP3K via TAB2. TAK1, in turn, phosphorylates NIK (NF-
B-inducing kinase) to activate IKK (IB kinase) complex in a non-canonical NF-
B manner22,33,34. Activated IKK phosphorylates IB to destabilize the IB-NF-B 
complex thereby liberating NF-B which subsequently translocates into the nu-
cleus for the transcription of osteoclastic genes which includes one of the key 
transcription factor, NFATc1.35 The phosphorylated IB is ubiquitinated and de-
graded by the proteasome machinery. In a canonical NF-B pathway, activation 
of TRAF6 and p62 can also phosphorylate IKK via PKC which binds to p62 
through its N-terminal PB1 domain. PKC initiates the activation of NF-B via the 
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IKK phosphorylation and release of NF-B P65 and P50 and their translocation 
into the nucleus.35 Both the canonical and non-canonical NF-B pathways have 
been reported to be involved in the osteoclast differentiation and survival. In the 
case that one of the NF-B pathways is blocked or downregulated, the other 
pathway compensates for the functioning of osteoclasts (Fig 1.8) 22,33-36. 
Although RANKL –RANK signaling is the key pathway for osteoclast differentia-
tion, it is not sufficient to drive osteoclastogenesis without the co-stimulation by 
several transmembrane adaptor proteins such as DAP12, FcR, and DAP10. The 
extracellular domains of these adaptor proteins are small and cannot interact di-
rectly with the ligands. They associate with cell surface receptors via paired 
charged residues in the transmembrane regions of these adaptors known as im-
munoreceptor tyrosine-based activation motifs (ITAM). During the early stages of 
osteoclast differentiation, DAP12 co-stimulates RANK signaling by recruitment 
and activation of Syk, which sequentially induces the activation of BTK and Tec 
kinases as well as PI3K leading to subsequent activation of PLC and thereby 
driving Ca2+ oscillations. Ca2+ stimulates calcineurin to dephosphorylate 
NFATC1 to enable its translocation into the nucleus for transcription of osteoclast 
genes22. Ca2+-mediated activation of NFATc1 also triggers the autoamplification 
loop of NFATc1 and ensures a sustained NFATc1-dependent transcriptional pro-
gram in which osteoclast-specific genes are activated by a transcriptional com-
plex that involves NFATc1, AP-1, and other cooperators (Fig 1.8)22,33,34,36,37. 
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The induction of NFATc1 is a distinctive characteristic of pre-osteoclasts. It is one 
of the key target genes of NF-B as well as Ca2+-calcineurin pathway during the 
early stage of osteoclastogenesis37. Reports on NFATc1- deficient mice indicate 
that deletion of NFATc1 causes embryonic lethality and that ectopic expression 
of NFATc1 caused bone marrow-derived precursor cells to differentiate into os-
teoclasts even in the absence of RANKL22. Interestingly, another molecule which 
is a member of NFAT family, NFATc2 preexists even before RANKL stimulation 
and is also activated and recruited to the promoter site of NFATc1 along with NF-
B to activate NFATc1 cooperatively37,38. This step is crucial for the robust induc-
tion of NFATc1 during osteoclast differentiation within a short time of RANKL in-
duction (Fig 1.8)22,33,34,36.  
c-Fos is also identified as a key determinant in the differentiation of mye-
loid precursors to osteoclasts and macrophages.39 As a result of RANKL-RANK 
signaling, c-Fos is activated which in turn complexes with c-Jun to form the Acti-
vator protein-1 (AP1) transcription factor. It functions as a switch between osteo-
clast and macrophage differentiation from myeloid precursors. In the absence of 
c-Fos, the myeloid precursors differentiate into macrophages but not osteoclasts 
causing severe osteopetrosis as exhibited in c-Fos-deficient mice.35,39 This phe-
notype can be rescued by bone marrow transplantation or ectopic overexpres-
sion of c-Fos. Also, DAP12-induced Ca2+ prompts CaMKIV (calcium/calmodulin-
dependent protein kinase type IV) to activate c-Fos in RANK-dependent manner 
which translocate into the nucleus to form AP-1 dimers and work in coordination 
with NFATc1, NF-B, MITF, PU.1 and other transcription factors to promote the 
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transcription of osteoclastic genes.35,38 Accumulating evidence indicates that the 
cooperation of NFAT and AP1 is responsible for the specific activation of 
NFATc1 promoter and its auto-amplification (Fig 1.8)33,34,36,39. 
Maturation: The initiation of maturation phase is characterized by the fusion of 
mononucleated osteoclasts to form multinucleated polykaryons followed by their 
recruitment to site of resorption.  The multinucleation of osteoclasts is the most 
striking morphological feature that distinguishes osteoclasts from their precur-
sors.38 The osteoclast cell-cell fusion is highly regulated since their functions of 
bone resorption, and secretion of digested bone are so dependent upon extreme-
ly active membrane dynamics, including formation of the ruffled border and high 
rates of endocytosis, vesicle fusion, and transcytosis.34 The function of syncytin1, 
CD47, dendritic cell-specific transmembrane protein (DC-STAMP) and osteo-
clast-stimulatory transmembrane protein (OC-STAMP) in early fusion events, and 
of connexin 43 at a later stage enables the engulfment of mononuclear cells by 
more mature, multinucleated osteoclasts.34,38 DC-STAMP and OC-STAMP are 
two related transmembrane proteins which have been reported to be essential for 
mononucleated osteoclast fusion and are strongly induced by RANKL during the 
osteoclastic differentiation.34,40 Recent work by Yagi et al., Miyamoto et al. and 
Hanna et al. showed that mice with knockout of DC-STAMP and OC-STAMP had 
defect in the fusion of mononuclear osteoclasts as characterized by the block in 
the formation of fusion bridges which are necessary for cell-cell junction.34,41-43 
Also, the mononucleated osteoclasts from these mice demonstrated decreased 
pit resorption capacity.42,43 Another study by Noam Levaot et.al. attempted to un-
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derstand the cellular mechanisms underlying the fusion biology of osteoclasts 
and suggested that the process of fusion is initiated by a small subset of mature 
osteoclast precursors (~2.4%) stimulated by M-CSF and RANKL are known as 
fusion-founder cells. These cells can fuse with less mature osteoclast precursors 
to generate multinucleated osteoclasts. Diffusible cytoplasmic molecules are ex-
changed between fusion-founder and fusion-competent cells by the formation of 
protrusions interconnecting the fusing cells.44 However, it is still unclear from this 
study whether fusion occurs precedes osteoclast differentiation or vice versa or 
they occur simultaneously (Fig 1.8)38. 
During maturation, several osteoclast-specific genes such as Cathepsin K, matrix 
metalloprotease 9 (MMP9), c-Src, osteoclast-associated receptor (OSCAR), Tar-
tarate- resistant acid phosphatase (TRAP), chloride channel protein 7 (CIC7), β3 
integrin, αv integrin and Latent transforming growth factor binding protein 3 
(LTBP3) are activated by a transcriptional complex that contains NFATc1 along 
with other transcription factors such as AP1, PU.1 and MITF.45,46 NFATc1 - AP-1 
complex is essential for the induction of the TRAP and calcitonin recep-
tor genes.34 The transcriptional complex with NFATc1, PU.1, and MITF is neces-
sary for the expression of cathepsin K and OSCAR. Importantly, the components 
of the NFATc1 complex are not always the same, i.e., for instance, the coopera-
tion between NFATc1 and PU.1/MITF was not observed on the calcitonin recep-
tor promoter, suggesting that the differential composition of the transcriptional 
complex may contribute to the spatiotemporal expression of each gene during 
osteoclastogenesis (Fig 1.8).38,45 
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NFATc1 plays a vital role in the process of osteoclast fusion via up-regulation of 
the DC-STAMP and the d2 isoform of vacuolar ATPase V0 domain (Atp6v0d2). 
Recently, NFATc1 has been shown to activate Atp6v0d2 via co-activation with 
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Figure 1.8: Signaling cascade involved in osteoclast differentiation and 
maturation.  
Modified  from Kazuo Okamoto and Hiroshi Takayanagi. Regulation of bone by the adaptive immune sys-
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Activation: Osteoclast activation is a multi-step process which follows multinu-
cleation of osteoclasts. The process of osteoclast activation is divided into four 
steps which are: (1) Polarization of the osteoclast to the mineralized bone matrix 
and reorganization of actin cytoskeleton. (2) Formation of the ruffled border. -3) 
The release of bone matrix-degrading enzymes and acid within the ruffled border 
and sealing zone to degrade the organic matrix and minerals. (4) Removal of re-
sorbed products from the osteoclast (Fig. 1.9)47.  
Osteoclast polarization: During bone resorption, osteoclasts are polarized with an 
apical membrane at the contact with bone and a basolateral membrane at its op-
posite. Osteoclasts recognize proteins containing Arg-Gly-Asp sequence motif on 
the bone matrix and attach through vitronectin is the first step in the polarization 
of osteoclasts.48 Physical properties of bone such as hardness and roughness 
contribute to the induction of osteoclast polarity. Presence of hydroxyapatite –
collagen complex also enables the polarization of osteoclasts. The release of 
protons from osteoclasts onto the bone matrix aids in recognition of bone by the 
osteoclasts. Further, attachment to the bone surface occurs through the function 
of integrin specifically, αvβ3 integrin, a vitronectin receptor. The αvβ3 integrin 
forms a thin actin complex known as podosome which recognizes the proteins 
with RGD-motif such as osteopontin, vitronectin and bone sialoprotein in the 
bone matrix.47,49  Individual podosomes form part of the subcellular structures 
that continuously self-organizes during osteoclast attachment and 
polarization.48,49 Podosome clusters and evolves into dynamic rings at intermedi-
ate stages and end up forming peripheral podosome belts in mature cells. These 
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podosome belts fuse to form the sealing zone.49 During polarization, osteoclasts 
become apical-basal polarized with an apical membrane at the contact with bone 
and a basolateral membrane at its opposite along with specific submembrane 
domains to form the sealing zone.49 In actively resorbing osteoclasts, the sealing 
zone is characterized by a broad circular band of actin surrounded by a double 
ring of vinculin.47,48  
At molecular level, podosomes contain F-actin core and actin regulatory proteins 
including cortactin, Wiskott–Aldrich Syndrome Protein (WASP) and Arp2/3.49 
During osteoclast polarization, cytoskeleton rearrangement occurs, and M-CSF 
plays a crucial role in controlling the v3 integrin signaling via c-Src, Pyk2, Syk 
and c-Cbl.48 In fact, DAP12/Syk association is the point of convergence between 
M-CSF and αvβ3 integrin signaling during cytoskeleton rearrangement. M-CSF 
binding to c-Fms promotes the stable interaction with αvβ3 integrin via phosphor-
ylated sites on c-Fms. Integrin αvβ3 mediates cytoskeleton organization through 
the cytoplasmic domain of β3 subunit. Binding of integrin αvβ3 to its ligand leads 
to phosphorylation and activation of c-Src, which is constitutively associated with 
the cytoplasmic domain of β3 subunit. Activated c -Src then phosphorylates Syk, 
whose SH2 domains recognize and bind to the phosphotyrosine residues of the 
ITAM protein and DAP12 to activate their coupling to c-Fms.48,49 The αvβ3 –c-
Src-Syk complex then recruits Slp76, an adaptor for Vav3. Vav3, a guanine nu-
cleotide exchange factor is activated via Slp76 which converts small GTPases of 
the Rho family from the inactive GDP form to the active GTP-bound form.47 Rac 
is a Rho family GTPase expressed in osteoclasts and is involved in αvβ3 -
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mediated reorganization of the osteoclast cytoskeleton.48,50 Rac1 and Rac2 are 
two key effector molecules of the αvβ3 integrin signaling and their deletion re-
sults in a severe dysregulation in the osteoclast cytoskeleton and 
osteopetrosis.48,50 Cdc42 is another Rho GTPase, which promotes cytoskeletal 
effect through PKC. Integrin αvβ3-mediated cytoskeleton organization leads to 
the formation of the dense actin belt-like structures called the F-actin ring, which 
isolates the resorptive space from its surroundings therefore forming a sealing 
zone.  The resorptive bone lacuna is separated by the F-actin ring to limit the 
flow of protons and bone-degrading enzymes thereby maintaining low pH for ef-
fective degradation of the bone matrix.48,50 
Formation of ruffled borders: During resorption, the plasma membrane enclosed 
by the F-actin ring expands and rearranges to attain highly convoluted structures 
upon attachment to the bone surface called the ruffled borders. These borders 
are not only a morphological characteristic of the osteoclast but also the cell’s 
resorptive organelle as they serve as exit for protons and lysosomal proteases 
onto the resorbing surface.51 The ruffled border membrane is formed by the in-
sertion of the proton pump, H-ATPase, and cathepsin K-bearing vesicles into the 
plasma membrane attached to the bone.52 These borders vary in size based on 
the activity of the cell and dependent on αvβ3 integrin signaling thereby providing 
a large surface area for the release of protons and osteolytic enzymes. In un-
bound osteoclasts, acidifying vesicles containing the proton pumps are distribut-
ed diffusely throughout the cytoplasm and upon attachment of osteoclasts to 
bone, matrix-derived signals such as αvβ3 integrin prompt these vesicles to lo-
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calize and integrate into the plasma membrane facing the bone.51,52 Acidic vesi-
cles fuse with the plasma membrane in the ruffled borders which is mediated by 
SNARE proteins. Fusion of exocytotic vesicles with the osteoclast plasma mem-
brane is mediated by SNARE proteins (v-SNARE and t-SNARE). The function of 
SNARE function is regulated by synaptotagmins (Syt), a family of vesicular traf-
ficking proteins.47,51,52 
Studies on Ca2+ flux and ruffled borders in resorbing osteoclasts suggested that 
calcium regulates the secretion of intracellular granules at the time of resorption. 
The osteoclasts that are actively resorbing are exposed to high calcium concen-
trations in the ruffled borders but the internal concentration of calcium is main-
tained at ~100Nm. However, αvβ3 integrin signaling induces a robust increase in 
the intracellular calcium to 0.5-0.8 mM along with formation of calcium puffs.47,52 
Hence, it was postulated that these drastic increases in calcium levels may corre-
late with the pronounced increase in the release of intracellular vacuoles but no 
evidence can corroborate this hypothesis.  
Release of bone matrix-degrading enzymes and acid to degrade the organic ma-
trix and minerals: During bone resorption, osteoclasts activate a variety of intra-
cellular pathways. The ruffled border of osteoclast has a vacuolar-type proton 
ATPase (V-ATPase) inserted into it which enables the release of large amounts 
of acid to degrade bone matrix.  V-ATPase is placed in the ruffled borders via its 
release from lysosome.47,51,52 The source of the cytoplasmic protons is carbonic 
acid, which is generated by carbonic anhydrase II from carbon dioxide and water. 
Carbonic anhydrase II is localized close to the ruffled border. To maintain elec-
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troneutrality, Cl- are also transported into the resorption compartment via chloride 
channels which are charge-coupled to the V-ATPase and also present in the ruf-
fled border membrane.51,52 The secretion of protons across the ruffled border 
membrane into the extracellular resorbing compartment leaves the conjugate 
base, bicarbonate (HCO 3- ) inside the osteoclast and to maintain electroneutrali-
ty, bicarbonate must be removed from the cell. Further, the osteoclast also must 
maintain efflux of Cl- ions to remove excess bicarbonate as well as supply for 
chloride channels. For this, a passive chloride-bicarbonate exchanger is present 
in the basolateral position of the plasma membrane of osteoclasts. The co-
ordinated function of V-ATPases and chloride channels leads to a net release of 
hydrochloric acid into the resorption lacuna (Fig. 1.9).47,51,52 
TRAP is an acid phosphotase that cleaves phosphomonoesters and is the only 
known enzyme to be expressed in the osteoclast precursors. Osteoclasts gener-
ate large quantities of TRAP which localize to the intracellular vesicles and vacu-
oles near the ruffled borders. TRAP is released in the resorption lacuna to partial-
ly dephosphorylate osteopontin, bone sialoprotein and bone matrix phosphopro-
teins. This allows the osteoclast migration and further resorption to occur. In 
knockout studies, TRAP-/- mice exhibit a mild osteopetrosis and osteoclasts de-
rived from these mice are unable to dephosphorylate osteopontin leading to an 
accumulation of the protein in the resorption zone and inside the cells in electron 
dense vacuoles (Fig. 1.9).47,52 
The degradation of the organic component of bone matrix is accomplished by the 
lysosomal protease, cathepsin K. High expression levels of cathepsin K are pre-
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sent at the ruffled border and released into the resorption lacuna via lysosomes 
to digest native collagen fibers at acidic pH.53,54  These information indicates that 
lysosomal secretion is a major pathway for resorbing enzymes via the localiza-
tion of LAMP1 and LAMP2 to the surface of lysosomes.53 Lysosomes are of two 
types which have been reported to be active in resorbing osteoclasts. One is se-
cretory lysosomes and the other is conventional lysosomes.54 Cathepsin K 
transport occurs through secretory lysosomes.53 Cathepsin K contains a man-
nose-6-phosphate (M-6-P) moiety which binds to Mannose-6-phosphate recep-
tors (MPRs) to assist in the transport of soluble lysosomal enzymes to the endo-
some-lysosome compartments.53,54 MPRs are highly expressed in osteoclasts to 
mediate the sorting of cathepsin K from the trans-golgi network to the secretory 
lysosomes. Lysosomal enzymes and MPRs are present in the endoplasmic retic-
ulum, golgi apparatus and in transport vesicles which fuse with the ruffled border 
in osteoclasts. The inhibition of M6P targeting pathway as a result of deletion of 
GNPTAB (GlcNAc-1-phosphotransferase , -subunits) dysregulates the for-
mation of secretory lysosomes.54 Due to a hindrance in the secretory lysosomal 
pathway, cathepsin K and TRAP are sorted into small post trans-golgi network 
vesicles leading to their increased secretion in the ruffled borders of these osteo-
clasts in comparison to wild-type osteoclasts (Fig. 1.9).47,53  
Several MMPs have been identified to solubilize collagen in the bone areas dur-
ing resorption. Osteoclasts express MMP1, MMP9, and MMP14 which localizes 
to the ruffled borders to resorb bone matrix.55 Deletion of these MMPs did not 
show any evident difference in the osteoclast resorption but had slower osteo-
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clast migration. However, calvariae of MMP13 knockout mice showed slower re-
sorption compared to their wild-type counterparts.55,56 These evidences suggest 
that none of the MMPs of osteoclastic origin are limiting for resorption but 
MMP13 which originates from osteocytes has proved to be limiting for resorp-
tion.55  
In addition to the matrix-degrading enzymes, many different families of proteins 
are known to play a crucial role in promoting an effective resorption. Rabs are 
small GTPases localized in the ruffled border of the resorbing osteoclast to regu-
late late endosomal / lysosomal vesicular trafficking. Rab 7 governs osteoclast 
lysosome biogenesis and its absence impairs osteoclast ruffled border formation 
and secretion of enzymes.53,57 Specifically, Rab 7 regulates the movements of 
lysosomes and actin cytoskeleton rearrangement through its interaction with 
Rac1. Plekm1 whose mutations cause osteopetrosis in ia/ia (incisors absent) rats 
and in a small set of patients with intermediate osteopetrosis, is reported to inter-
act with Rab 7 to function in osteoclast lysosomal trafficking. Osteoclasts in the ia 
rats and human patients have normal phenotype but with reduced resorptive 
function.57 Rab 3D is another Rab family protein that plays a crucial role in osteo-
clast activation and resorption. It governs the small post-trans golgi network vesi-
cles which are involved in ruffled border formation and bone resorption.58 Recent 
studies on Syt VII in osteoclasts suggested that it is a lysosome-associated pro-
tein that co-localizes with cathepsin K and LAMP2 and promotes the fusion of 
lysosomes containing osteoclast enzymes, proton pumps and chloride channels 
into the ruffled border.59 It interacts with lysosome-specific SNARE/ TI-VAMP, 
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which in turn complexes with syntaxin 4 to localize lysosomes containing resorp-
tive proteins to the ruffled borders.47,53 
Removal of resorbed products from the osteoclast: Osteoclast function in bone 
resorption requires both the dissolution of crystalline apatite and the enzymatic 
degradation of the organic bone matrix. This results in the release of large 
amounts of calcium, phosphate and collagen fragments, which need to be re-
moved from the resorption lacuna to prevent their accumulation to levels that can 
be toxic to osteoclasts. The removal of these products is accomplished by 
transcytosis via a vesicular process. The transcytosis is a sequential multistep 
process. First, degraded products are endocytosed, then transported along a 
transcytotic vesicular pathway toward the anti-resorptive side of the cell, and fi-
nally released out of the cell by exocytosis at the top of the osteoclast.60 Rab 7 
and Rab 3D has been reported to be involved in the regulation of transcytosis 
and exocytosis respectively.58 Rab 7 promotes the processing and degradation of 
collagen fibers via transcytosis.57 Clathrin, its adaptor protein AP-2, and the large 
GTPase dynamin are localized at the central area of the ruffled border to enable 
clathrin-mediated budding necessary for the initial formation of the transcytotic 
vesicles.54 Diverse sizes of the transcytotic vesicles are observed suggesting that 
in addition to endocytosis, micropinocytosis occur to give rise to large endocytic 
vacuoles called macropinosomes.60,61 However, it is still to be elucidated how mi-
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Figure 1.9: Mechanism of osteoclast activation and bone resorp-
tion.  
 Obtained from Naoyuki Takahashi, Nobuyuki Udagawa & Tatsuo Suda . Vitamin D endocrine system 
and osteoclasts. BoneKEy Reports (2014) 3, 495. 
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Apoptosis:  osteoclast apoptosis is recognized as a critical regulatory mecha-
nism to control osteoclast differentiation and function and alteration in it can lead 
to pathological condition. One of the most potent mechanism for osteoclast apop-
tosis in mature osteoclasts is the Fas/ FasL signaling.62 Fas is a member of the 
death receptor family and is expressed in mature osteoclasts as well as in unat-
tached TRAP positive osteoclastic precursors. Its expression increases during 
differentiation suggesting that Fas is important for the survival of osteoclasts. 
FasL binds to Fas and recruits FADD which initiates downstream caspase activa-
tion cascade and amplifies the death signal to the downstream targets such as 
BID. Truncated BID translocates to the mitochondria from the cytosol to activate 
Bax/Bak for the release of cytochrome c from the mitochondria leading to activa-
tion of caspase 3 and caspase 9 thereby causing cell death. Binding of RANKL to 
RANK receptor initiates the recruitment of c-Src, PI3K and AKT to the TRAF6 
complex. Activated Akt phosphorylates Bad and caspase 9 thus preventing the 
activation of apoptotic machinery.63  
Among BCL-2 family members, Bcl-xL is highly expressed in osteoclast for their 
survival. M-CSF, RANKL and TNF signaling promotes the expression of Bcl-xL in 
mature osteoclasts to prolong their life span and prevent apoptosis.64 Another 
anti-apoptotic protein, Bim is expressed by osteoclasts to increase osteoclast 
survival. In the presence of M-CSF, Bim expression is downregulated and the 
cells undergo apoptosis. Bim-/- osteoclasts are increased in number because of 
their increased survivability but have decreased resorptive function which indi-
cates that Bim might regulate osteoclast activation.65,66  
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Vicious cycle of bone metastasis 
Conventionally, bone metastases are characterized as either osteolytic, osteo-
sclerotic or mixed based on the radiographic and pathological appearance of the 
lesions.67,68 Osteolytic bone lesions are the most common feature of the breast 
and multiple myeloma cancer. Osteolysis is caused by the release of osteoclast 
activating factors by the tumor cells in the bone microenvironment to stimulate 
the differentiation and activation of osteoclasts which results in bone resorption at 
a highly elevated rate. The function of osteoclasts provides an environment that 
is favorable to the metastasized tumor cells and allows them to survive, prolifer-
ate and establish as a bone metastasis at the interface of bone and bone mar-
row.68 Although osteolysis is the dominant type of lesion occurring in bone me-
tastases in breast and myeloma cancer, there is always a basal level of bone 
formation that is associated with it.67 The basal activity of osteoblasts represents 
a physiological attempt to repair damaged bone. However, as the rate of bone 
resorption is higher than the rate of bone formation, the predominant effect of 
bone metastases in breast and myeloma cancer remains to be a significant bone 
loss. In contrast to this, bone metastases occurring in melanoma cancer and to 
an extent in prostate cancer is predominantly osteoblastic in nature.69 Osteo-
blastic metastases are a result of the release of factors by tumor cells that stimu-
late the initiation, proliferation, differentiation and subsequent activation of osteo-
blasts leading to an uncontrolled bone formation.67  The complex interactions be-
tween the tumor cells, bone and bone matrix constitute a vicious cyclic feedback 
loop of osteoblast-mediated bone metastases. Moreover, newly formed bone 
 
40 | P a g e  
 
provides a fertile soil for the tumor cells to survive, proliferate and in turn activate 
osteoblasts to promote bone metastasis. Interestingly, the rate of bone metasta-
ses occurrence is slower in osteoblastic lesions than in osteolytic disease. This 
phenomenon can be due to an initial increase in bone as a result of osteoblastic 
activity and may limit the space available for the tumor cells thereby confining the 
tumor cells.68,69  Release of tumor-derived factors and RANKL-secreting osteo-
blasts can both activate osteoclasts leading to a nominal level of bone resorption, 
which subsequently creates more space for more osteoblastic lesions. As a re-
sult of bone resorption, cytokines are released from the bone matrix which in turn 
can enhance this vicious cycle by facilitating the continued proliferation of tumor 
cells and osteoblasts causing bone metastasis. Osteolytic and osteoblastic bone 
lesions are two extremes of the extent of activity of bone cells to drive tumor-
mediated bone destruction (Fig. 1.10).67,68  
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Figure 1.10: Vicious cycle of bone metastasis  
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Based on the information from case studies of prostate cancer patients with bone 
metastasis, mixed osteoblastic/ osteolytic lesions are observed in these patients 
with the balance slightly shifting towards more osteoblastic lesions with a basal 
level of osteolysis.69 Recent reports by Russell Taichman group suggested that 
tumor cells that metastasize to bone are initially homed in the hematopoietic 
niche which is present as discrete areas near the interface of bone and bone 
marrow.70,71 In the niche, these tumor cells remain dormant release growth fac-
tors that can direct the differentiation of hematopoietic stems cells into osteo-
clasts. The active osteoclasts resorb bone and release growth factors that enable 
the survival of tumor cells in the bone microenvironment. Once the tumors grow 
and proliferate, they release osteogenic factors to induce osteoblast differentia-
tion and maturation leading to increased osteogenesis (Fig1.11).70,71 The osteo-
blasts induced by prostate cancer cells lay the bone in an irregular manner lead-
ing to an uneven bone formation. As a result of this, the bone that is formed is 
weak and more prone to fracture as it loses its strength and integrity. Further-
more, the bone homeostasis is dysregulated because of increased osteogenesis 
with a nominal level of osteolytic function causing SREs in patients with bone 
metastatic prostate cancer. 
  
 
43 | P a g e  
 
  
Figure 1.11: Schematic illustration of prostate cancer cells homing to the 
Hematopoietic Stem Cell Niche within the Bone Microenvironment and 
development of overt metastasis. 
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Treatment strategies for prostate cancer bone metastasis 
In mCRPC patients with bone metastasis, the current standard treatment regime 
includes systemic therapy with taxanes such as Docetaxel who in randomized 
trials showed to increase the overall survival of the patients with least palliation of 
bone pain. Furthermore, not all can tolerate the treatment as many patients with 
mCRPC might not be healthy enough to receive docetaxel owing to poor perfor-
mance status and comorbidities.72 Other systemic disease-modifying agents in-
clude cabazitaxel, novel hormone-based therapies (abiraterone and enzalutam-
ide) and immunotherapy (sipuleucel-T). Currently, Cabazitaxel is administered to 
patients progressing on or after docetaxel treatment. Hormone-based therapies 
with abiraterone and enzalutamide are approved for use in patients with mCRPC 
either before or following chemotherapy. These hormone therapies have shown 
to improve survival and skeletal outcome at least time to the first skeletal related 
events (SRE) in this setting.73  Treatment with an immunotherapeutic vaccine, 
Sipuleucel-T has significantly improved the overall survival of men with mCRPC. 
Sipuleucel-T is preferred in chemotherapy-naive mCRPC patients, which limits its 
use in combination therapy. Further, administration of Sipuleucel-T in mCRPC 
patients has severe side effects with no change in the status of SREs.74  
Use of osteoclast-targeting agents such as zolendronic acid and denosumab is 
widely accepted for the treatment of bone metastatic prostate cancer. Preclinical 
studies revealed that nitrogen-containing bisphosphonates such as zolendronic 
acid is highly potent in inhibiting the osteoclast-mediated bone resorption.75 From 
the studies conducted separately by Alliance (CALGB 90202) and ZEUS groups, 
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it can be concluded that zolendronic acid is specifically effective in treating SREs 
in patients with early stages of mCRPC and bone metastasis and ineffective for 
the prevention of bone metastasis in high risk localized and castration-sensitive 
prostate cancer patients.75 Denosumab is a human monoclonal antibody to 
RANKL that blocks the binding of RANKL to RANK receptor on osteoclasts to 
prevent their differentiation and function leading to decreased bone loss. Infor-
mation from two independent phase II trials indicates that denosumab reduced 
the bone resorption in patients independent of prior bisphosphonate treatment. 
Comparing the potency of denosumab and zolendronic acid in patients with 
mCRPC and bone metastasis, a randomized, double-sided phase III trial showed 
that denosumab was able to prolong the time to the first occurrence of SREs and 
decrease bone marker turnover (BALP and uNTx) than zolendronic acid. Howev-
er, administration of osteoclast targeting agents on patients has adverse compli-
cations which include hypocalcemia, nephrotoxicity (only with use of zolendronic 
acid), osteonecrosis of the jaw and immune dysfunction.76 The limitations of the 
current treatment strategies advocate the necessity of the understanding of the 
molecular mechanisms that can be extrapolated to develop an effective therapy. 
CHAPTER 1C: Molecular mechanisms in osteoclasts in bone metastasis 
Recent evidence on molecular pathways in healthy and metastatic bone 
In healthy bone, M-CSF and RANKL are the critical inducers which work in con-
cert to enable the commitment, survival, differentiation, maturation, and activation 
of osteoclasts. Osteoblasts remain the primary source of these cytokines along 
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with fibroblasts and T regulatory cells contributing to the overall pool. OPG re-
leased by osteoblasts inhibit the RANK-RANKL pathway thereby controlling the 
osteoclast differentiation and function. Growth factors such as TNF-, PTHrP, 
VEGF, and interleukins such as IL-1, IL-6, IL-8, IL-11, IL-15, IL-17 and IL-32 are 
reported to work along with M-CSF and RANKL to promote 
osteoclastogenesis.77,78  Current reports on prostate cancer bone metastasis 
suggest that metastatic prostate cancer cells once in the hematopoietic niche re-
lease growth factors such as EGF, TNF-, PTHrP, IL-1, IL-6, IL-8 and VEGF to 
manipulate the hematopoietic stem cells to commit to osteoclast lineage.78,79 
These tumor-induced osteoclasts degrade bone to release factors such as TGF-, 
IGF-1, BMP6, FGF-8, and PDGF to enable the survival of metastatic prostate 
cancer cells in bone and advocate their interaction with osteoblasts to develop 
into overt osteoblastic metastasis.80 Although the identification of factors has pro-
vided insight into their role in prostate cancer bone metastasis, use of inhibitors 
or osteoclast targeting agents could not rescue the overall architecture of the 
bone causing severe bone pain and can result in decreased mortality in prostate 
cancer patients with bone metastasis. There is growing evidence that osteoclasts 
are the potential proponents for the prostate cancer cells to survive in strenuous 
bone microenvironment during the early stages of homing and survival thereby 
making osteoclasts a potential target for therapy. However, there exist gaps in 
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Introduction to Neuropilin family 
Neuropilins are non-tyrosine kinase glycoproteins expressed on the surface of 
the cell to function mainly as co-receptors for vascular endothelial growth factor 
(VEGF) and the class III Semaphorin family of molecules by interacting with 
VEGF receptors and Plexins, respectively.81 They were initially reported to be in-
volved in the chemorepulsion function of Semaphorins in axonal guidance during 
neural development. They are extensively known for their functions in physiologi-
cal processes such as angiogenesis, lymphangiogenesis, cardiovascular devel-
opment, cell survival, migration and in pathological disorders such as cancer. 
Neuropilins are type I transmembrane proteins with molecular mass of 120 kDa 
and are reported to be expressed in neuronal cells, endothelial cells, epithelial 
cells of endodermal origin and various immune cells such as macrophages, den-
dritic cells (DCs), T cells, B cells, and mast cells.81  
Neuropilins exist as two isoforms as a result of gene duplication namely Neuro-
pilin 1 (NRP1) and Neuropilin 2 (NRP2). Structurally, NRP1 and NRP2 share 
similar structural layout consisting of an N-terminal extracellular domain followed 
by a transmembrane region and a short cytosolic tail of 43–44 amino acids. Neu-
ropilins comprise of four different domains, two repeats of CUB [complement 
binding factors C1s/C1r, Uegf, BMP1 (bone morphogenetic protein 1)] (a1/a2) 
domains, two repeats of Factor V/VIII homology (b1/b2) domain, a b-c linker fol-
lowed by a MAM (meprin, A5 antigen, receptor tyrosine phosphatase μ) (c) do-
main, a single transmembrane domain and relatively short cytoplasmic domains 
(44 amino acids for NRP1 and 43 for NRP2). The CUB (a1/a2) domains (approx. 
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110 amino acid residues each) is essential for the binding of class 3 Semaphorin 
group of ligands. The b1/b2 domain (approx. 150 amino acid residues each) with 
its ability to bind cell surface-specific anionic phospholipids, is necessary for cell-
cell adhesion and ligand binding for VEGF and Sema3A. The MAM domain is a 
170 amino acid residue region which is thought to mediate homodimerization or 
oligomerization of hemophilic proteins to maintain protein stability (Fig. 1.12).81 
NRP1 and NRP2 have several isoforms as a result of alternate splicing. NRP1 
has been reported to exist as membrane-bound truncated NRP1 (Δexon16) 
(lacks 51 nucleotides corresponding to exon 16) and soluble NRP1 (sNRP1), i.e., 
s12NRP1 (644 amino acids), sIIINRP1 (551 amino acids) and sIVNRP1 (609 
amino acids). SNRP1 has the a1/a2 and b1/b2 domains but lacks the MAM (c), 
transmembrane and cytoplasmic domains which enable it to become a decoy re-
ceptor that can competitively bind and sequester ligands such as VEGF165 and 
Sema3A to inhibit their signaling process. NRP2 also exists as membrane-bound 
NRP2a and NRP2b and soluble sNRP2 isoforms. NRP2a share 44% homology 
with NRP1 at amino acid level. The C-terminal three amino acids, SEA, present 
in NRP1 and the NRP2a isoform, form a consensus PDZ domain-binding motif, 
which mediates association with PDZ domain proteins such as NIP1 (neuropilin-
interacting protein-1), synectin and GIPC (RGS-GAIP-interacting protein). NRP2b 
is identical to NRP2a in its extracellular domain but has 11% homology at trans-
membrane and cytoplasmic domains. The difference in the cytoplasmic domains 
of NRP2a and NRP2b may suggest their diverse physiological and pathological 
functions. Expression of NRP2a and NRP2b is high in brain and NRP2a is specif-
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ically expressed in the liver, lung, small intestine, kidney, and heart but NRP2b is 
restricted to heart and skeletal muscle. NRP2a exists as splice variants such as 
NRP2a (17), and NRP2a (22) in humans, and NRP2a (0), NRP2a (5), NRP2a 
(17), and NRP2a (22) in mice. These splice variants are a result of insertion of 0, 
5 and 17 amino acids after 809 residues located between the MAM and trans-
membrane domains. NRP2a (22) is a derivative of NRP2a (17) with five addition-
al amino acids. NRP2b as a result of alternate splicing has insertion of 0 and 5 
amino acid residues after residue 808 (NRP2b (0) & NRP2b (5)). Along with 
these membrane-bound splice variants, there exists s9NRP2 (1785 bp, 555 ami-
no acids, 62.5 kDa) consisting of the two a1/a2 domains the b1 domain and a 
truncated b2 domain followed by the nine amino acids VGCSWRLPL encoded by 
intron 9 (Fig. 1.12).81 
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Figure 1.12: NRP basic structure and splice variants. 
Obtained from Sohini Roy et. al. Multifaceted Role of Neuropilins in the Immune System: Potential Targets 
for Immunotherapy. Front Immunol. 2017 Oct 10;8:1228. 
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Neuropilins transduce signals for all five VEGFs along with three VEGFR mem-
bers of VEGF family. Knockout of NRP1 in mice demonstrates significant cardio-
vascular and neuronal dysfunction along with defect in angiogenesis causing 
embryonic lethality. In addition, overexpression of NRP1 also causes embryonic 
lethality due to hypervascularization. The vascular phenotype of NRP1 depletion 
in mice coincides to that of VEGF-A heterozygous mice and knockout of VEGR-
2. NRP1 works in cooperation with VEGF-A/ VEGF-R2 to promote angiogenesis 
and NRP1 localizes to the endothelial tip cells for their fate determination. It func-
tions downstream of Notch and limits BMP9 and TGF- signaling in tip cells. 
Specifically, isoforms of VEGF i.e. VEGF165 binds VEGFR2 induces cell prolif-
eration and migration and these functions are enhanced by the complexing with 
NRP1. NRP1 also interacts with VEGF-B and PIGF-2 via VEGF-R1 and VEGF-E 
through VEGF-R2 to promote cell migration and mitogenic activity. NRP1 has 
been reported to function as a receptor for extracellular microRNAs (miRNAs) 
commonly found in biological fluids and circulate either in encapsulated form or 
bound to protein argonaute-2 (AGO2). NRP1 binds AGO2/miRNA complexes to 
facilitate their cellular internalization, which may have consequences under nor-
mal and pathophysiology. NRP2 is reported to bind to VEGF-A isomers, 
VEGF165 and VEGF145 to promote vascular development. NRP2 also associ-
ates with VEGF-C and VEGF-D to a lesser extent along with VEGF-R2 to induce 
angiogenesis and with VEGF-R3 to promote lymphangiogenesis (Fig. 1.13).82 
  
 




Figure 1.13: NRPs and their binding partners-VEGF family growth fac-
tors. 
Obtained from Christian Lange et. al. Vascular endothelial growth factor: a neurovascular target in neuro-
logical diseases. Nature Reviews Neurology  vol12, pages439–454 (2016). 
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NRPs are known for their role in neuronal guidance. For this, they act as modu-
lates with dual binding sites, one for semaphorin (ligand) and the second for plex-
in (receptor). Class III semaphorins are reported to bind to the a1/a2/b1 domain 
of NRP1 or NRP2 with different affinities and specificities and form a holorecep-
tor complex with NRPs and PlexinA1 or PlexinA2. A unique feature of class III 
semaphorins is that they bind to NRPs but not to plexins and thus NRPs act as 
mediators of semaphorin - plexin signaling. NRP1 binds all class III semaphorins 
with high affinity for Sema3A to modulate growth cone collapse activity. NRP2 
mainly binds to Sema3F, but not 3A and Sema3C with low affinity and plexinA3 
to facilitate selective axonal guidance of neurons. Recent report on NRP2 con-
cluded that Sema3F-NRP-2/PlexA3 signaling controls both synapse development 
and synaptic plasticity (Fig. 1.14)82 
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Figure 1.14: NRPs and Semaphorin-Plexin signaling. 
Obtained  from Caroline Pellet-Many et. al. Neuropilins: structure, function and role in disease. 
Biochem J. 2008 Apr 15;411(2):211-26.  
 
55 | P a g e  
 
Neuropilins in normal bone and prostate cancer bone metastasis. 
In the bone, Neuropilins are expressed by both osteoblasts and osteoclasts. Re-
ports by Hayashi et al. suggested that NRP1 binds Sema 3A released by osteo-
blasts impairs immunoreceptor tyrosine-based activation motif (ITAM) and 
RhoA signaling to inhibit the RANKL-induced osteoclastogenesis. Interestingly, 
they also reported that Sema3a−/− or Nrp1Sema– mice showed severe dysfunc-
tion of osteogenesis with increase osteoclast and adipocyte number and that 
Sema 3A works via canonical Wnt signaling in part through FARP2-mediated 
Rac1 activation during osteogenesis.83 Further, binding of NRP1 with PlexinA1 
via discoidin domain receptor 2 resulted in the inhibition of osteoclast differentia-
tion and function. In human peri-prosthetic osteolysis (PPO) samples, high NRP1 
expression in osteoclasts was observed suggesting its role in the disease.84 
Osteoblasts, as well as osteoclasts, also express NRP2. Evidence from the com-
parison of the bones from Nrp2+/+ and Nrp2−/− mice showed a reduction in tra-
becular bone mass characterized by decreased osteogenesis but increased os-
teoclast number in NRP2 deficient mice. However, no study has been conducted 
to understand the exact molecular mechanism/s through which NRP2 functions 
to regulate bone homeostasis. In pathological conditions such as osteosarcoma, 
RNA levels of NRP2 were highly elevated and correlates with hypervascularity 
and poor prognosis.85 Cumulatively, NRP2 is crucial for the functioning of bone 
cells (both osteoblasts and osteoclasts), but the exact mechanism of action is still 
unknown. 
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Multiple studies on NRP2 has shown that NRP2 provides chemoresistance to 
prostate cancer cells during therapy and that removal of NRP2 from the prostate 
cancer cells sensitizes them to chemotherapeutic drugs. Evidence from the stud-
ies by HL Goel et al. indicated that NRP2 is expressed by prostate cancer stem 
cells and when bound to VEGF causes the activation of PREX-RAC1-ERK sig-
naling leading to ineffectiveness of anti-VEGF therapy (bevacizumab) on prostate 
cancer stem cells.86 Further, these chemoresistant prostate cancer cells can pro-
gress and metastasize to different organs specifically to bone. In the bone, pros-
tate cancer cells home to hematopoietic niche where they induce osteoclast dif-
ferentiation and activation to release growth factors trapped in the bone matrix 
necessary for their survival and advancement into osteoblastic metastasis. As 
osteoclast activation precedes the osteogenesis in prostate cancer bone metas-
tasis, targeting osteoclast function can prove to be beneficial during therapy. Fur-
ther, NRP2 is expressed by osteoclasts suggesting its role in bone homeostasis. 
Since, metastatic prostate cancer cells dysregulate bone homeostasis, it would 
be essential to understand the role of NRP2 in osteoclasts in promoting prostate 
cancer bone metastasis. 
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General objectives and Hypothesis 
Over the past few decades, multiple studies have established vital roles of NRP2 
in malignant diseases such as prostate cancer, breast cancer, osteosarcoma and 
colon cancer.87-89 The expression of NRP2 is significantly altered during the pro-
gression, metastasis, and chemoresistance of prostate cancer. This propagated 
a question as to what role does NRP2 have in the bone which is the most com-
mon site for mCRPC to metastasize. Specifically, little is known about the func-
tion of NRP2 in the tumor-bearing bone microenvironment, i.e., the NRP2 ex-
pressing- bone cells which interact with cancer cells during colonization and de-
velopment of overt bone metastasis. Previous reports on NRP2 suggested its 
role in the regulation of bone homeostasis in a healthy bone by explicitly control-
ling osteoclast differentiation and activation while promoting osteogenesis.85 Alt-
hough, mCRPC promotes hyperactivation of osteoblasts, osteoclasts are the first 
cells which are activated by mCRPC in the hematopoietic niche and NRP2 may 
have a crucial role in the regulation of osteoclast function to promote osteoblastic 
bone metastasis.71 Hence, a comprehensive understanding of the role of NRP2 
in osteoclasts in promoting prostate cancer bone metastasis can aid in develop-
ing a successful treatment strategy. The focus of my study is to understand the 
function of NRP2 in osteoclasts in prostate cancer bone metastasis. I hypothe-
sized that mCRPC induces NRP2 expression in OC and is necessary for promot-
ing prostate cancer bone metastasis. 
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Our study therefore can address whether NRP2 on osteoclasts can be targeted 
for therapy in prostate cancer patients with bone metastasis which is incurable. 
Altogether, the objectives of my dissertation research are: 
1.    To investigate the role of NRP2 in osteoclasts in promoting prostate cancer 
bone metastasis. 
2.    To elucidate the molecular mechanisms of NRP2 in regulating the osteoclas-
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CHAPTER 2A: Materials 
Prostate cancer cell lines 
Bone metastatic prostate cancer cell line, LNCaP C4-2B was kindly gifted by Dr. 
Donald Tindall, and PC3 bought from ATCC. LNCaP C4-2B is a selected deri-
vate of a human prostate cancer cell line, LNCaP. These cells were isolated from 
metastatic prostate cancer lesions found in the lumbar spine of an athymic 
mouse. The mouse implanted with LNCaP C4-2 and by selective mechanism 
caused bone metastasis. LNCaP C4-2B has faster growth rate when compared 
to its parental cell line and is osteoblastic with low osteolytic function. Hence, 
LNCaP C4-2B provides a model to explore the mechanisms of osteoblastic le-
sions in prostate cancer. 
PC3 (purchased from American type culture collection) is one of the most com-
monly used human prostate cancer cell line used in studying bone metastasis. It 
was derived from human bone metastasis and produce osteolysis and metasta-
size to femur, tibia, rib, pelvis, mandibles and lymph nodes in NOD/SCID mice 
after orthotopic or intracardiac injection. As PC3 is purely osteolytic in nature, it 
can be an ideal model for studying the function of osteolysis in prostate cancer 
bone metastasis. 
Mouse models 
All Mice used in this study were maintained under specific pathogen-free condi-
tions. All procedures performed were in accordance with institutional guidelines 
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and approved by the University of Nebraska Medical Center Institutional Animal 
Care and Use Committee (IACUC). Our study used two different mouse models, 
C57BL/6 and Transgenic CSF1R-cre; NRP2 Flox/Flox mice. 
C57BL/6: These mice were purchased from Charles river at the age of 6-10 
weeks for isolation of bone marrow. 
Generation of transgenic CSF1R-cre; NRP2 Flox/Flox mice: The NRP2flox/flox 
mouse was developed Max Planck Research Unit for Neurogenetics by Dr. Peter 
Mombaerts. These mice were initially generated by insertion of Nrp2 targeted 
mutation in 129P2/OlaHsd derived E14 ES cells and had a loxP-tauGFP-pA+-
FNF cassette inserted into the first intron and a corresponding loxP site inserted 
upstream of the start codon. The generated mice were bred with Tg(ACTB-
flp)4917Dym to remove FRT-flanked neomycin resistance sequence (FNF) which 
yielded Nrp2tm1.1Mom targeted mutation in a mixed background that is predom-
inantly 129P2 and C57BL/6. Our research collaborator in University Hospital 
Bonn, Germany, Dr. Michael Muders bred these mice with C57BL/6 to get pure 
background mice and gave them as a kind gift to us. The transgenic FVB- 
Tg(Csf1r-Mer-iCre-Mer)1Jwp/J mice were purchased from Jackson Laboratories. 
These mice were initially developed by Dr. Jeffrey W Pollard, Albert Einstein Col-
lege of Medicine, NY. A transgenic construct containing tandem copies of 
icre/Esr1*, or Mer-icre-Mer, under the control of the mouse Csf1r, colony stimu-
lating factor 1 receptor, promoter, was injected into fertilized FVB/N mouse eggs. 
The founder line 1 was established and submitted to the Jackson Laboratory 
where they were crossed with FVB/NJ to establish the colony. These mice ex-
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press a Cre recombinase/mutant murine estrogen receptor double-fusion protein 
under the control of the Csf1r (colony stimulating factor 1 receptor) promoter. The 
MerCreMer double fusion protein consists of Cre recombinase flanked on each 
end with a mutated murine estrogen receptor (mer) ligand binding domain (amino 
acids 281-599, G525R); which does not recognize its natural ligand (17'-
estradiol) at physiological concentrations but will bind with higher affinity to the 
synthetic estrogen receptor ligands 4-hydroxytamoxifen (OHT or tamoxifen) and, 
with lesser sensitivity, ICI 182780. Restricted to the cytoplasm, MerCreMer can 
translocate from cytoplasm to the nuclear compartment only after exposure to 
tamoxifen. When these Tg(Csf1r-Mer-iCre-Mer)1Jwp mice are bred with mice 
containing a loxP-flanked sequence of interest, tamoxifen-inducible, Cre-
mediated recombination will result in deletion of the flanked sequences in Csf1r-
expressing cells specifically myeloid lineage cells. 
For our research, the CSF1R-cre; NRP2 Flox/Flox mice in a pure background 
were generated by a three-step breeding process. The first step involved back-
crossing of FVB-Tg(Csf1r-cre/Esr1*)1Jwp/J (CSF1R- Cre) mice with C57BL/6 
pure background mice. Backcrossing was done for at least seven generations. 
This step enables the generation of 80% pure background CSF1R-Cre mice. The 
second step involves breeding of CSF1R- Cre with Nrp2tm1.1Mom/MomJ 
(NRP2flox/flox) to generate transgenic mice with CSF1R-Cre; NRP2flox/+ geno-
type. These mice were then bred with NRP2flox/flox mice to obtain CSF1R-Cre; 
NRP2flox/flox mice. The generated transgenic mouse (CSF1R-Cre; NRP2flox/flox) 
expresses a tamoxifen-inducible Mer-iCre fusion protein driven by the Csf1r pro-
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moter which upon administration with either tamoxifen intraperitoneally (75 
mg/Kg body weight) in mice or (Z)-4-Hydroxytamoxifen in-vitro leads to activation 
of Cre recombinase. The Cre recombinase targets the deletion of NRP2 in the 
loxP-flanked regions. The ablation of NRP2 occurs in myeloid cells as they spe-
cifically express CSF1R. These transgenic mice are ideal for studying the osteo-
clast-related functional as well as molecular mechanisms in physiological and 
pathological conditions (Fig. 2.1) 
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Reagents 
RPMI 1640 medium, DPBS, 0.25% (w/v) Trypsin, MEM Non-Essential Amino Ac-
id solution (100X), sodium pyruvate (100 mM), HEPES (1 M) and Penicillin-
Streptomycin (5,000 U/ml) were procured from ThermoFisher Scientific. Minimum 
Essential Medium (MEM) Alpha Medium (10-022-CV) was purchased from Corn-
ing. Fetal bovine serum and goat serum were obtained from GIBCO. 
Antibodies such as NRP2 (D39A5), NF-KB (D14E12), -Actin (D6D8), Histone 
H2A (D603A) were purchased from Cell signaling technology, NFATc1 (7A6) 
from ThermoFisher Scientific, HDAC1(ab7028) from Abcam, Rho-GDI (C2, sc-
374579) and HSC70 (B-6, sc-7298) from Santa Cruz Biotechnology. Secondary 
antibodies were ordered, i.e., goat anti-rabbit IgG-HRP (sc-2004) from Santa 
Cruz Biotechnology and sheep anti-mouse IgG-HRP (AC111P) from EMD Milli-
pore. Secondary antibodies conjugated with Alexa fluor such donkey anti-rabbit 
Alexa Fluor 546 for NF-B (cat.no.- A10040) and goat anti-mouse Alexa Fluor 660 
for NFATc1 (cat.no. – A21054) were obtained from ThermoFisher Scientific. siR-
NA against mouse NRP2 and non-targeting control (ON-TARGET plus, smart 
pool) was bought from Dharmacon. Recombinant murine M-CSF (315-02) and 
RANK Ligand (315-11) were acquired from Peprotech. TRAP staining kit was 
purchased from Cosmo bio (PMC-AK04F-COS) and Osteo assay surface micro-
plates (24-well, #3987) from Corning. Reagents such as (Z)-4-Hydroxytamoxifen 
(H7904), HEPES, KCl, DTT, NP-40, Glycerol, MgCl2, EDTA, PMSF, cyclosporine 
A, protease inhibitors such as aprotinin, and leupeptin were purchased from 
Sigma-Aldrich. Halt, Trizol and Powerup SYBR Green master mix were bought 
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from ThermoFisher Scientific.  cDNA kit was obtained from Roche and primers 
from IDT. The primer sequences are listed in Table. 
CHAPTER 2B: Methods 
Cell culture 
Prostate cancer cell lines 
PC3 and LNCaP C4-2B were cultured in RPMI complete medium supplemented 
with 10% fetal bovine serum and antibiotics (Penicillin-streptomycin). Upon con-
fluency, these cells were washed with DPBS and either brief rinse (LNCaP C4-
2B) or treated with 0.25% (w/v) Trypsin-EDTA (PC3) to detach the cells from the 
plate. The cells were collected in equal volumes of complete medium to neutral-
ize the effect of trypsin. The cells were pelleted by centrifugation at 1000 g for 5 
mins. The cells are then suspended in fresh complete media and plated in a T-
175 flask and cultured in a tissue culture incubator maintained at 37 0C and 5% 
CO2. 
Collection of conditioned medium 
To collect conditioned medium from PC3 and LNCaP C4-2B, the 1 x 106 cells 
were plated in a T-75 culture flask and allowed to grow until 70% confluency. 
Once 70% confluent, the cells were washed with DPBS to remove any traces of 
exhausted medium and 5 ml of fresh serum-free RPMI complete medium is add-
ed to the flask. The cells were then incubated for another 24hrs to collect condi-
tioned medium. After obtaining the conditioned medium, it was centrifuged at 
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1000 g for five mins to remove cells and cell debris from the medium and filtered 
using 0.45 m filter to remove any residual debris remaining after centrifugation. 
The conditioned medium was either used fresh for experiments or aliquoted in 
small volumes based on usage and stored at -80 0C for future use. 
Isolation of mouse bone marrow-derived osteoclasts 
Mouse osteoclastic precursors were isolated from 6-10 weeks old C57BL/6 male 
mice and transgenic mouse model (CSF1R-Cre; NRP2flox/flox) after euthanizing 
and cervical dislocation. Long bones from the mice were harvested, and the bone 
marrow was collected in centrifuge tubes by flushing the bones with a 30 ml sy-
ringe with needle containing DPBS.  The remaining processing was done in ster-
ile conditions. The bone marrow was subjected to centrifugation at 2000 g for ten 
mins. The pellet obtained was suspended in MEM alpha medium containing 10% 
fetal bovine serum, 1% antibiotic, 1% sodium pyruvate, 1% MEM Non-Essential 
Amino Acid and HEPES (pH 7.4). The cells are then filtered through a cell strain-
er of 70 µM pore size to remove fibrous cellular debris and make a single cell 
suspension. The cell suspension was then centrifuged, and the pellet was then 
subjected to Ficoll-Paque gradient to isolate mononuclear cells. These cells were 
plated in MEM alpha complete medium containing 10 ng/ml of recombinant mu-
rine M-CSF and cultured overnight to separate macrophages (which will attach to 
the surface of the plate), and the non-adherent cells were harvested to be used 
as osteoclastic precursors for all the experiments (Fig.2.2). 
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Figure 2.2: Procedure for isolation of osteoclast precursors and their differen-
tiation under different conditions.  
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For our research study, three different culturing conditions were applied to mimic 
the osteoclasts in physiological and pathological bone metastasis. To understand 
the differentiation and function of osteoclasts in healthy bone, the osteoclastic 
precursors were differentiated into osteoclasts by addition of 20 ng/ml of recom-
binant M-CSF and 100 ng/ml of recombinant RANK Ligand for seven days with a 
boost of growth factors every alternate day from the start of the experiment.  In 
the case of bone metastasis, conditioned media collected from metastatic pros-
tate cancer cell lines, PC3 and LNCaP C4-2B (20% v/v) were mixed with MEM 
alpha complete medium separately. (Various reports have been published on the 
use of conditioned media in osteoclast differentiation, but none of these reports 
presented an exact method of conditioned media isolation and use. Hence, 
standardization was conducted to check their effect on osteoclast differentiation 
with different concentrations of conditioned media. The osteoclastic precursors 
are plated in these media separately to differentiate into osteoclasts. Every con-
secutive day, a boost either with RANKL and M-CSF or conditioned media was 
added. On day 7, the mature osteoclasts from all the three conditions were then 
used for isolation of protein or RNA based on the experiment conducted 
(Fig.2.2).  
Depletion of NRP2 using RNA interference and knockout model 
After isolation of osteoclastic precursors from C57BL/6 mice, these cells were 
depleted of NRP2 by using Lonza nucleofector kit (VPA-1007) and nucleofector 
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2b device. The procedure followed for nucleofection was as per the manufactur-
er’s protocol. 25 nM of NRP2 and scrambled siRNA were used. After nucleofec-
tion, the osteoclast precursors were maintained in nucleofector solution contain-
ing medium for 8 hrs after which MEM alpha complete medium containing either 
M-CSF and RANK Ligand or conditioned medium from prostate cancer cell lines 
was added to each plate and allowed to differentiate for seven days. 
Osteoclastic precursors isolated from transgenic mice, CSF1R-Cre; 
NRP2 f lox/ f lox were treated with 0.3 M/ml of (Z)-4-Hydroxytamoxifen to de-
plete NRP2 from osteoclasts specifically. A parallel set of osteoclastic precursors 
where no (Z)-4-Hydroxytamoxifen was added as control for each experiment. 
The control and knockout osteoclastic precursors were then differentiated into 
mature osteoclasts (7 days) either with M-CSF and RANK Ligand or conditioned 
medium from prostate cancer cell lines. 
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Figure 2.3: Depletion of NRP2 using siRNA and addition of hydroxytamoxifen 
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Tartarate-resistant acid phosphatase staining 
 
 
To confirm the presence of osteoclasts, TRAP staining was conducted. For better 
understanding of the differentiation pattern, osteoclasts were stained from day 4 
to day 7 of differentiation. TRAP staining kit was purchased from CosmoBio 
(Cat.no. - PMC-AK04F-COS) and stored at 4C. Briefly, monocytes were differ-
entiated using standard as well as conditioned media treatment in 24- well plate. 
On day 4, cells were washed with PBS twice to remove any traces of media and 
unattached cells. The attached osteoclasts were fixed with 10% Formalin at room 
temperature for 10 mins. The osteoclasts were then washed three times with ex-
cess deionized water. The kit contains lyophilized vials of chromogenic substrate 
and Tartrate-containing buffer. For each vial of substrate, 5ml of Tartrate-
containing buffer was added and mixed thoroughly. To each well of 24- well 
plate, 150 l of the chromogenic substrate was added and incubated at 37C for 
1-2 Hrs. based on the time taken by the osteoclasts to stain for TRAP. After 
completion of 1-2 Hrs., the cells were washed with deionized water to remove the 
substrate and stop the reaction. 2 or more nucleated TRAP-positive cells were 
counted and compared between control and NRP2-depleted osteoclasts under 
all three conditions and a mean and standard error of mean was calculated and 
represented graphically. This procedure was repeated until day 7 of osteoclast 
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Pit formation assay 
Pit resorption is a function of activated osteoclasts. Osteoassay plates (24 – well) 
were bought from Corning Inc. (cat.no. - 3987). These plates are coated with in-
organic bone biomimetic synthetic surface that allows the assessment of the at-
tachment, differentiation, and function of osteoclasts. Monocytes derived from 
bone marrow of mice were plated in each well of the osteoassay plate under dif-
ferent conditions to analyze the efficacy of the conditions inactivation of osteo-
clasts. On day 4 along with TRAP staining, the pit formation was also assessed. 
To visualize the pits, 10% bleach diluted in deionized water was added for 10 
mins at room temperature to remove cells from the plate. Each well was washed 
with deionized water and dried for 3 to 5 hrs at room temperature. Pit clusters 
were observed and captured using phase contrast microscope. Images obtained 
were analyzed for the measurement of coated surface resorbed using photoshop 
(magic wand tool). The percent surface area resorbed was calculated and plotted 
with standard deviation under different treatment conditions. Pit assays were 
done thrice for statistical significance. 
Immunobloting 
For protein analysis, osteoclasts were washed with PBS to remove any traces of 
media. The cells were lysed with ice cold lysis buffer containing CHAPS buffer 
pH 7.4 (40 mM HEPES, 0.3% CHAPS, 10 Mm  - Glycerophosphate, 10 mM so-
dium pyrophosphate, 2 mM EDTA) and combination of protease inhibitors, 20 
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µg/mL Leupeptin, 10 µg/mL Aprotinin, 1mM PMSF and Halt protease. The cells 
were scraped using cell scraper and ultrasonicated to lyse the cells. 
For separation of nuclear and post-nuclear fraction in osteoclasts, 250 µL of buff-
er A (10 mM HEPES pH 7.8, 10 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 10 µg/mL 
Leupeptin, 10µg/mL Aprotinin, 3 mM DTT, 1mM PMSF and Halt protease) was 
added to each sample and incubated on ice for 17 mins. 20 µL of 10% NP- 40 
detergent was added to each sample containing buffer A and vortexed for two 
mins and centrifuged at 14,000 RPM for five mins. The supernatant containing 
the post-nuclear proteins was separated from the pellet and labeled for protein 
analysis. The pellet was resuspended in 50 µL of buffer C (50 mM HEPES pH 
7.8, 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 10% (v/v) glycerol, 10 µg/mL 
Leupeptin, 10µg/mL Aprotinin, 3 mM DTT, 1mM PMSF and Halt protease) and 
vortexed and placed on a rotating rack for 1 hour to dissolve the pellet containing 
the nuclear proteins. The dissolved pellet was then centrifuged at 14000 RPM for 
10 mins. The supernatant containing the nuclear proteins was separated from the 
pellet which contains DNA. 
Total protein was estimated using Bradford reagent and calculated for the re-
quired concentration of protein for analysis by western blot. The samples were 
prepared by the addition of SDS sample buffer containing -mercaptoethanol and 
boiled at 95 ºC for five mins to denature the protein complexes. The prepared 
samples were then loaded on a precast 4–20% Mini-PROTEAN® TGX™ Gel 
(BioRad) and run alongside a protein loading marker ladder as reference. After 
the completion of the run, the proteins on the gel are transferred on to a PVDF 
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membrane (Life Technologies) and stained with Ponceau dye for confirmation of 
proper transfer. The membrane was then blocked in 5% non-fat dry milk in 1X 
TBST (1X Tris Buffered Saline, 0.1% Tween-20) for at least 30 mins following 
which primary antibody diluted in 1X PBS was added and incubated overnight at 
4ºC with continuous shaking at low speed. On the next day, membrane was 
washed with 1X TBST for four times for 5min and incubated in appropriate dilu-
tion of secondary antibody conjugated with HRP for 1hr in 1X TBST with continu-
ous shaking at low speed at room temperature. The membranes were washed in 
1X TBST every 5min for at least 5-7 times, and the protein bands were detected 
using a combination dilution of SuperSignal™ West Femto Maximum Sensitivity 
Substrate and SuperSignal™ Pico Maximum Sensitivity Substrate which was 
captured on an X-ray film. The X-ray film was developed using a Kodak film de-
veloper, and the protein bands were identified and compared and presented as 
an image using ImageJ software. 
RNA isolation 
On day 7, osteoclasts were washed twice with PBS. Total RNA was isolated by 
adding 1mL of TRIzol Reagent (ThermoFisher Scientific, CA) per 1 million cells 
as per manufacturer’s protocol and gently scraped using cell scraper and collect-
ed in 1.5 mL microcentrifuge tubes and allowed to stand for 5mins at room tem-
perature. Each tube was then added with 300 l of chloroform and mixed well by 
inverting the tubes for 20 seconds and allowed to stand for 5mins at room tem-
perature following which they were centrifuged at 12000 rpm for 15mins at 4ºC. 
The clear layer was extracted without disturbing the cellular layer and collected 
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into fresh tubes. To this, 500 µL isopropanol and 1 µL of Glycogen (RNA graded 
from Invitrogen) were added and mixed. The samples were allowed to stand for 
5mins at room temperature. The samples were then centrifuged at 12000rpm for 
15min at 4ºC. The supernatant was discarded without disturbing the pellet and 
1mL of 75% ethanol was added to wash the pellet and centrifuged at 7500rpm 
for 5mins at 4ºC. The wash with 75% ethanol was repeated twice to ensure re-
moval of salts and impurities. The supernatant was decanted, and the pellet was 
air-dried briefly to remove traces of alcohol. The pellet was resuspended in re-
quired amount of RNAase-free DNAase-free distilled water. The concentration 
and quality of the RNA were analyzed using Nanodrop Spectrophotometer. The 
RNA was either stored at -80ºC until use or processed immediately for cDNA 
synthesis. 
cDNA was synthesized with Transcriptor First strand cDNA synthesis kit (Roche 
Diagnostics Corporation) as per the instructions provided by the manufacturers. 1 
g RNA was used to generate cDNA. 
Real-time quantitative PCR 
For real-time PCR, cDNA (50ng) was used, and each reaction was performed in 
duplicates in 25 μl volume in a 96-well PCR plates using SYBR green detection 
system (Applied Biosystems Group) in an ABI 7500 Fast and Real-Time PCR (2 
min at 50°C, 10 min at 95°C and 40 cycles of 15 s at 94°C and 1 min at 60°C) 
with 200-300 nM concentration of primers. The list of the primers used in this 
study is listed in Table 1. The expression was calculated relative to that of control 
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cells and normalized with 36B4 measured under the same conditions (Applied 
Biosystems/Roche, Branchburg, NJ), using the 2–ΔΔCT method. 
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Gene        Primer sequence 
36B4 
F: 5’   ATGCAGCAGATCCGCATGT   3’ 
 
R: 5’  TCATGGTGTTCTTGCCCATCA  3’ 
 
NRP2 
F: 5’  GTGAAGAGTGAAGAGACTACCA   3’ 
 
R: 5’  GCTGAAGTTTTCCCCACACT   3’ 
 
DC-STAMP 
F: 5’  GTATCGGCTCATCTCCTCCA   3’ 
 
R: 5’  ACTCCTTGGGTTCCTTGCTT   3’ 
 
Car II 
F: 5’   ATTGGACCTGCCTCACAAGG   3’ 
 
R: 5’  CCACATGAGACACCTGGGTC   3’ 
 
MMP9 
F: 5’   CGTCTTCCCCTTCGTCTTCC   3’ 
 
R: 5’  TGTCTGCCGGACTCAAAGAC   3’ 
 
ATP6V0D2 
F: 5’   AGAGGGGTTGCGGTTGTTAG  3’ 
 
R: 5’  GCCAGTGAGCAGGAAGTCAT   3’ 
 
RANK 
F: 5’  CAAACCTTGGACCAACTGCAC    3’ 
 
R: 5’  TGGTCTCCTCAGTGTCATGGAAG  3’ 
 
TRAP 
F: 5’  TACTTCACTGGAGTGCACGAT   3’ 
 
R: 5’  GAAGTTCCAGCGCTTGGAGA  3’ 
 
Cathepsin K 
F: 5’  GAGGGCCAACTCAAGAAGAA  3’ 
 
R: 5’  GCCGTGGCGTTATACATACA   3’ 
  
Table 1: List of primers used in real-time PCR. 
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Enzyme-linked immunosorbent assay (ELISA) 
Human M-CSF and GM-CSF Quantikine ELISA kits were procured from R&D 
systems (cat.no. - DMC00B, DGM00 respectively) and Human RANKL from 
Abcam (cat.no. - ab213841) to measure the amount of these cytokines in the 
conditioned media obtained from PC3 and LNCaP C4-2B cell lines. The assays 
were conducted according to the standard protocol provided by the manufactur-
er. Briefly, microplates coated with monoclonal antibody specific for human M-
CSF and GM-CSF were supplied with the kits. Standards and samples (Condi-
tioned media) were added into the wells to allow the binding of the growth factors 
present in the conditioned media. Unbound cytokines were washed, and the an-
tibody specific for these growth factors were added. Following this, the antibody 
was removed followed by washing, and substrate solution was added to the wells 
and incubated until color developed. The color development was stopped, and 
the intensity of the color was measured at 450nm. For wavelength correction, 
readings were obtained at 540 nm or 570 nm, and these reading were subtracted 
from readings at 450 to correct optical imperfections of the plate. 
Cytokine profiling assay 
To detect the expression levels of cytokines and chemokines in the conditioned 
media, proteome profiler array (human cytokine array panel A, cat.no. ARY005) 
from Abcam was used. According to the array procedure, the nitrocellulose 
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membranes containing 36 different capture antibodies was blocked with blocking 
buffer. In separate sets, 1mL of each conditioned medium was diluted with array 
buffer and antibody cocktail was added to the solution and incubated for one hr. 
The blocking buffer was removed from the membranes and the solution contain-
ing the conditioned media and the antibody cocktail was added and incubated on 
a rocking platform shaker overnight at 4°C. On the following day, the membranes 
were washed with washed buffer thrice and 2 mL of the solution containing strep-
tavidin-HRP was added to the membranes and incubated at room temperature 
for 30 mins on a rocking platform shaker. The membranes were washed three 
times with wash buffer and chemiluminescent detection reagent mix were added 
sequentially. The light produced at each spot in the membrane is proportion to 
the amount of cytokine bound which was captured on an x-ray film and devel-
oped using an x-ray film developer. The positive signals obtained were identified 
by placing the transparency overlay template on the array image and aligning it 
with the pairs of reference spots on the array membranes. The identifies cyto-
kines and chemokines were measured for their pixel density to compare the dif-
ference in the expression pattern in the conditioned media using imageJ software 
and represented as a graph with statistical significance.  
Immunofluorescence   
Osteoclasts grown in the three different conditions were stained for the detection 
of translocation of NF-B and NFATc1 from cytoplasm to the nucleus. The cells 
were grown in glass chamber slides for better attachment and convenience of 
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staining. Based on the requirement of the study, osteoclasts from day 2 or day 3 
of differentiation were used for the immunostaining. To prepare the cells for im-
munofluorescence, osteoclasts were washed with 1X PBS three times and fixed 
with 4% buffered formaldehyde for 15 mins. The cells were washed thoroughly 
thrice with 1X PBS. The blocking buffer containing 0.3% TritonX-100 and 5% 
goat serum in 1X PBS was added for one hour to block nonspecific binding of 
primary antibody. The primary antibody (1:500 dilution) prepared in the blocking 
buffer was added to the cells and incubated overnight at 4°C. On the next day, 
the cells washed three times with 1X PBS containing 0.3% TritonX-100 and incu-
bated in the secondary antibody (Alexa-546 for NF-B and Alexa-660 for NFATc1) 
diluted 1:1000 in 0.3% TritonX-100 and 5% goat serum in 1X PBS for one hour at 
4°C in the dark. After completion of secondary antibody incubation, the cells were 
washed with 1X PBS containing 0.3% TritonX-100 at least four times to decrease 
non-specific background. The cells were finally mounted with mounting solution 
containing DAPI and covered with a glass coverslip and sealed. The cells were 
stored in 4°C in the dark and were observed using Zeiss LSM 800 with Airyscan 
microscope located in the UNMC confocal core facility, and data were analyzed 
and processed with the Zeiss Zen 2010 software. All confocal data were ana-
lyzed using Adobe Photoshop and quantified using ImageJ software and graph-
ical illustrations made using GraphPad Prism software. 
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Statistical significance 
Data are presented as mean ± standard error of the mean (SEM). Statistical 
analysis was performed using the standard two-tailed Student’s t-test using 
PRISM-6 software (GraphPad Inc.). Statistical comparisons of more than two 
groups were performed using unpaired student t-test. In all cases, a P < 0.05 was 
considered as highly significant. 
  
 











NRP2 regulates osteoclastic differentiation and activation in promoting 
prostate cancer bone metastasis  
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Introduction 
Prostate cancer (PCa) is one of the most frequently diagnosed cancers and is 
the second leading cause of cancer-related deaths in men in the United States. 
The incidence of PCa will likely continue to increase with the aging population. 
Early detection of prostate cancer in patients can lead to successful medical in-
tervention by use of treatment strategies such as radiotherapy and prostatectomy 
leading to 100% survival rates11. However, in patients with the locally advanced 
stage of PCa, androgen deprivation therapy is the standard treatment strategy12. 
Although the hormonal treatment is effective in inhibiting the progression of PCa, 
the disease attains resistance and becomes castration-resistant PCa (CRPC) 
within 18 to 24 months of the therapy7. Patients with CRPC have a poor progno-
sis and a predicted survival rate of fewer than two years from the initial time of 
progression, comprising a significant portion of the prostate cancer-related 
deaths per year. Currently, CRPC is an incurable disease and represents a sig-
nificant clinical hurdle. 
Bone is the most common site for the CRPC to metastasize with 70-80% of the 
advanced stage PCa patients developing skeletal metastases. Patients with bone 
metastasis suffer from severe bone pain, pathologic fractures, spinal cord and 
nerve compression syndromes, hypercalcemia, and increased mortality. Radio-
graphic studies of PCa characterized bone metastases promoted by PCa as os-
teoblastic lesions as opposed to osteolytic lesions with decreased bone mineral 
density69. However, it is lucid from the histological evidence that PCa bone me-
tastases show a complex blend of osteoblastic and osteolytic functions with the 
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balance shifted to favor pronounced osteoblastic metastasis13,68,76. PCa bone 
metastases are resistant to most of the commonly available therapies. Current 
treatment strategy for PCa patients with metastatic bone disease includes tax-
ane-based chemotherapy which can effectively limit the progression of the dis-
ease for a short-term but eventually relapses within the first year of 
treatment68,73,80.  Till date, bone metastases remain to be a frequent and incura-
ble complication in PCa patients and its management is clinically challenging and 
requires the identification of the new molecular target(s) that can be therapeuti-
cally exploited to improve patient outcome. 
The occurrence of metastatic bone disease is a result of interaction between 
cancer cells and the bone cells namely osteoblasts, osteoclasts, and osteocytes 
which contribute to a vicious cycle that provides fertile soil for the metastatic 
growth of cancer cells in the bone. Metastatic prostate cancer cells secrete 
growth factors and cytokines to stimulate bone cells. Osteoblasts are activated 
due to the release of these growth factors and cytokines. Activated osteoblasts 
deposit new woven bone which results in the release of osteoblast- or bone-
derived factors that stimulate cancer cells to grow and further activate osteo-
blasts. Therefore, bone metastasis of prostate cancer is predominantly osteo-
blastic, although activation of osteoclast has been detected in prostate cancer 
and is important for its metastasis70,71.  Activated osteoblast in tumor microenvi-
ronment can induce osteoclast by releasing RANKL which is a crucial osteoclas-
tic differentiation factor. Osteoclast can be directly activated as well by tumor-
derived growth factors. As a result, osteoclastic precursors are recruited to the 
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resorption site where they differentiate and become active osteoclasts. These 
active osteoclasts resorb the bone thereby releasing growth factors that facilitate 
the growth of prostate cancer cells in the bone microenvironment. Osteoclastic 
markers such as TRAP, CA II, and Cathepsin K are found to be elevated in the 
serum of bone metastatic prostate cancer patients suggesting an overall increase 
in the bone remodeling process in bone metastasis induced by prostate cancer 
cells69. Further, a clinical study on bone metastasis in prostate cancer patients 
reported that nearly 84% of the patients with prostate cancer bone metastasis 
are associated with lysis and sclerosis suggesting that along with osteoblasts, 
osteoclasts are also involved in the process of dysregulated bone resorption and 
formation68,73,81. All these studies therefore indicate that a multifaceted interplay 
between prostate cancer cells and the osteoclasts is instrumental in the initial 
stages of development of the bone metastasis. Hence, targeting osteoclasts for 
therapy can contribute to the curbing of prostate cancer cells growth in the bone. 
However, the knowledge of the exact mechanisms through which the cancer 
cells affect this interplay is still to be elucidated and can be crucial for either im-
proving the existing therapies or for the development of new effective treatment 
strategy. 
The NRPs are type 1 transmembrane glycoproteins. It belongs to a family of non-
tyrosine kinase, cell surface receptors widely functioning in multiple cellular sig-
naling in normal physiology as well as pathological conditions. They are central in 
VEGF family-dependent angiogenesis and lymphangiogenesis as well as sema-
phorin-dependent neuronal guidance. They are known for the regulation of 
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VEGF- and semaphorin-mediated signaling cascade and the cross-talk between 
these two signaling to enable normal functioning of the fundamental physiological 
processes such as cardiovascular, neuronal and immune systems84. As de-
scribed in detail in the chapter 3, there exists two members in NRP family, NRP1, 
and NRP2 which share a conserved domain structure with nearly 40% similarity 
at amino acid level. They are over-expressed in various neoplasms and corre-
lates with stress-induced cancer survival, progression, metastasis and poor 
prognosis. NRP1 is well studied in bone physiology and is reported to be osteo-
protective via Sema 3A in healthy bone83.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
On the contrary, NRP2 is reported to be expressed by bone cells, but the exact 
function and the mechanisms are unknown at large. A study by Lieve Verlinder et 
al. showed that NRP2 is expressed by bone cells and a total knockout of NRP2 
in mice resulted in decreased osteoblasts and increased osteoclast number85. 
However, this study did not address whether the increase in osteoclast number is 
a consequence of increased differentiation caused by the deletion of NRP2 and 
what are the molecular signaling pathways that are regulated by the NRP2 on 
osteoclasts. In a pathological condition where bone homeostasis is dysfunctional 
such as prostate cancer-induced bone metastasis, the function of osteoclasts is 
vital for the metastatic propensity of prostate cancer cells in the bone. Interesting-
ly, our previous studies on NRP2 in metastatic prostate cancer cells suggested 
that NRP2 promotes survival of cancers against chemotherapies89. Although this 
information is beneficial in targeting the cancer cells, the role of NRP2 in the can-
cer-induced bone microenvironment especially osteoclasts needs to be ad-
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dressed.  Having a comprehensive knowledge of the function of NRP2 in osteo-
clasts in prostate cancer bone metastasis can prove to be beneficial in the devel-
opment of an effective treatment strategy. 
In this section, we focused on understanding how the expression of NRP2 on os-
teoclasts affect their differentiation and activation from monocytes (precursors of 
osteoclasts) under physiological as well as pathological conditions, i.e., bone 
metastatic prostate cancer. With the use of bone-marrow-derived osteoclasts 
from transgenic mice developed in our laboratory where NRP2 can be depleted 
explicitly in the myeloid population including monocytes and osteoclasts, we 
found that NRP2 downregulates osteoclastogenesis and function in physiological 
as well as by prostate cancer cells, which promotes mixed or osteoblastic le-
sions. However, osteolytic prostate cancer evades the regulation of NRP2 on os-
teoclasts. Together, our study suggests that NRP2 negatively regulates the dif-
ferentiation and functions of osteoclasts, which are bypassed by metastatic pros-
tate cancer cells that promotes osteolysis. 
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Results 
NRP2 is expressed by osteoclasts induced by metastatic prostate cancer. 
The expression of NRP2 was investigated during the in vitro osteoclast differenti-
ation, and activation under the influence of either RANKL and M-CSF (physiolog-
ical condition) or treatment with conditioned medium (CM) collected from meta-
static prostate cancer cell lines, LNCaP C4-2B and PC3. Being a derivative of 
LNCaP with its ability to metastasize to bone, LNCaP C4-2B is a prostate cancer 
cell line that can induce mixed bone lesions with high osteoblastic activity while 
maintaining a detectable osteolytic function. Therefore, LNCaP C4-2B closely 
enacts the physiology of metastatic prostate cancer. The other cell line, PC3 is a 
bone metastatic prostate cancer cell line which promotes high osteolytic lesions 
with less or no osteoblastic function. Standardizations were conducted to deter-
mine the effect of conditioned media from PC3 and LNCaP C4-2B on osteoclast 
differentiation and activation (data not shown). Under the conditions of physiolog-
ical (RANKL and M-CSF) and pathological influence (conditioned medium from 
PC3 and LNCaP C4-2B simultaneously), we tested whether NRP2 is expressed 
in osteoclasts differentiated from its precursors obtained from the bone marrow of 
C57BL6 mice’s forelimbs and hindlimbs. We found that osteoclasts expressed 
NRP2 in all the three conditions. This observation became apparent when we 
performed a time course study (0-6 days) in the differentiating osteoclasts in all 
the three conditions and found that NRP2 expression increases with time both at 
transcriptional and protein levels (Fig.3.1, 3.2). In fact, the expression of NRP2 in 
RANKL and M-CSF differentiated osteoclasts is higher than its expression in the 
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osteoclasts induced by the prostate cancer CM (Fig.3.3). Furthermore, the 
mouse osteoclastic precursors did not express NRP2 at protein and mRNA lev-
els. 
 To confirm the presence and function of multinucleated osteoclasts, TRAP stain-
ing and activity assay were conducted. We observed that with time an increase in 
TRAP activity along with the formation of giant multinucleated TRAP-positive os-
teoclasts upon treatment with RANKL and M-CSF became evident (Fig.3.4 A). In 
comparison to the physiological condition, we found small multinucleated (3 or 4 
nuclei) osteoclasts in PC3 which is more osteolytic in nature (Fig.3.6 A). In the 
presence of LNCaP C4-2B CM which shows low osteolysis function, differentia-
tion of osteoclasts was limited to 1 or 2 nucleated cells with rare 3-nucleated os-
teoclasts in the later days of differentiation (Fig.3.5 A). The TRAP activity of os-
teoclasts in the CM of PC3 and LNCaP C4-2B was comparable but higher than 
the untreated osteoclast precursors (Fig.3.7 B).  
The central role of osteoclasts is to degrade bone and release the growth factors 
that are essential for the differentiation of osteoblasts in healthy bone as well aid 
cancer cells in their survival and progression in the bone. The activation of oste-
oclasts is confirmed by their ability to resorb bone or bone mimetic coated on the 
surface of tissue culture plate and form pits. The resorptive function of osteo-
clasts increases with time as they fuse and increase their diameter thereby cov-
ering more bone surface area resulting in bigger pits. To evaluate the activation 
of osteoclasts, we performed pit resorption assay by plating osteoclastic precur-
sors on the osteoassay plate which has bone mimetic layered on its surface. On 
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this surface, the precursors attach and differentiate into osteoclasts and actively 
resorb the bone mimetic forming pits under physiological as well as pathological 
conditions. In an in vitro setup, the activation of osteoclasts starts mostly at day 4 
of osteoclastogenesis leading to pit resorption. We found that at day 4 of differen-
tiation, osteoclasts activated by the function of RANKL and M-CSF formed mod-
erate pits, but the size of the pits increases gradually with time. By day 6 of dif-
ferentiation where the osteoclasts are highly active, nearly 30% of the surface 
area of the plate was resorbed (Fig.3.4 B). In the case of osteoclast differentia-
tion induced by PC3 CM, we observed small pits scattered all over the surface of 
the osteoassay plate (Fig.3.6 B). This observation suggests that osteolytic PC3 
differentiates osteoclasts but allow a moderate level of osteoclast fusion which is 
sufficient to make the bone porous rather than resorb bone. On the contrary to 
the PC3-induced osteolysis, conditioned media from LNCaP C4-2B induced dif-
ferentiation of osteoclasts but the osteoclasts formed are either not active or 
have a very low level of resorption capability (Fig.3.5 B). Comparing the function 
of osteoclasts differentiated by physiological with the prostate cancer-induced 
condition, the resorbed area is higher in physiological condition followed by mod-
erate resorption in the PC3 and no or less resorption in osteoclasts activated by 
LNCaP C4-2B CM (Fig.3.5 B, Fig.3.6 B).  
Osteoclast differentiation results in the expression of enzymes and proteins that 
aid in their resorptive function. To understand whether the osteoclastic markers 
are expressed by the osteoclasts, we evaluated the osteoclastic markers such as 
RANK, TRAP and Cathepsin K at mRNA level in all the three conditions. Our re-
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al-time PCR data suggests that in comparison to the untreated osteoclastic pre-
cursors, all the osteoclastic markers were upregulated in the conditions of 
RANKL and M-CSF (Fig.3.7 A). We observed a 20-fold increase in RANK, 900-
fold in TRAP and 6000-fold in Cathepsin K mRNA expression in the osteoclasts 
treated with RANKL and M-CSF (Fig.3.7 A). With a high expression of these 
markers, osteoclasts in RANKL and M-CSF condition can actively resorb bone. 
In the PC3 CM-treated osteoclasts, the expression of some of these markers in-
creased. Specifically, the expression of TRAP and Cathepsin K were increased 
by 150-fold and 180-fold respectively. However, the expression of RANK in-
creased only by 3-fold in the osteoclasts induced by PC3 CM. Interestingly, we 
observed a two-fold, 40-fold and 90-fold increase in RANK, TRAP and Cathepsin 
K respectively in LNCaP C4-2B CM-induced osteoclasts (Fig.3.7 A). Together, 
our data suggest that NRP2 is expressed by osteoclasts induced either by 
RANKL and M-CSF or CM from PC3 and LNCaP C4-2B. 
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Figure 3.1: Time course of NRP2 expression at protein level in osteoclasts 
induced by RANKL and M-CSF, LNCaP C4-2B CM and PC3 CM 
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Figure 3.2: Time course of NRP2 expression at mRNA level in osteoclasts 
induced by RANKL and M-CSF, LNCaP C4-2B CM and PC3 CM 
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Figure 3.3: Comparison of NRP2 expression in osteoclasts induced by 
RANKL and M-CSF, LNCaP C4-2B CM and PC3 CM at day 3 of osteo-
clast differentiation. 
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Figure 3.4: Osteoclast differentiation and function in RANKL+M-CSF at 
different days A. TRAP staining B. Pit resorption. 
 




Figure 3.5: Osteoclast differentiation and function in LNCaP C4-2B CM 
at different days A. TRAP staining B. Pit resorption 
 





         
  
Figure 3.6: Osteoclast differentiation and function in PC3 CM at different 
days A. TRAP staining B. Pit resorption 
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Figure 3.7: Osteoclast differentiation and function in RANLK+M-CSF, PC3 
CM and LNCaP C4-2B CM A. mRNA expression of osteoclastic genes. 
RANK, TRAP & Cathepsin K B. TRAP enzymatic activity measured at 540 
nm. 
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Depletion of NRP2 in osteoclast precursor cells upregulates osteoclast dif-
ferentiation and function. 
To understand the significance of NRP2 in osteoclasts, we depleted NRP2 in os-
teoclast precursors and induced these cells to differentiate into osteoclasts in 
physiological and metastatic prostate cancer conditions. Depletion of NRP2 in 
osteoclast precursors was conducted either by transfection with siRNA against 
NRP2 or knockout NRP2 from osteoclast precursors isolated from a transgenic 
mouse model generated in our lab, CSF1R-cre; NRP2 Flox/Flox where NRP2 is 
depleted explicitly in osteoclast precursors by the addition of 4-hydroxytamoxifen. 
Using these methods, ~80% and 90% depletion of NRP2 was achieved in siRNA 
and hydroxytamoxifen addition respectively (Fig. 3.8 B, Fig 3.10 B). Depletion of 
NRP2 and treatment with RANKL and M-CSF in the osteoclastic precursors re-
sulted in a drastic increase in osteoclast differentiation and activation (Fig. 3.8 A, 
Fig 3.10 A). We found extremely large multinucleated structures in NRP2-
depleted osteoclasts in the TRAP staining and increased TRAP activity (Fig. 3.8 
C, Fig 3.10 C). The number of osteoclasts per well of a 24-well plate increased 
by 2-fold in NRP-2 depleted condition than in control (Fig. 3.11). On the day 4 of 
differentiation, osteoclasts in NRP2-reduced state started to fuse with each other 
and form a polykaryon. By day 5, these multinucleated osteoclasts started re-
sorbing the surface of the osteoassay plate actively. We observed a significant 
increase in the area of the resorbed pit in NRP2- depleted osteoclasts in compar-
ison to the control in the pit assay (Fig. 3.13). By day 6, we found that nearly 75% 
of the surface of the osteoassay plate was resorbed due to deletion of NRP2. As 
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a result of hyperactivation of osteoclasts in NRP2 nullified condition, the pits 
formed are more prominent in size when compared to the control osteoclasts 
treated with RANKL and M-CSF (Fig. 3.13).  A striking difference was also ob-
served in the expression of osteoclastic markers. In comparison to the normal 
osteoclasts, the NRP2 depleted osteoclasts showed a significant increase in the 
expression of osteoclast markers. RANK expression increased by 10 fold in 
NRP2 knocked out osteoclasts compared to the NRP2 expressing cells. The ex-
pression of TRAP increased 5 fold while Cathepsin K showed a 2.5-fold increase 
in expression due to NRP2 depletion. Other osteoclast markers such as DC-
STAMP, ATP6V0D2, carbonic anhydrase II (Car II), matrix, ATP6i and metallo-
protease 9 (MMP9) also showed elevated expression profiles in the absence of 
NRP2 in osteoclasts. (Fig. 3.9, Fig. 3.12) 
Similar to RANKL and MCSF treatment, the depletion of NRP2 in osteoclasts in-
duced by LNCaP C4-2B CM resulted in an escalation of osteoclast differentiation 
and function. TRAP staining showed an increase in the fusion of osteoclasts 
even by day 4 leading to the formation of giant, multinucleated cells (Fig. 3.14 A, 
Fig. 3.16 A). Also, the number of osteoclasts that are attached to the plate is 
higher in NRP2 devoid osteoclasts (Fig. 3.17). However, when we compared the 
NRP2 depleted osteoclasts induced by RANKL and M-CSF and LNCaP C4-2B 
CM, the rate of osteoclast differentiation is much higher in RANKL and M-CSF 
followed by LNCaP C4-2B CM. The increase in the osteoclastogenesis as a re-
sult of NRP2 depletion caused an intensification of the osteoclastic resorption. In 
contrast to the NRP2 expressing osteoclasts induced by LNCaP C4-2B CM, the 
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NRP2 deleted osteoclasts showed increased resorptive function. Nearly 45% in-
crease in pit resorption was observed as a consequence of NRP2 ablation by 
day 6 (Fig. 3.19). Further, mRNA expression analysis of NRP2 expressing as 
well as depleted osteoclasts in the LNCaP C4-2B CM showed an exponential in-
crease in the expression of osteoclast-associated genes in NRP2 deprived condi-
tion compared to the control. Increase in TRAP (25-fold), Cathepsin K (80-fold), 
DC-STAMP (1000-fold), ATP6V0D2 (21-fold), Car II (33-fold), ATP6i (2-fold) and 
MMP9 (11-fold) were observed as an effect of depletion of NRP2 in osteoclasts 
differentiated by LNCaP C4-2B CM (Fig. 3.15, Fig. 3.18). An interesting observa-
tion was made when comparing TRAP staining of NRP2  depleted osteo-
clasts in LNCaP C4-2B CM in siRNA and addition of Hydroxytamoxifen. Although 
we observed an increase in the number of osteoclasts attached to the plate in 
both treatments compared to their respective controls, we observed less fusion in 
transient knockdown of NRP2 in comparison to prominent fusion in NRP2 knock-
out in LNCaP C4-2B CM (Fig. 3.14, Fig. 3.16).  
Interestingly, in PC3 CM-induced osteoclasts, depletion of NRP2 did not show 
any changes in the osteolytic differentiation and activation. No apparent differ-
ence was observed in the TRAP staining after NRP2 reduction compared to the 
control osteoclasts induced by PC3 CM (Fig. 3.20, Fig. 3.22). There seems to be 
a slight increase in the number of osteoclasts attached to the plate after NRP2 
deletion in PC3 CM (Fig. 3.23). However, the resorption function of the NRP2 
downregulated osteoclasts in PC3 CM did not differ from their control counter-
parts (Fig. 3.25). In case of the osteoclastic markers, deletion of NRP2 caused 
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either no change or decrease in the expression of osteoclastic genes. We found 
no difference in the expression of RANK, TRAP, Cathepsin K and Car II while 
nearly 50% reduced expression was observed in MMP9, DC-STAMP, 
ATP6V0D2, and ATP6i in NRP2 depleted osteoclasts in PC3 CM (Fig. 3.21, Fig. 
3.24). Together, the data suggest that NRP2 removal in osteoclasts induced by 
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Figure 3.8: Effect of depletion of NRP2 in osteoclast precursors by siRNA 
against NRP2 and induced by RANKL and M-CSF. A. TRAP staining. B. Ef-
ficiency of NRP2 depletion in osteoclastic precursors C. TRAP activity.  
 






Figure 3.9: Effect of depletion of NRP2 in osteoclast precursors by siRNA 
against NRP2 and induced by RANKL and M-CSF. Comparison of osteo-
clastic gene expression in scrambled and NRP2 knockdown osteoclasts 
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Figure 3.10: Effect of depletion of NRP2 in osteoclast precursors isolated 
from transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-
hydroxytamoxifen and induced by RANKL and M-CSF. A. TRAP staining. B. 
Efficiency of NRP2 depletion in osteoclastic precursors C. TRAP activity.  
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Figure 3.11: Effect of depletion of NRP2 in osteoclast precursors isolat-
ed from transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-
hydroxytamoxifen and induced by RANKL and M-CSF. Graphical repre-
sentation of number of multinucleated osteoclasts per well of a 24-well 
plate. 
 







Figure 3.12: Effect of depletion of NRP2 in osteoclast precursors isolated 
from transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-
hydroxytamoxifen and induced by RANKL and M-CSF. Comparison of oste-
oclastic gene expression in control and NRP2 knockout osteoclasts. 
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Figure 3.13: Effect of depletion of NRP2 in osteoclast precursors isolated 
from transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-
hydroxytamoxifen and induced by RANKL and M-CSF. A. Pit resorption on 
osteoassay plate. B. Comparison of Pit resorption function in control and 
NRP2 knockout osteoclasts. 
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Figure 3.14: Effect of depletion of NRP2 in osteoclast precursors by siRNA 
against NRP2 and induced by LNCaP C4-2B CM. A. TRAP staining. B. Effi-
ciency of NRP2 depletion in osteoclastic precursors C. TRAP activity.  
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Figure 3.15: Effect of depletion of NRP2 in osteoclast precursors 
by siRNA against NRP2 and induced by LNCaP C4-2B CM. Com-
parison of osteoclastic gene expression in scrambled and NRP2 
knockdown osteoclasts 
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Figure 3.16: Effect of depletion of NRP2 in osteoclast precursors isolated from 
transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-hydroxytamoxifen and 
induced by LNCaP C4-2B CM. A. TRAP staining. B. Efficiency of NRP2 depletion 
in osteoclastic precursors C. TRAP activity.  
 





      
Figure 3.17: Effect of depletion of NRP2 in osteoclast precursors iso-
lated from transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 
4-hydroxytamoxifen and induced by LNCaP C4-2B CM. Graphical 
representation of number of multinucleated osteoclasts per well of a 
24-well plate. 
 






Figure 3.18: Effect of depletion of NRP2 in osteoclast precursors isolated from 
transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-hydroxytamoxifen 
and induced by LNCaP C4-2B CM. Comparison of osteoclastic gene expres-
sion in control and NRP2 knockout osteoclasts 
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Figure 3.19: Effect of depletion of NRP2 in osteoclast precursors isolated 
from transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-
hydroxytamoxifen and induced by LNCaP C4-2B CM. A. Pit resorption on os-
teoassay plate B. Comparison of Pit resorption function in control and NRP2 
knockout osteoclasts. 
 





           
  
Figure 3.20: Effect of depletion of NRP2 in osteoclast precursors by siRNA 
against NRP2 and induced by PC3 CM. A. TRAP staining. B. Efficiency of 
NRP2 depletion in osteoclastic precursors C. TRAP activity.  
 






Figure 3.21: Effect of depletion of NRP2 in osteoclast precursors by siRNA 
against NRP2 and induced by PC3 CM. Comparison of osteoclastic gene ex-
pression in scrambled and NRP2 knockdown osteoclasts. 
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Figure 3.22: Effect of depletion of NRP2 in osteoclast precursors isolated 
from transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-
hydroxytamoxifen and induced by PC3 CM. A. TRAP staining. B. Efficiency 
of NRP2 depletion in osteoclastic precursors C. TRAP activity.  
 





Figure 3.23: Effect of depletion of NRP2 in osteoclast precursors isolated 
from transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-
hydroxytamoxifen and induced by PC3 CM. Graphical representation of 
number of multinucleated osteoclasts per well of a 24-well plate. 
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Figure 3.24: Effect of depletion of NRP2 in osteoclast precursors isolated from 
transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-hydroxytamoxifen 
and induced by PC3 CM. Comparison of osteoclastic gene expression in con-
trol and NRP2 knockout osteoclasts 
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Figure 3.25: Effect of depletion of NRP2 in osteoclast precursors isolated from 
transgenic mice, NRP2
Flox/Flox
; CSF1R-Cre by addition of 4-hydroxytamoxifen 
and induced by PC3 CM. A. Pit resorption on osteoassay plate B. Comparison 
of Pit resorption function in control and NRP2 knockout osteoclasts. 
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Discussion 
Understanding the osteoclasts physiology in prostate cancer is imperative for the 
development of a novel therapy. Current information on NRP2 in osteoclasts is 
limited and no study till date has addressed the role of NRP2 in osteoclasts in-
volved in the development of bone metastasis in prostate cancer patients. In the 
present section of the study, we have reported the expression of NRP2 in physio-
logical and pathological condition, prostate cancer bone metastasis. Our results 
showed the expression of NRP2 in the osteoclast precursors from mice does not 
express NRP2. However, the levels of NRP2 increase during the differentiation of 
precursors into osteoclasts. The expression of NRP2 is highly induced by the 
treatment of positive inducers such as RANKL and M-CSF which supports the 
earlier report by Leive Verlinden et. al.85 However, no reports have been pub-
lished till date on NRP2 in a pathological condition such as prostate cancer bone 
metastasis. Our study is the first to report the expression of NRP2 in osteoclasts 
promoted by bone metastatic prostate cancer. Our results showed a robust in-
crease in the expression of NRP2 in osteoclasts differentiated by PC3 CM and 
LNCaP C4-2B CM. In fact, the NRP2 expression was quite evident in the time 
course analysis of differentiating osteoclasts under the influence of CM from 
prostate cancer cell lines. However, comparison of the expression of NRP2 dur-
ing the osteoclast differentiation in normal and prostate cancer bone metastasis 
showed that the NRP2 expression was elevated in osteoclasts influenced by 
RANKL and M-CSF than in the CM from the prostate cancer cell line. The ex-
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pression of NRP2 in osteoclasts promoted by the PC CM and LNCaP C4-2B CM 
were comparable.  
TRAP staining of osteoclasts in healthy and pathological bone conditions in vitro 
showed that RANKL and M-CSF induced osteoclastic differentiation with high ef-
ficacy followed by moderate differentiation in PC3 CM and decreased differentia-
tion in LNCaP C4-2B CM. This data again support the earlier reports on CM of 
the PC3 being purely osteolytic while LNCaP C4-2B showed predominant osteo-
genic and limited osteolytic function. Resorption of the bone is the central func-
tion of osteoclasts. Our pit assays suggest that the formation of pits as a result of 
bone mimetic resorption were higher in osteoclasts activated by RANKL and M-
CSF. The pits formed by PC3 CM are smaller but increased in number which 
again supports our TRAP staining of osteoclasts in PC3 CM. Being osteolytic, 
PC3 may promote the formation of 3-4 nucleated osteoclasts to actively degrade 
bone by forming small pits and thereby cover more surface area than expending 
energy reserves to create large multinucleated osteoclasts. This event can make 
the bone porous and weak leading to fractures in human prostate cancer pa-
tients. In contrast to PC3 CM, LNCaP C4-2B CM-induced the formation of 2-3 or 
single-nucleated osteoclasts observed by TRAP staining and the pit formation by 
these osteoclasts are minimal in size and less in number suggesting that resorp-
tive function of LNCaP C4-2B CM promoted osteoclasts is low. The role of 
LNCaP C4-2B in bone cells is to induce predominantly osteogenic differentiation 
with low osteolytic function, and our data also confirms this fact. Also, the mRNA 
analysis of the expression of osteoclastic genes indicated that osteoclasts in-
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duced by RANKL and M-CSF expressed elevated levels of these genes followed 
by increased expression in PC3 CM (but not to the levels as in healthy osteo-
clasts) and moderate levels in LNCaP C4-2B CM.  
With the information that NRP2 is expressed in the physiological as well as in 
prostate cancer-induced osteoclastogenesis, a question was asked. What is the 
function of NRP2 in osteoclasts in physiological and prostate cancer bone metas-
tasis? To address this, we depleted NRP2 in the osteoclast precursors and in-
duced their differentiation in all the three conditions. Intriguingly, NRP2 depletion 
in RANKL and M-CSF influenced osteoclasts showed a drastic increase in oste-
oclast differentiation and activation. The NRP2 –depleted osteoclasts showed 
increased expression of osteoclastic genes as well as increased resorptive ca-
pability. Together, our results in RANKL and M-CSF condition indicated that 
NRP2 downregulates the differentiation and function of osteoclasts in healthy 
bone. 
Another interesting observation came to our focus upon depletion of NRP2 in os-
teoclastic precursors followed by differentiation with LNCaP C4-2B CM. With high 
osteogenic differentiation with nominal osteolysis, the functions of LNCaP C4-2B 
closely depict prostate cancer cells in the bone microenvironment. In the ab-
sence of NRP2, osteoclasts induced by LNCaP C4-2B CM showed a substantial 
increase in the differentiation and function of osteoclasts. Large, multinucleated 
osteoclasts in comparison to the control were observed in NRP2 depleted osteo-
clasts upon addition of LNCaP C4-2B CM. Further, the resorbing capacity of 
these cells increased exponentially from their control counterparts. We also 
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found an increase in the expression of osteoclastic genes as a result of deletion 
of NRP2. This information further reinforces our findings in RANKL and M-CSF 
conditions. Cumulatively, NRP2 functions as a negative regulator of osteoclasts 
induced by the RANKL and M-CSF and in prostate cancer bone metastasis. 
Contradicting our findings in RANKL and M-CSF and LNCaP C4-2B CM, PC3 
which is purely osteolytic, did not display any change in the osteoclast differentia-
tion and activation upon removal of NRP2. The NRP2-ablated osteoclasts 
showed no noticeable difference in the TRAP staining when compared to the 
control osteoclasts stimulated by PC3 CM. Also, the resorption function of osteo-
clasts did not differ due to NRP2 deletion and no change in the expression of os-
teoclast genes was observed. These data imply that PC3 CM-induced osteo-
clasts evade the regulation of NRP2.  
In summary, NRP2 functions as negative regulator of osteoclasts in healthy as 
well as osteoclasts induced by prostate cancer cells that promote predominantly 
osteoblastic metastasis. We have identified a novel inhibitory role of NRP2 in 
physiology and pathology of osteoclasts. However, osteolytic PC3 bypass the 
NRP2 regulation. With the function of NRP2 established, we will address the ex-
act molecular pathway that NRP2 functions through to regulate osteoclastogene-
sis which will be the focus of the next chapter. 
  
 











NRP2 regulates the functions of NFATc1 and NFκB in osteoclasts  
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Introduction 
Osteoclasts are the major players in the skeletal development in an embryo as 
well as homeostasis in an adult. They are central to the fundamental processes 
of bone, i.e., endochondral ossification during early development, bone fabrica-
tion during the growth phase and bone remodeling in adulthood. The coordinated 
functioning of osteoclasts and osteoblasts imparts rigidity and strength. Osteo-
clasts are explicitly found on the bone matrix to resorb the bone surface. Osteo-
clasts are formed by the differentiation of myeloid cells of monocyte/macrophage 
lineage derived from the hematopoietic stem cells along with cues from the sur-
rounding bone microenvironment24,25,29,34. Osteoclasts undergo different stages 
such as early commitment of hematopoietic stem cells to monocytes, differentia-
tion, fusion, and activation depending upon the requirements of the bone micro-
environment. The formation and survival of the osteoclasts and their unique abil-
ity to resorb bone are controlled by complex signaling pathways leading to the 
activation of various transcription factors. During the process of differentiation of 
hematopoietic stem cells to bone resorbing osteoclasts, transcription factors such 
as PU.1 and MITF play crucial roles. In response to M-CSF, PU.1 signals the 
early determination of bone marrow progenitors to myeloid cells by stimulating 
the expression of CSF1R, the receptor of M-CSF19,26,33,34,39. PU.1 also regulates 
the proliferation of monocytes to induce osteoclastic differentiation. Activation of 
MITF by M-CSF is vital for the induction of Bcl-2 to promote survival of the osteo-
clastic precursors before their migration and attachment to the target bone re-
sorption site. 
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During the initiation stage of differentiation, the RANKL/RANK signaling induces 
a complex signaling cascade resulting in the expression of osteoclastic genes 
essential for their resorptive function. The osteoclastic genes’ expression is cu-
mulatively coordinated by the action of transcription factors stimulated by 
RANKL/RANK signaling. Binding of RANKL to RANK receptor promotes the acti-
vation of NF-B which translocates to the nucleus to promote transcription of os-
teoclastic genes. NF-B is the first transcription factor activated during differen-
tiation of osteoclasts via the RANKL/RANK and M-CSF/c-Fms signaling. In dif-
ferentiating osteoclasts, both the canonical as well as non-canonical signal acti-
vation of NF-B is reported to co-occur. RANKL/RANK binding stimulates the re-
cruitment of TRAF6 and p62 leading to the complex formation and their subse-
quent activation. The TRAF6-p62 complex further induces the activation of PKC 
that then phosphorylates IKK. The active IKK releases NF-B from the complex 
of IB by signaling the ubiquitination of IB. The free NF-B p65 and p50 com-
ponents translocate to the nucleus from cytoplasm for gene expression. Parallel 
to this, NF-B is activated by the function of NIK to induce IKK to process p100 
to p52 via the proteasomal function. The RelB- p52 complex translocates to the 
nucleus for gene transcription. The non-canonical NF-B signaling is prolonged 
and sustained than the canonical pathway due to the slow translocation of the 
RelB-p52 complex into the nucleus. The differentiating osteoclasts favor which 
NF-B pathway is based on the requirement and stage of differentiation of the 
cells. Once in the nucleus, the functional NF-B promotes the transcription of a 
key transcription factor, NFATc134,38,46. 
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NFATc1 is central to the differentiation and function of osteoclasts. Its expression 
is induced by the recruitment and binding of NF-B and NFATc2 whose expres-
sion and activation occurs in monocytic precursors. The induction of NFATc1 ex-
pression is also promoted by the association of DAP12/ ITAM co-receptor with 
RANK to costimulate it. After activation, the DAP12/ ITAM/ RANK complex syn-
ergistically recruits Syk to induce BTK, Tec, and PI3K which sequentially prompts 
PLC to drive Ca2+ oscillations. Ca2+ stimulates calcineurin to dephosphorylate 
NFATC1 to enable its translocation into the nucleus for transcription of osteoclast 
genes37,46. Ca2+-mediated activation of NFATc1 also triggers the autoamplifica-
tion loop of NFATc1 and ensures a sustained NFATc1-dependent transcriptional 
function. c-Fos is also recruited to the promoter site of NFATc1 and is reported to 
be indispensable for the early induction of NFATc1. However, the exact mecha-
nism of action of c-Fos on NFATc1 is still to be elucidated. NFATc1 is known to 
be master transcription factor which in cooperation with transcriptional factors 
such as AP-1, PU.1, MITF, NF-B and others to transcribe osteoclastic genes. 
Nearly 70% of the osteoclast genes that are functionally important are expressed 
through the function of NFATc1 but with different transcription binding partners31. 
Further, the cooperation of NFATc1 with varying transcription factors leads to ex-
pression of different osteoclastic genes and also the expression of genes may 
vary with different binding partners under physiological and pathological condi-
tions. It is still a question unanswered as to what transcriptional factors bind 
along with NFATc1 to what gene promoter site to promote transcription under a 
specific condition or disease. 
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The expression of NFATc1-regulated osteoclastic genes that are necessary for 
the resorptive function are TRAP, Cathepsin K, CA II, CIC7, LTBP3, ATP6i (H+ 
ATPase proton pump), serpin peptidase inhibitor, clade D, member 1 (Serpind1) 
and MMP9. It also directly activates the genes associated with fusion of osteo-
clasts such as ATP6V0D2, OC-STAMP, and DC-STAMP. Proteins involved in 
cytoskeleton rearrangement and exocytosis such as Rho C, Rab38, 
Na+/H+ exchanger-like domain-containing protein 2 (Nhedc2) and adenylate 
cyclase 3 (Adcy3) are NFATc1-dependent. Further, NFATc1 is a crucial regulator 
of osteoclast migration and adhesion as it induces the expression of αvβ3 integ-
rin and c-Src necessary for the formation of ruffled borders and F-actin ring ar-
rangement37. Together, NFATc1 is important for the formation of mature osteo-
clasts through direct regulation of various genes involved in osteoclast differen-
tiation and activation. Interestingly, a recent study showed that osteoclastogene-
sis induced by metastatic prostate cancer-derived factors increases the basal 
levels of Ca2+ causing Ca2+ fluctuations which subsequently promote the translo-
cation of NFATc1 into the nucleus. Inhibition of NFATc1 signaling decreases the 
ability of bone metastatic prostate cancer cells to promote osteoclast differentia-
tion and activation27. 
In the previous chapter, we showed the expression of NRP2 in healthy as well as 
prostate cancer-induced osteoclasts and that the depletion of NRP2 caused a 
dysregulation leading to hyperactivation of osteoclasts in RANKL and M-CSF and 
LNCaP C4-2B CM. The hyperactivated osteoclasts in NRP2 devoid state evalu-
ated for the expression of osteoclastic genes showed elevated mRNA levels of 
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TRAP, cathepsin K, DC-STAMP, ATP6V0D2, CA II, MMP9 and ATP6i in both the 
conditions. In this chapter, we studied how NRP2 governs the osteoclastic gene 
expression to inhibit osteoclast differentiation and activation. Here, we focused 
on identifying which key transcription factors are involved in the regulation of os-
teoclasts by NRP2. Our results implicate that NRP2 critically inhibits NFATc1 and 
NF-B in osteoclasts differentiated by RANKL and M-CSF. In LNCaP C4-2B CM, 
NRP2 depletion although caused an upregulation of NFATC1 expression and its 
activity, no increase in NF-B function was observed. Our results therefore sug-
gested activation of transcription factors in osteoclasts is condition-dependent 
and further pointed out the molecular mechanisms by which NRP2 negatively 
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Results 
NRP2 regulates the expression and function of NFATC1 and NF-B in 
RANKL/MCSF treated osteoclasts. 
Our previous results discussed in chapter 3 implicated that the depletion of NRP2 
in RANKL/MCSF-treated osteoclasts leads to their hyperactivation. The function 
of osteoclasts is mainly dependent on the expression and activation of the tran-
scription factor,  NFATc1. Hence, we evaluated whether NRP2 has any effect on 
NFATc1 expression and activation during osteoclast differentiation. In RANKL 
and M-CSF treatment, protein analysis at day 2 and day 3 of osteoclastic differ-
entiation showed that the total protein of NFATc1 increases in NRP2-depleted 
cells compared to the controls (Fig 4.1 B, Fig. 4.2 B). We then investigated 
whether NFATc1 translocates to the nucleus for its activity in the presence or ab-
sence of NRP2. Using immunofluorescence microscopy, we evaluated the ex-
pression of NFATc1 in the nucleus in differentiating osteoclasts under RANKL 
and M-CSF at day 2 and day 3. We observed bright cells with high expression of 
NFATc1 in control as well as NRP2-ablated osteoclastic precursors. Interestingly, 
we observed in each field very few NFATc1-expressing cells (Fig 4.1 A, Fig. 4.2 
A). However, the total expression of NFATc1 in the nucleus calculated as cor-
rected total cell fluorescence (CTCF) increases by 2-fold in the NRP2-depleted 
osteoclasts than in the NRP2-expressing cells in day 2 and day 3 (Fig 4.1 C, Fig. 
4.2 C). Additionally, the total number of NFATc1 expressing cells in the NRP-2 
deleted condition increases than in control condition. These data advocates that 
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presence of NRP2 negatively regulates the osteoclast differentiation and activa-
tion by restraining the expression and translocation of NFATc1 in osteoclasts. 
Although our data suggest the NRP2 regulation of NFATc1 which is central to 
osteoclast differentiation and function, NFATc1 cannot work alone in the tran-
scription of osteoclast genes. The coordinated function of NFATc1 with other fac-
tors such as NF-B has been widely studied. NF-B is the first transcription factor 
that is activated by the signaling of RANKL/RANK during the early differentiation 
of osteoclasts. Hence, we investigated whether NRP2 conducts its regulation via 
NF-B in osteoclasts. For this, we depleted NRP2 in osteoclastic precursors and 
analyzed the NF-B protein localization via fractionation of nuclear and post-
nuclear proteins (membrane and cytoplasmic proteins) in RANKL and M-CSF. 
We detected high expression of NF-B in the control and NRP2-depleted cells in 
RANKL and M-CSF condition. In comparison to the control, the nuclear expres-
sion of NF-B was increased in NRP2-depleted osteoclasts (Fig 4.3). These data 
were confirmed by the observations from immunofluorescence staining of NF-B. 
We examined the osteoclasts induced by RANKL and M-CSF for the localization 
of NF-B in the nucleus. NRP2 removal in osteoclasts resulted in an increase in 
the nuclear localization of NF-B (Fig 4.4). In summary, RANKL/MCSF-treated 
osteoclasts express NRP2 to control the expression and localization of NFATc1 
and NF-B during osteoclastic gene transcription. Absence of NRP2 in osteo-
clasts leads to their hyperactivation because of increased activity of NFATc1 and 
NFκB.  
 




Figure 4.1: Localization of NFATc1 in the nucleus following depletion of NRP2 in 
osteoclast precursors induced by RANKL and M-CSF at day 2. A. Immunofluo-
rescence staining of NFATc1 (Alex 660, pink) and nucleus with DAPI (blue). B. 
Protein analysis of NFATc1 comparing its total expression in control and NRP2 
knockout osteoclasts. C. Graphical representation of the corrected total cell flu-
orescence (CTCF) of NFATc1 in the nucleus between control and NRP2 knock-
out osteoclasts. 
 
135 | P a g e  
 
  
Figure 4.2: Localization of NFATc1 in the nucleus following depletion of NRP2 
in osteoclast precursors induced by RANKL and M-CSF at day 3. A. Immuno-
fluorescence staining of NFATc1 (Alex 660, pink) and nucleus with DAPI 
(blue). B. Protein analysis of NFATc1 comparing its total expression in control 
and NRP2 knockout osteoclasts. C. Graphical representation of the corrected 
total cell fluorescence (CTCF) of NFATc1 in the nucleus between control and 
NRP2 knockout osteoclasts. 
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Figure 4.3: Localization of NFκB in the nucleus following depletion of 
NRP2 in osteoclast precursors induced by RANKL and M-CSF at day 
3. Analysis of NFκB protein in the   nuclear and post nuclear fractions 
in control and NRP2 knockout osteoclasts 
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Figure 4.4: Localization of NFκB in the nucleus following depletion of NRP2 
in osteoclast precursors induced by RANKL and M-CSF at day 3. A. Immu-
nofluorescence staining of NFκB (Alex 540, red) and nucleus with DAPI 
(blue). B. Graphical representation of the corrected total cell fluorescence 
(CTCF) of NFκB in the nucleus between control and NRP2 knockout osteo-
clasts. 
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 NRP2 controls osteoclastogenesis via NFATc1 but not by NFκB in the CM 
of osteoblastic prostate cancer cells, LNCaP C4-2B. . 
NFATc1 has been reported to be crucial for osteoclastogenesis promoted by 
metastatic prostate cancer. To understand the signaling mechanism through 
which NRP2 regulates the functions of osteoclasts in prostate cancer bone, we 
depleted NRP2 in osteoclasts and treated with CM from LNCaP C4-2B to induce 
osteoclast differentiation. As previously described, LNCaP C4-2B promotes both 
osteoblastic and osteoclastic differentiation similar to what is observed in pros-
tate cancer patients with bone metastasis. We analyzed the expression and acti-
vation of NFATc1 at day 2 and day 3 of osteoclastogenesis. We did not observe 
NFATc1 at protein level in day 2 in both the control and NRP2 depleted osteo-
clasts. In day 3 at the protein level, we found that LNCaP C4-2B-derived factors 
increase the total expression of NFATc1 in NRP2-depleted osteoclasts in com-
parison to the NRP2 expressing osteoclasts (Fig. 4.6 B). Further confirmation 
came from the immunofluorescence studies where we stained osteoclasts with 
NFATc1 antibody to evaluate its expression and translocation into the nucleus. 
Surprisingly, a contrasting difference was observed in the expression and locali-
zation of NFATc1 in NRP2-depleted osteoclasts in LNCaP C4-2B CM. Similar to 
our protein analysis; we found expression of NFATc1 is more in NRP2-depleted 
osteoclasts. Interestingly, the control cells show no or less localization of NFATc1 
in the nucleus suggesting NFATc1 is mainly in the cytoplasm in osteoclasts when 
treated with CM of LNCaP C4-2B cells.  However, when we depleted NRP2 in 
these osteoclasts in LNCaP C4-2B CM, we observed osteoclasts that are highly 
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expressing NFATc1 (Fig. 4.5 A, Fig. 4.6 A).  More importantly, the localization of 
NFATc1 in the nucleus increased by 6- and 14-fold at day 2 and day 3 respec-
tively due to the decrease in NRP2 (Fig. 4.5 B, Fig. 4.6 C). These data cumula-
tively prove that NRP2 negatively regulates NFATc1 in osteoclasts during their 
differentiation by LNCaP C4-2B CM. 
We further evaluated the status of NF-B after depletion of NRP2 in osteoclasts 
following its treatment with LNCaP C4-2B CM. The NRP2-expressing osteoclasts 
differentiated by LNCaP C4-2B -derived factors showed the presence of NF-B 
in the nucleus. However, removal of NRP2 caused a drastic decrease in the nu-
clear localization of NF-B (Fig. 4.7). This data contradicts our findings in RANKL 
and M-CSF induced osteoclasts suggesting that the increase in osteoclastic ac-
tivity following NRP2 depletion in osteoclasts differentiated by LNCaP C4-2B CM 




140 | P a g e  
 
  
Figure 4.5: Localization of NFATc1 in the nucleus following depletion of 
NRP2 in osteoclast precursors induced by LNCaP C4-2B CM at day 2. A. 
Immunofluorescence staining of NFATc1 (Alex 660, pink) and nucleus with 
DAPI (blue) B. Graphical representation of the corrected total cell fluores-
cence (CTCF) of NFATc1 in the nucleus between control and NRP2 knock-
out osteoclasts. 
 
141 | P a g e  
 
  
Figure 4.6: Localization of NFATc1 in the nucleus following depletion of 
NRP2 in osteoclast precursors induced by LNCaP C4-2B CM at day 3. A. 
Immunofluorescence staining of NFATc1 (Alex 660, pink) and nucleus with 
DAPI (blue). B. Protein analysis of NFATc1 comparing its total expression in 
control and NRP2 knockout osteoclasts. C. Graphical representation of the 
corrected total cell fluorescence (CTCF) of NFATc1 in the nucleus between 
control and NRP2 knockout osteoclasts. 
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Figure 4.7: Localization of NFκB in the nucleus following depletion of NRP2 in 
osteoclast precursors induced by LNCaP C4-2B CM at day 3. Analysis of 
NFκB protein in the   nuclear and post nuclear fractions in control and NRP2 
knockout osteoclasts 
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Discussion 
Resorption by osteoclasts is central to the functionality of the bone. The shape, 
size, and strength of the bone are modulated by osteoclasts in coordination with 
osteoblasts. The differentiation and activation of osteoclasts require different 
genes at different stages working in a specific framework to enable the function-
ing of osteoclasts at a determined space and location. Any change in the expres-
sion of these genes can lead to a pathological conditions observed frequently 
during prostate cancer bone metastasis. The expression of these genes is con-
trolled by the function of transcription factors which function in a sequential man-
ner to manage the requirement of the osteoclast based on its differentiation and 
activation status. Many transcription factors have been widely studied in osteo-
clasts in context to bone remodeling under physiological condition. Major tran-
scription factors that are reported to function in the release of osteoclastic genes 
are NFATc1, NF-B, PU.1, AP1, and MITF. Any change or loss of function in 
these transcription factors is detrimental for the differentiation and activation of 
osteoclasts.  Previous reports on signaling in osteoclasts have implicated the re-
quirement of RANKL/RANK, M-CSF/ c-Fms as well as DAP12/ FcR and interleu-
kins such as IL-1, IL-6, and IL-8 in association with unknown signaling partners to 
activate these transcription factors. 
Despite extensive research on the regulation of transcription factors in osteo-
clasts, not many regulators has been reported to date that can control the func-
tion of osteoclast-specific transcription factors. In this study, we report for the first 
time that NRP2 regulates the activation of key transcription factors, NFATC1 and 
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NF-B in osteoclasts. Our data indicate that NRP2 depletion increases the trans-
location of important transcription factor, NFATc1 into the nucleus to transcribe a 
range of osteoclastic genes. Moreover, protein expression of NFATc1 is also in-
creased upon NRP2 depletion. Interesting facts were releveled by the immuno-
fluorescence staining of NFATc1 in osteoclasts induced by RANKL and M-CSF. 
We observed few osteoclasts in a given area exhibit high expression of NFATc1. 
During osteoclast fusion, it was reported that some of the osteoclasts act as 
mother cell and form fusion bridges to recruits nearby mononuclear osteoclasts 
for fusion. To form the fusion bridge, the mother cell increases its fusion -
associated genes which are in turn transcribed by NFATc140,44. Hence to com-
pensate for the increase in demand for fusion genes, we believe the mother cell 
increases the expression of NFATc1 and thereby activates it to localize in the 
nucleus for gene transcription. Interestingly, depletion of NRP2 further enhanced 
the number of osteoclasts that are high in NFATc1 expression in RANKL and M-
CSF condition. Therefore, we deduce from our findings that NRP2 by controlling 
the expression and localization of NFATc1 in the RANKL and M-CSF-induced 
osteoclasts maintains an optimum level of osteoclast activation required for its 
physiological function. In the absence of NRP2, osteoclast becomes hyperac-
tivated because of increased localization of NFATc1. We predict that depletion of 
NRP2 may thus lead to pathological conditions with enhanced osteolytic activity 
in bone. Our results further indicated that NFκB, which is known to bind coopera-
tively with NFATc1 for osteoclastic gene activation, was regulated similarly by 
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NRP2. Together, they can induce robust activation of osteoclast following the 
depletion of NRP2. 
 The osteolysis induced by prostate cancer CM has been reported to induce dif-
ferent osteoclastic genes. Although these genes are actively transcribed by the 
function of various transcription factors, no study has reported the involvement of 
transcription factors in the promotion of osteoclast differentiation and function in 
cancerous condition. Furthermore, not many mediators have been disclosed to 
regulate the activation of osteoclasts. Our study marks the first reporting of a 
regulator that controls the activation of transcription factors in osteoclast in pros-
tate cancer bone metastasis. Our experimental evidence supports the regulation 
of NFATc1 by NRP2 in LNCaP C4-2B treated osteoclasts. The total expression 
of NFATc1, as well as the nuclear localization of NFATc1 increased in the ab-
sence of NRP2 in osteoclasts differentiated by LNCaP C4-2B CM suggesting that 
NRP2 restricts the activation and nuclear localization of NFATc1 in these osteo-
clasts under this condition. In addition to these findings, we observed high ex-
pression of NFATc1 in some of the osteoclasts which may function as mother cell 
similar to the results reported previously in RANKL and M-CSF treatment. How-
ever, to our surprise, NF-B nuclear localization was inhibited in NRP2 depleted 
osteoclasts in LNCaP C4-2B CM suggesting a different regulation in osteoclast 
when induced by prostate cancer cells. We speculate that NFB has limited in-
fluence in promoting osteoclastic activity in the presence of CM of LNCaP C4-2B 
cells. This is because osteoclastic activity is significantly low in osteoclasts when 
differentiated by CM of LNCaP C4-2B, despite the presence of detectable level of 
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NFB in the nucleus. Moreover, NRP2 depletion although can increase the oste-
olytic activity in this condition, we detected no NFB in the nucleus. The question 
is then what can be the dominant transcription factor/s that drive the osteoclasto-
genesis when stimulated by LNCAP C4-2B especially when NRP2 was depleted. 
Our data indicated that NFATc1 can be the factor as it is not present in a signifi-
cant level in NRP2-expressing osteoclasts when treated with CM of LNCaP C4-
2B and thus can explain the low activity of the osteoclasts in this condition. Inter-
estingly, NFATc1 protein level is not only increased in NRP2-depleted osteo-
clasts but there is almost 3-fold increase in its translocation in the nucleus, which 
correlates with the increase in osteolytic activity. Our results therefore suggested 
differential regulation of transcription factors by NRP2 in osteoclasts, which are 
based upon the way they are differentiated. We believe that both NFATc1 and 
NFB are important for inducing osteoclastogenesis in RANKL and MCSF-
treated conditions thus explaining the robust osteolytic activity in comparison to 
when treated with CM of cancer cells. The osteolytic activity has enhanced fur-
ther upon NRP2 depletion as both the transcription factors can localize more in 
the nucleus. On the other hand the osteolytic activity is low in osteoclasts when 
treated with CM of LNCaP C4-2B, because of less NFATc1 in the nucleus even 
detectable level of NFB is present. The activity was increased following NRP2 
depletion as NFATc1 started entering into the nucleus, although NFκB was re-
duced during the same condition. Since NFATc1 and NFκB are known to act co-
operatively to enhance robust osteolytic activity, the absence of NFκB in the nu-
cleus during LNCaP C4-2B CM treated condition might explain why the in-
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creased osteolytic activity was not comparable with the activity that we observed 
in RANKL/MCSF-treated osteoclasts following the depletion of NRP2.    
  
 










Elucidation of how PC3 CM evades the regulation of NRP2 regulation in 
prostate cancer bone metastasis  
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Introduction 
In humans, prostate cancer bone metastasis is identified as mixed lesions with 
both osteoblastic and osteolytic phenotypes. Clinically, the progression of pros-
tate cancer-induced osteoblastic metastases is slow compared to osteolytic le-
sions. The occurrence of osteolytic lesions is rare but once established; it pro-
gresses at a rapid rate to degrade bone rendering it weak and prone to skeletal 
complications such as fractures, brittleness, hypercalcemia, and anemia. Till 
date, the pathophysiology of osteolytic bone metastasis is still not well under-
stood. It is clear from the research conducted in the past three decades that os-
teoclast activation is often a predominant phenomenon in osteolytic prostate 
cancer. In our study, we utilized CM collected from PC3 which is a known osteol-
ysis promoting cell line. Many previous reports have confirmed the osteolytic 
function of PC3 in prostate cancer bone metastasis both in in vitro as well as in 
vivo model systems. The secreted factors from PC3 can induce osteoclast differ-
entiation. These osteoclasts are capable of releasing proteins necessary for the 
resorption of bone. However, reports have suggested the release of MMP9 by 
PC3 CM-induced osteoclasts and no precise information is available on the other 
genes involved in osteoclastic differentiation, activation, and function. 
We reported earlier the signaling molecule central to this study, NRP2 is ex-
pressed in the osteoclasts differentiated by PC3 CM and that removal of NRP2 in 
osteoclastic precursors showed no evident changes in the osteoclastogenesis 
induced by PC3 CM. This raises a question as to how do PC3 CM-induced oste-
oclasts evade the function of NRP2. In this section, we attempted to address this 
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aspect. Our initial evidence came from the TRAP staining of osteoclasts differen-
tiated by PC3 CM. It suggested that PC3 CM did not promote fusion of osteo-
clasts irrespective of the presence or absence of NRP2. Even with many induc-
ers, the osteoclasts do not form multinucleated cells. The studies performed in 
this chapter have addressed those issues by providing the underlying molecular 
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Results 
Osteoclastic NFATc1 and NF-B are not affected by PC3 CM 
Our previous results discussed in chapter 3 implicated NRP2 is expressed in the 
osteoclasts in prostate cancer bone metastasis. The deletion of NRP2 affected 
the differentiation and function of osteoclasts in LNCaP C4-2B CM. However, no 
difference was observed in the osteoclasts depleted of NRP2 and treated with 
PC3 CM. Although NRP2 is expressed by PC3 CM-treated osteoclasts, removal 
of NRP2 did not affect differentiation or function suggesting that PC3 CM pro-
motes signaling that bypasses the control by NRP2 in osteoclasts.  
In osteolytic prostate cancer such as PC3, NFATc1 is reported to be expressed 
and functional in osteoclast differentiation. Hence, we checked the status of 
NFATc1 in osteoclasts induced by PC3 CM. We found very low or no expression 
of the total NFATc1 in the PC3 CM treated osteoclasts and no change in the total 
protein was observed after depletion of NRP2 (data not shown). Furthermore, in 
immunofluorescence staining, we observed the localization of NFATc1 in the cy-
toplasm but not in the nucleus in both the NRP-2 expressed as well as depleted 
osteoclasts in PC3 CM (Fig 5.1, Fig. 5.2). Hence, this suggests that NRP2 does 
not regulate NFATc1 in PC3 CM-induced osteoclasts. 
NF-B is reported to be involved in the osteoclastic gene regulation. Hence, we 
analyzed the NF-B protein localization in PC3 CM. We compared the control 
and NRP2 knockout osteoclasts to understand whether NF-B is vital for the 
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functions of osteoclasts in PC3 CM. We observed NF-B localization in the cyto-
solic compartment but completely absent in the nucleus in NRP2-expressing and 
knockout osteoclasts (Fig. 5.3). This data implicates that PC3 CM induces NF-B 
expression in osteoclasts, but it is rendered inactive in both NRP2-expressing or 
knockout conditions as it is localized in the cytosol of the osteoclasts. Together, 
NFATc1 and NF-B do not function in the osteoclastic gene expression in PC3 
CM. 
 With the information that NFATc1 and NF-B are not the transcription modula-
tors of osteoclastic genes in PC3 CM, we attempted to identify other transcription 
factors involved in the osteoclastic gene expression induced by PC3 CM. We as-
sessed the expression of transcription factors that have been reported to play a 
role in osteoclastic gene expression at mRNA level. PC3-derived factors induced 
the expression of high expression of PU.1, ATF family (ATF1, ATF2, and ATF4), 
c-Fos, c-Jun, and TFE3. In addition to these factors, TAL1 which is a regulator of 
DC-STAMP is highly expressed in osteoclasts induced by PC3 CM (data not 
shown). Although we reported the expression of many transcription factors in-
volved in osteoclastogenesis in prostate cancer, the expression at mRNA level 
does not necessarily imply their activation in osteoclasts. Hence, further studies 









Figure 5.1: Localization of NFATc1 in the nucleus following depletion of NRP2 
in osteoclast precursors induced by PC3 CM at day 2. A. Immunofluores-
cence staining of NFATc1 (Alex 660, pink) and nucleus with DAPI (blue). B. 
Graphical representation of the corrected total cell fluorescence (CTCF) of 
NFATc1 in the nucleus between control and NRP2 knockout osteoclasts. 
 





Figure 5.2: Localization of NFATc1 in the nucleus following depletion of NRP2 in 
osteoclast precursors induced by PC3 CM at day 3. A. Immunofluorescence 
staining of NFATc1 (Alex 660, pink) and nucleus with DAPI (blue). B. Graphical 
representation of the corrected total cell fluorescence (CTCF) of NFATc1 in the 
nucleus between control and NRP2 knockout osteoclasts. 
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Figure 5.3: Localization of NFκB in the nucleus following depletion of NRP2 
in osteoclast precursors induced by PC3 CM at day 3. Analysis of NFκB pro-
tein in the   nuclear and post nuclear fractions in control and NRP2 knockout 
osteoclasts. 
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GM-CSF is highly detected in CM from PC3. 
Our TRAP staining data on PC3 CM-induced osteoclasts showed that these os-
teoclasts do not differentiate into large multinucleated cells but are restricted to 
either 2 or 3 nucleated osteoclasts. Also, the pits formed by these osteoclasts are 
small and high in number. This indicates that PC3 CM induces osteoclast to an 
extent that they are active even in 2-3 nucleated state with moderate expression 
of osteoclastic genes sufficient for the resorptive function. It also implicates that 
the differentiation and function of osteoclasts in PC3 CM differ from those in 
LNCaP C4-2B CM and that NRP2 does not play any role in these osteoclasts.  
Cytokines released by prostate cancer cells have been reported to play crucial 
roles in the disease progression and metastasis. Secretion of certain cytokines is 
cell-specific and is dependent on their requirement in the microenvironment. 
Prostate cancer cells are known to release various growth factors and signaling 
molecules to promote their survival and progression in the bone microenviron-
ment. It is understood from the functions of PC3 and LNCaP C4-2B CM that they 
secrete different factors to regulate the functioning of osteoclasts. However, it is 
still unknown what secreted factors from these cell lines govern the variance in 
their functions in osteoclasts. Hence, we evaluated the CM of PC3 and LNCaP 
C4-2B for the secreted factors. As it is well-known that RANKL signaling is cen-
tral to osteoclast differentiation, we analyzed the levels of RANKL in the CM of 
PC3 and LNCaP C4-2B. We detected very low levels of RANKL nearly 1 pg/ml 
and 2 pg/ml in PC3 and LNCaP C4-2B CM respectively (Fig. 5.5). This suggests 
that RANKL signaling is not functional in prostate cancer-induced osteoclasts. In 
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a metastatic bone microenvironment, RANKL is released by other cells such as 
osteoblasts. Hence, we elevated the differentiation and function of osteoclasts in 
PC3 CM by supplementing with RANKL at a concentration of 50 ng/mL. We ob-
served that even at day 6 of differentiation, the osteoclasts looked similar in non-
treated and RANKL-treated condition in the presence of PC3 CM. Also, no 
change was observed after depletion of NRP2 in these conditions. This suggests 
that RANKL/RANK pathway is not central to the osteoclasts differentiated in the 
presence of PC3 CM (Fig. 5.6). 
  We next checked the levels of another potent growth factor, M-CSF which is a 
determinant in the commitment of myeloid progenitors into osteoclast and mac-
rophage precursors. It is also involved in osteoclastic differentiation via the 
RANKL signaling. ELISA of the CM from PC3 and LNCaP C4-2B was conducted 
to analyze the concentration of M-CSF. We detected around 500 pg/ml of M-CSF 
in LNCaP C4-2B CM and 600 pg/ml in PC3 CM (Fig. 5.7). The presence of M-
CSF in the CM of prostate cancer cell lines indicate that the early commitment of 
myeloid progenitors to osteoclastic precursors occurs confirmed by TRAP stain-
ing where we observed mononucleated TRAP-positive cells, but the differentia-
tion of osteoclasts is not solely mediated by M-CSF and requires the signaling 
from other secreted cytokines and growth factors.  
To evaluate the presence of osteoclast promoting factors in the CM of prostate 
cancer cell lines, we conducted a cytokine array where we analyzed the pres-
ence of 36 different cytokines in the CM. Interestingly, we found few cytokines in 
LNCaP C4-2B CM. CXCL1, CXCL12, IL-8, MIF, and Serpin E1 were detected in 
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LNCaP C4-2B CM. Of these, IL-8 and CXCL1 which are positive inducers of os-
teoclasts were found to be present in high levels. On the contrary in PC3 CM, we 
detected several osteoclast inducing factors that were reported in the literature.  
We observed CCL12, CXCL1, CXCL10, CXCL12, G-CSF, GM-CSF, IL-1, IL-
1F3, IL-6, IL-8, IL-18, MIF, and Serpin E1 in the PC3 CM. Among these secreted 
factors, CXCL1, G-CSF, GM-CSF, IL-1, IL-6, and IL-8 which are reported to 
have functions in osteoclast differentiation were found to be highly present. Inter-
estingly, GM-CSF is a potent inhibitor of early osteoclastic differentiation and fu-
sion and is present at a prominent level in the PC3 CM (Fig. 5.4). An ELISA to 
analyze the levels of GM-CSF in PC3 and LNCaP C4-2B CM was conducted. We 
observed very low level of GM-CSF in LNCaP C4-2B CM and very high concer-
tation of 590 pg/ml was detected in PC3 CM (Fig. 5.8). GM-CSF in high concen-
trations can induce immature dendritic cell commitment which by the function of 
c-Fos can differentiate into TRAP-positive osteoclasts. There is a possibility that 
PC3 CM-induced osteoclasts are derived from immature dendritic cells rather 
their osteoclastic precursors and this switch in precursors of osteoclasts can be 
related to the evasion of NRP2 regulation in PC3 CM osteoclasts. 
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Figure 5.4: Cytokine analysis of LNCaP C4-2B and PC3 CM. A. Immunoblot 
and table showing cytokine array profile in CM. B. Graphical illustration of the 
comparison of cytokines identified in the CM of LNCaP C4-2B and PC3. 
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Figure 5.5: Graphical representation of RANKL concentration 
(pg/ml) in LNCaP C42B and PC3 CM. 
 






Figure 5.6: TRAP staining of osteoclasts at day 6 in control and NRP2 
depleted state in PC3 CM without and with RANKL (50 ng/mL). 
 






Figure 5.7: Graphical representation of M-CSF levels in LNCaP C42B 
and PC3 CM 
 







Figure 5.8: Graphical representation of GM-CSF levels in LNCaP C42B 
and PC3 CM 
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GM-CSF inhibits osteoclast differentiation and fusion in healthy osteo-
clasts and LNCaP C4-2B induced osteoclasts. 
To test whether high GM-CSF levels can inhibit osteoclast differentiation and fu-
sion, we treated osteoclasts with varying concentrations of GM-CSF in conditions 
of RANKL and M-CSF. On day 2 of osteoclastic differentiation, we observed a 
decrease in the no. of TRAP-positive osteoclasts which can occur due to the 
commitment of myeloid precursors to immature dendritic cells rather than osteo-
clastic precursors (Fig. 5.9). Our observations also indicate the presence of 
mononuclear cells suggesting a delay in the fusion of these osteoclasts in the 
presence of GM-CSF in comparison to the control. However, at day 3 of differen-
tiation, the number of TRAP-positive osteoclasts in GM-CSF treated condition 
were comparable to the untreated osteoclasts, but the delay in the fusion as 
characterized by the mononuclear osteoclasts persisted in the GM-CSF treated 
state (Fig. 5.10). We observed similar effect in osteoclasts depleted of NRP2 and 
treated with RANKL and M-CSF (Fig. 5.9, Fig. 5.10). These findings indicate that 
GM-CSF inhibited the early differentiation and fusion of osteoclasts and removal 
of NRP2 did not rescue the cells from the inhibition. However, in the later stages 
of osteoclast differentiation, GM-CSF inhibited the fusion of osteoclasts but did 
not restrict the osteoclast differentiation.  
LNCaP C4-2B has low osteolytic function which is depicted in their differentiation 
ability of osteoclasts. Depletion of NRP2 increased the osteolytic capability of the 
osteoclasts in this condition. The osteoclasts induced by LNCaP C4-2B CM are 
generally mononucleated or rarely binucleated, but NRP2 removal caused the 
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cells to fuse and become functional multinucleated osteoclasts and further the 
secreted GM-CSF levels in the CM of LNCaP C4-2B is low. In such a condition, 
we wanted to test whether the addition of GM-CSF can inhibit the osteoclastic 
differentiation and function in NRP2 depleted osteoclasts in LNCaP C4-2B CM. 
We observed significant reduction of osteolytic activity upon GMCSF addition in 
NRP2-depleted osteoclasts in LNCaP C4-2B CM during early differentiation. At 
day2, we observed a decrease in the total number of TRAP positive mononuclear 
osteoclasts in GM-CSF treatment (Fig. 5.11). Also, we witnessed a delay in the 
fusion of osteoclasts in NRP2-depleted cells indicating that GM-CSF inhibits os-
teoclast differentiation and fusion in NRP2 depleted osteoclasts during early dif-
ferentiation. Similar to osteoclasts in RANKL and M-CSF condition, GM-CSF did 
not inhibit differentiation at day 3 but inhibited osteoclast fusion (Fig. 5.12). 
Taking together all these results, we can deduce that GM-CSF is an inhibitor of 
early osteoclast differentiation and fusion. The secretion of GM-CSF by PC3 may 
contribute to the maintenance of osteoclasts in mononucleated state and thus 
help the cells to bypass the regulation of NRP2. 
  
 





Figure 5.9: A. TRAP staining of osteoclasts at day 2 in control and NRP2 
depleted state in RANKL and M-CSF without and with GM-CSF (600 
pg/mL). B. Graphical representation of the quantification and comparison 
of TRAP-positive MNCs/well in control and GM-CSF treated osteoclasts 
in NRP2WT and NRP2KO osteoclasts. 
 






Figure 5.10: A. TRAP staining of osteoclasts at day 3 in control and NRP2 de-
pleted state in RANKL and M-CSF without and with GM-CSF (600 pg/mL). B. 
Graphical representation of the quantification and comparison of TRAP-
positive MNCs/well in control and GM-CSF treated osteoclasts in NRP2WT and 
NRP2KO osteoclasts. 
 





Figure 5.11: A.TRAP staining of osteoclasts at day 2 in control and NRP2 
depleted state in LNCaP C4-2B CM without and with GM-CSF (600 
pg/mL). B. Graphical representation of the quantification and comparison 
of TRAP-positive MNCs/well in control and GM-CSF treated osteoclasts in 
NRP2WT and NRP2KO osteoclasts. 
 






Figure 5.12: A. TRAP staining of osteoclasts at day 3 in control and 
NRP2 depleted state in LNCaP C4-2B CM without and with GM-CSF 
(600 pg/mL). B. Graphical representation of the quantification and com-
parison of TRAP-positive MNCs/well in control and GM-CSF treated os-
teoclasts in NRP2WT and NRP2KO osteoclasts. 
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Discussion 
Osteolytic prostate cancer is rare in occurrence but is aggressive leading to de-
crease in the quality of life and can cause deaths. Understanding the biology of 
osteolysis induced by prostate cancer can be helpful in developing a better ther-
apy. Our study addressed the regulatory function of NRP2 in osteoclasts in phys-
iological condition and prostate cancer bone metastasis condition. We reported in 
chapter 4 that NRP2 regulates the localization and thus functions of both 
NFATc1 and NFB in osteoclasts differentiated by RANKL/MCSF and only 
NFATc1 in LNCaP C4-2B CM. Contrary to these findings, no change in NFATc1 
or NFB was found in PC3 CM after depletion of NRP2 in osteoclasts In fact, 
both NFATc1 and NFκB were undetected in the nucleus in our experimental con-
dition suggesting the involvement of other transcription factors who may play a 
dominant role in inducing osteoclast-specific gene expression following the 
stimulation of PC3 CM. Currently, the identity of these transcription factors are 
not known, although we hypothesize that their activities are not regulated by 
NRP2. We checked the expression of various transcription factors and detected 
PU.1, AP1, ATF1, ATF2, ATF4, TAL1 and TFE3 at mRNA level in osteoclast. In-
terestingly, TAL1 is an inhibitor of osteoclastic fusion, and its expression is in-
creased in osteoclasts induced by PC3 CM. TAL1 is reported to suppress osteo-
clast fusion gene, DC-STAMP at the transcriptional level by counteracting the 
function of active PU.1 and MITF. Our previous findings in PC3 CM showed that 
osteoclasts induced by PC3 CM promote the differentiation and activation of os-
teoclasts, but the fusion of osteoclasts is restricted thereby maintaining mononu-
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clear phenotype. In fact, active osteoclasts are not always multinucleated but 
small, mononuclear osteoclasts also exist which are fully functional. The reason 
for retaining the osteoclasts in the mononuclear state can be related to their de-
creased metabolism and higher bone surface coverage. In the presence of TAL1, 
PC3 CM-induced osteoclasts may control fusion events to promote energy effi-
cient osteolysis. However, the expression of these transcription factors was de-
tected at mRNA level which does not necessarily rely into protein that can active-
ly localize in the nucleus and transcribe genes. Hence, future studies will address 
the role of these transcription factors in the osteoclasts induced by PC3 CM.  
The osteoclasts induced by PC3-derived factors have moderate resorptive capa-
bility, but show decreased fusion events. This indicates that PC3 releases signal-
ing factors that regulate the differentiation and fusion of osteoclasts. Our cytokine 
profile analysis detected various cytokines and growth factors released by PC3 
cells. Many of the secreted factors such as IL-1, IL-6, IL-8, CCL1, CXCL1, 
CXCL10, CXCL12 and G-CSF are known inducers of osteoclasts. However, one 
growth factor GM-CSF is released by PC3 at a prominent level. GM-CSF is a 
known inhibitor of early osteoclast differentiation. In the presence of GM-CSF, 
myeloid progenitors become osteoclasts in a two-step differentiation. GM-CSF 
signals the myeloid cells to commit to become immature dendritic cells. These 
immature dendritic cells upon activation of c-Fos differentiate to become TRAP-
positive mononuclear osteoclast-like cells. Further, GM-CSF inhibits the expres-
sion of DC-STAMP to downregulate fusion of osteoclasts.  Together, all of this 
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information indicates that GM-CSF secretion can be crucial for the type of osteo-
clasts we frequently observed when cultured in PC3 CM. 
In the final part of our study, we addressed whether GM-CSF has an inhibitory 
effect on osteoclast differentiation either in the presence of RANKL/M-CSF or 
when treated with CM of LNCaP C4-2B especially when NRP2 was deleted. . 
Our TRAP staining suggests that, GM-CSF delayed osteoclastic differentiation, 
as well as fusion of osteoclasts during their early differentiation by RANKL/M-
CSF. Importantly, depletion of NRP2 in the presence of GMCSF failed to pro-
mote the hyperactivation of osteoclasts.   A delay in osteoclast differentiation and 
fusion was also observed due to addition of GM-CSF during early differentiation 
of osteoclasts induced by LNCaP C4-2B CM and once again depletion of NRP2 
failed to hyperactivate their differentiation.   These results therefore suggested 
that GMCSF has a distinct effect on the normal process of osteoclast differentia-
tion, and it also uncouples the regulation of NRP2 on osteoclasts. It is under-
stood from the previous reports, GM-CSF sways the myeloid cells towards imma-
ture dendritic cells, which are able to express bone resorbing enzymes although 
rarely form multinucleated structures. Because they follow a different differentia-
tion program, it is likely that the transcription factors involved here are different 
from the classically known transcription factors involved in osteoclast differentia-
tion. Our failure to detect NFATc1 and NFB in the nucleus of the osteoclasts 
when treated with PC3 CM, despite being able to express osteoclastic genes 
supports this hypothesis and thus highlights the involvement of a different set of 
transcription factors, which are distinct from NFATc1 and NFB. Although, we 
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could detect RNA expression of other transcription factors known for their ability 
to promote osteoclast differentiation in PC3 CM treated osteoclasts, their contri-
bution in osteoclastic gene expression under this condition is currently unknown. 
It is also possible that some novel transcription factors play critical roles in induc-
ing osteoclastic genes following their activation by PC3 CM. We detected several 
cytokines such as IL-6, IL-1, IL-18, CD54 and Serpin E1, which are uniquely 
expressed in the CM of PC3 and are known for their ability to differentiate osteo-
clast. These cytokines along with GMCSF potentially regulate a transcriptional 
machinery specific for PC3 CM for the expression of osteoclastic genes. We also 
speculate that in the absence of GMCSF, the positive inducers of osteoclastic 
differentiation present in PC3 CM can commit the myeloid cells to become osteo-
clastic progenitors and thus promote a canonical differentiation program and fur-
ther sensitize the osteoclasts to NRP2 regulation. These are important questions, 
which will be  the focus in our future studies.  
  
 








Major conclusions and limitations 
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NRP2: A crucial regulator of osteoclasts in prostate cancer bone metasta-
sis. 
Prostate cancer bone metastasis is a complex disease. The incidence of bone 
metastasis in advanced-stage prostate cancer patients is very high (nearly 80%). 
Unlike other cancers such as breast and multiple myeloma where osteolytic le-
sions are predominant, the bone metastasis induced by prostate cancer cells 
show mixed osteoblastic and osteolytic lesions. Although radiological evidences 
from prostate cancer patients implicate the occurrence of osteoblastic metasta-
ses is high over osteolytic lesions, the manifestation of prostate cancer causes 
functional dysregulation in bone cells causing mixed lesions. Recent studies on 
osteoclasts in prostate cancer bone metastasis reported that the circulating pros-
tate cancer cells establish in the bone at discrete sites where hematopoietic stem 
cells are present during initial stages of homing in the bone. In the hematopoietic 
niche, the prostate cancer cells release cytokines and growth factors to induce 
dysfunctional osteoclasts leading to osteolysis of bone. This function of osteoly-
sis is important for the survival, proliferation and progression of cancer cells in 
the hypoxic bone environment. Therefore, therapies targeting osteoclasts such 
as bisphosphonates, denosumab (RANKL inhibitors) have been developed. Un-
fortunately, these treatment strategies are mainly palliative in nature and are 
used to treat skeletal related events (SREs) associated with bone metastasis. 
Clinically, these patients are beyond the scope of any curative treatment. Moreo-
ver, the overall complex architecture of the bone cannot be rescued with these 
therapies. Hence, the understanding of the biology as well as the signaling of 
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prostate cancer cells with osteoclasts is a prerequisite for developing an effective 
treatment strategy. 
In this dissertation, I have examined the role of NRP2 in osteoclasts and have 
elucidated its function as a negative regulator of osteoclastic differentiation and 
activity both during physiological condition or when induced by metastatic pros-
tate cancer cells. My studies have therefore indicated a role of NRP2 in harness-
ing the activity of osteoclast in an optimum level required for the physiological 
functions of bone and also during the metastatic progression of prostate cancer. 
Hyperactivity of osteoclasts is associated with osteoporotic lesions as frequently 
detected in Paget’s disease, metastatic breast cancer, multiple myeloma and 
other diseases. The loss of function of NRP2 like regulators is often detected as 
the underlying molecular mechanism for the pathological activation of osteoclasts 
and therefore should be thoroughly studied. Further, I have discussed one of the 
intriguing findings that the key transcription factor, NFATc1 is regulated by NRP2 
in osteoclasts. The detailed summary of all the findings in this study is as follows. 
 
NRP2 expressed in osteoclasts in prostate cancer bone metastasis. 
Previous reports from our group has shown that NRP2 is expressed on prostate 
cancer cells that are metastasized to bone and its removal causes the sensitiza-
tion of cancer cells to therapeutic agents such as Docetaxol. Therefore, NRP2 
axis can be a potential therapeutic target for prostate cancer bone metastasis. A 
therapy targeting NRP2 is unlikely be specific for cancer cells and can potentially 
block NRP2 axis in other cells present in cancer microenvironment. I am there-
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fore interested to understand what might be the effect of inhibiting NRP2 axis in 
those cells and their overall effect in cancer growth. A recent study showed that 
osteoclasts express NRP2 in healthy bone. Therefore, I was interested to know 
whether expression of NRP2 is maintained in osteoclast during its induction by 
metastatic prostate cancer cells and its implications in prostate cancer bone me-
tastasis. In this respect, it is also important to note that the previous study did not 
address the importance of NRP2 in osteoclastogenesis during physiological bone 
remodeling process. Here, I showed for the first time that prostate cancer cells 
induce the osteoclasts to express NRP2. PC3 is a prostate cancer cell line, which 
promotes osteolysis and LNCaP C4-2B induces mixed lesions in mice. Interest-
ingly, the expression of NRP2 in osteoclastic precursors remained undetected 
and upon differentiation, NRP2 levels increase at substantial rate in the osteo-
clasts. Furthermore, the expression of NRP2 in healthy (RANKL/M-CSF treated) 
osteoclasts is much higher than in osteoclasts induced by bone metastatic pros-
tate cancer cells. However, no difference in the expression of NRP2 was ob-
served between the osteoclasts differentiated by LNCaP C4-2B and PC3 CM. 
Altogether, NRP2 is induced in osteoclasts in prostate cancer bone metastasis. 
 
NRP2 regulates differentiation and function of osteoclasts in prostate can-
cer bone metastasis. 
The expression of NRP2 suggests that it has a function in osteoclasts. To under-
stand the function of NRP2, osteoclastic precursors were depleted of NRP2 and 
their differentiation and function was analyzed under prostate cancer CM. Intri-
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guingly, NRP2 depletion in RANKL and M-CSF influenced osteoclasts showed a 
drastic increase in osteoclast differentiation and activation. The NRP2–depleted 
osteoclasts showed increased expression of osteoclastic genes as well as in-
creased resorptive capability. In LNCaP C4-2B CM, removal of NRP2 showed a 
substantial increase in the differentiation and function of osteoclasts. Large, mul-
tinucleated osteoclasts in comparison to the control were observed in NRP2 de-
pleted osteoclasts and the resorbing capacity of these cells increased exponen-
tially from their control counterparts. Contrary to these observations, osteolytic 
prostate cancer such as PC3-induced osteoclasts did not show any change in 
differentiation and activation upon depletion of NRP2. Collectively, it can be con-
cluded that NRP2 negatively regulates osteoclast differentiation and function un-
der physiological condition and when induced by LNCaP C4-2B cells, which 
promote mixed lesions as observed in majority of prostate cancer patients with 
bone metastasis. Interestingly, PC3, which promotes mainly osteolytic lesions, 
induce osteoclasts through an NRP2-independent mechanism. 
 
NRP2 controls NFATc1 to regulate osteoclast differentiation and activation 
in prostate cancer bone metastasis.  
With the information that NRP2 regulates osteoclast differentiation and activation, 
it became imperative to address how NRP2 functions to hamper osteoclasts. In 
our earlier data, we observed a significant increase in the expression of many of 
the osteoclastic genes in the absence of NRP2, which directs our attention to-
wards signaling molecules such as transcription factors that promote gene tran-
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scription. Hence, we studied transcription factors that have been reported to be 
central to osteoclasts, NFATc1 and NF-B, to evaluate whether NRP2 regulates 
the function of these transcription factors. Compelling evidence from protein and 
immunofluorescence analysis implicate that NRP2 inhibits the expression and 
localization of NFATc1 in RANKL and M-CSF and prostate cancer bone metas-
tasis. Further, translocation of NF-B into the nucleus is regulated by the signal-
ing of NRP2 in RANKL and M-CSF condition suggesting that NF-B cooperative-
ly function with NFATc1 to promote osteoclastogenesis. In this scenario, it is in-
teresting to understand whether NF-B is activated prior to NFATc1 and that it is 
involved in the early induction of NFATc1. Also, we observed an increase in the 
global expression of NFATc1 in NRP2- depleted osteoclasts in RANKL and M-
CSF and LNCaP C4-2B CM. This data entails that NFATc1 which is central to 
the osteoclastogenesis is inhibited by NRP2 signaling. It is well understood that 
NFATc1 expression is regulated by its upstream signaling which includes Ca2+ 
signaling. Furthermore, NFATc1 upregulates its own transcription via the au-
toamplification mechanism. Future studies in this direction can provide insight 
into the mechanism of action of NRP2 in osteoclasts in prostate cancer bone me-
tastasis (Fig. 6.1). 
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Figure 6.1: Schematic illustration of the molecular pathways through which 
NRP2 regulates the gene transcription in osteoclasts. In RANKL and M-CSF, 
NRP2 inhibits NFATc1 and NF-κB translocation into the nucleus while only 
NFATc1 nuclear translocation is blocked by NRP2 in LNCaP C4-2B CM. Oste-
oclasts differentiated by PC3 CM do not work through NFATc1 and NF-κB but 
withunknown transcrition factors to promote osteoclastic gene transcription. 
 




Osteolytic PC3 evades the regulation of NRP2 in osteoclasts. 
Although the expression of NRP2 was observed in PC3 CM-induced osteoclasts, 
NRP2 depletion did not change the differentiation and function of osteoclasts. 
Few interesting observations in osteoclasts paved way to the further investigation 
of PC3 CM. We observed that PC3 CM-induced osteoclasts were able to conduct 
significant expression levels of osteoclastic genes and were not influenced by the 
status of NRP2. This hints that PC3 CM activates transcription factors, which are 
not regulated by NRP2 to enable the expression of osteoclastic genes. We did 
not observe the localization of NFATc1 and NF-B in the nucleus in PC3 CM in-
duced osteoclasts. This implies that these crucial factors that are central to oste-
oclasts are not activated by PC3 CM. Further studies into the transcription factors 
will enable the understanding of the signaling pathways activated by PC3 CM. 
Also, the osteoclasts in PC3 CM maintain 2-3 nucleated state and the resorptive 
function of these osteoclasts is limited to pore formations rather than large pits. 
This raised the question- what is present in the PC3 CM that is restricting the fu-
sion and function. Cytokine analysis of the PC3 CM showed high concentrations 
of GM-CSF, which is a reported inhibitor of early differentiation and fusion in os-
teoclasts. Addition of GM-CSF in osteoclasts induced by RANKL and M-CSF and 
LNCaP C4-2B CM caused a delay in the early differentiation and fusion of the 
osteoclasts. In addition, treatment of NRP2-depleted osteoclasts with GM-CSF 
also showed a lag in the differentiation and fusion of osteoclasts in these condi-
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tions. This event can be a result of uncoupling of the GM-CSF and NRP2 regula-
tion pathways. This further confirms our findings in PC3 CM that presence of 
GM-CSF restrains the osteoclast differentiation and fusion in PC3 CM. It will be 
important to study whether removal of GM-CSF from the PC3 CM can facilitate 
the regulation of NRP2 in osteoclasts. 
In summary, this study delineated the role of NRP2 in osteoclasts in prostate 
cancer bone metastasis. We report that NRP2 functions as a negative regulator 
of osteoclasts in prostate cancer bone metastasis but is rendered ineffective in 
osteolytic lesions. In future, this study can be further extrapolated to understand 
the mechanisms through which prostate cancer cells promote bone lesions and 
this insight can be helpful in developing better therapies for prostate cancer bone 
metastasis. 
Limitations: 
Although this study showed a novel mechanism of NRP2 in osteoclasts in pro-
moting prostate cancer bone metastasis, there exists some limitations in the un-
derstanding of the exact role of osteoclasts induced by prostate cancer cells. It 
includes but not limited to choice of model system, the experimental setup as 
well as in the interpretation of results. 
Choice of model system: For our study, we used conditioned media from hu-
man prostate cancer cell lines that metastasize to bone to induce osteoclasts de-
rived from mouse bone marrow. Use of CM from prostate cancer cell lines is 
widely used and is effective. However, many growth factors which are known in-
ducers of osteoclasts released by human prostate cancer cells cannot identify or 
bind to their receptor counterparts on mouse osteoclasts rendering them ineffec-
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tive. For example, IL-8 of human origin cannot bind its receptor on mouse osteo-
clasts. Hence, it would be important to understand whether CM from human 
prostate cancer cell lines can induce osteoclasts of human origin (PBMCs). Par-
allel to this, use of mouse model is essential for the elucidation of mechanisms 
involved promoting bone metastasis. So, this study can be conducted using CM 
from mouse prostate cancer cell lines such as RM1 which is reported to exhibit 
bone metastasis. This enables the use of mouse growth factors present in the 
CM to differentiate osteoclasts efficiently and study mechanisms involved in pros-
tate cancer bone metastasis. Further, these prostate cancer cells can not only be 
useful in in-vitro studies but also in in-vivo studies. 
Experimental setup: Our study mainly focused on the use of in-vitro system to 
understand the role of NRP2 in osteoclasts induced by CM from prostate cancer 
cells. Use of CM is effective in differentiating the osteoclasts but in a bone micro-
enviroment, osteoclasts function in co-ordination with osteoblasts and prostate 
cancer cells in close proximity. Monolayer culturing of osteoclasts is devoid of 
these interactions. Hence, co-culturing of osteoclasts, osteoblasts, and prostate 
cancer cells can enable better interaction as well as release of growth factors 
and binding of osteoblast membrane bound ligands to receptors on osteoclasts. 
Interpretation of results: As our model system has limitations in respect to hu-
man and mouse model, the cytokine/ growth factors detected in the cytokine 
analysis needs further validation. Analysis of CM from mouse prostate cancer 
cell lines can address the discrepancies between the model systems. Further, 
due to variance in the status of the prostate cancer cells, we observed a variance 
 
184 | P a g e  
 
in the quality of CM obtained from these cells. Rigorous standardization is re-
quired to successfully conduct an experiment. Other factors such as osteoclastic 
precursors, growth factors and fetal bovine serum affected the isolation, differen-
tiation and culturing of osteoclasts. 
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Directions for future work in this study: 
1. What are the upstream signaling modulators of NFATc1 controlled by NRP2? 
Our study has shown that NFATc1, a crucial transcription factor in osteoclasts is 
regulated by NRP2 signaling. Further, the expression of NFATc1 is also en-
hanced due to removal of NRP2. Previous studies have reported that NFATc1 is 
activated by the function of various signaling molecules. These are Ca2+/ cal-
cineurin pathway, c-Fos and autoamplification by NFATc1. Our future studies will 
address which signaling pathway leading to NFATc1 expression and transloca-
tion is prominently regulated by NRP2.  
2. Understand how NRP2 function is bypassed by the osteoclasts induced by PC3 CM. 
It is clear from our data that NRP2 regulation is avoided by the PC3 CM induced 
osteoclasts. In addition, high GM-SCF secreted by PC3 causes a delay in the dif-
ferentiation and fusion of osteoclasts as suggested by our results. The question 
arises whether removal of GM-CSF from the CM of PC3 can sensitize the osteo-
clasts to the regulation of NRP2. To accomplish this, we will transfect siRNA 
against GM-CSF in PC3 cells and collect the conditioned media which is devoid 
of GM-CSF and treat osteoclastic precursors in presence or absence of NRP2. 
3. Elucidation of the signaling factors that promote osteoclasts in PC3 CM. 
From earlier results, it is quite evident that PC3 CM downregulates the transloca-
tion of major transcription factors, NFATc1 and NF-B irrespective of the status 
of NRP2. Also, the expression of osteoclastic genes such as TRAP and cathep-
sin K suggest that there are transcription factors involved in the osteoclastic gene 
transcription. Further, mRNA studies on these osteoclasts hint the expression of 
transcription factors such as PU.1, AP1, TFE3 and TAL1. Hence, we will evalu-
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ate which transcription factors are functional in the expression of the osteoclastic 
genes in the PC3 CM.  
4. In-Vivo model to address prostate cancer bone metastasis. 
Prostate cancer bone metastasis exhibits mixed osteoblastic/osteolytic lesions 
which makes it clinically untreatable. Recent reports in prostate cancer bone me-
tastasis suggested that prostate cancer cells in the bone localize to the hemato-
poietic niche. In order to localize to the bone, the prostate cancer cells release 
growth factors to induce osteoclastic differentiation. The active osteoclasts resorb 
bone to release growth factors necessary for the survival of prostate cancer cells 
as well as make space for the cancer cells to settle and grow. Therefore, osteo-
clasts are the first cells in the bone to be activated. However, the prostate cancer 
cells proceed to induce osteoblastic thereby promoting mixed lesions. Our previ-
ous reports indicate that depletion of NRP2 from bone metastatic prostate cancer 
cells causes the cells to sensitize to therapeutic agents thereby killing the cells. 
Further, our data in this study suggest that NRP2 controls the osteoclast differen-
tiation and function. Altogether, our findings imply that NRP2 can be a therapeu-
tic target in prostate cancer bone metastasis. The disease can be targeted with 
the administration of inhibitors specific for NRP2. However, information is missing 
as to the effect of NRP2 inhibitors on the prostate cancer cells and the cells in 
the bone microenvironment. In order to propose NRP2 inhibitors for therapy, it is 
essential to address the functions of NRP2 in bone microenvironment. In vivo 
studies will be conducted by using RM1 cells (developed using the MPR model 
and syngeneic to C57BL/6 mice) as a model for studying the interactions be-
tween prostate cancer cells and bone stroma specifically osteoclasts. By injecting 
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the RM1 cells having stably expressing inducible NRP2 shRNA construct in-
tratibially into CSF1R-Cre; NRP2flox/flox mice, we will monitor the progression of 
prostate cancer in bone and how osteoclasts play a role in the development of 
bone metastasis. Under these circumstances, we will also evaluate the conse-
quences of removal of NRP2 in the prostate cancer cells by addition of doxycy-
cline as well as in the osteoclasts by administering Tamoxifen. Overall, these in 
vivo studies will address the critical question of the function of NRP2 in prostate 
cancer cells as well as osteoclasts and whether NRP2 can be a therapeutic tar-
get in prostate cancer bone metastasis. 
  
 











190 | P a g e  
 
  
1 Garisto, J. D. & Klotz, L. Active Surveillance for Prostate Cancer: How to Do It 
Right. Oncology (Williston Park) 31, 333-340, 345 (2017). 
2 Shenoy, D., Packianathan, S., Chen, A. M. & Vijayakumar, S. Do African-
American men need separate prostate cancer screening guidelines? BMC Urol 16, 
19, doi:10.1186/s12894-016-0137-7 (2016). 
3 society, A. c. Key Statistics for Prostate Cancer.  (2018). 
4 Stangelberger, A., Waldert, M. & Djavan, B. Prostate cancer in elderly men. Rev 
Urol 10, 111-119 (2008). 
5 Shah, N. & Ioffe, V. Frequency of Gleason score 7 to 10 in 5100 elderly prostate 
cancer patients. Rev Urol 18, 181-187, doi:10.3909/riu0732 (2016). 
6 Terris, M. K. Metastatic and Advanced Prostate Cancer.  (2018). 
7 Martha K Terris, S. M. Q. Metastatic and Advanced Prostate Cancer. 
8 Chen, N. & Zhou, Q. The evolving Gleason grading system. Chin J Cancer Res 
28, 58-64, doi:10.3978/j.issn.1000-9604.2016.02.04 (2016). 
9 Dawson, N. A.     (2017). 
10 Dawson, N. A. Patient education: Treatment for advanced prostate cancer 
(Beyond the Basics), <https://www.uptodate.com/contents/treatment-for-
advanced-prostate-cancer-beyond-the-basics> (2016). 
11 Shore, N. Management of Early-Stage Prostate Cancer. The American Journal of 
Managed Care (2015). 
12 Sumanasuriya, S. & De Bono, J. Treatment of Advanced Prostate Cancer-A 
Review of Current Therapies and Future Promise. Cold Spring Harb Perspect 
Med, doi:10.1101/cshperspect.a030635 (2017). 
13 Sweeney, C. J. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive 
Prostate Cancer. N Engl J Med 373, 737-746, doi:10.1056/NEJMoa1503747 
(2015). 
14 Chandrasekar, T., Yang, J. C., Gao, A. C. & Evans, C. P. Mechanisms of 
resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 4, 
365-380, doi:10.3978/j.issn.2223-4683.2015.05.02 (2015). 
15 Karantanos, T., Corn, P. G. & Thompson, T. C. Prostate cancer progression after 
androgen deprivation therapy: mechanisms of castrate resistance and novel 
therapeutic approaches. Oncogene 32, 5501-5511, doi:10.1038/onc.2013.206 
(2013). 
16 Nussbaum, N. et al. Patient experience in the treatment of metastatic castration-
resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis 19, 
111-121, doi:10.1038/pcan.2015.42 (2016). 
17 El-Amm, J. & Aragon-Ching, J. B. Targeting Bone Metastases in Metastatic 
Castration-Resistant Prostate Cancer. Clin Med Insights Oncol 10, 11-19, 
doi:10.4137/CMO.S30751 (2016). 
18 Florencio-Silva, R., Sasso, G. R., Sasso-Cerri, E., Simoes, M. J. & Cerri, P. S. 
Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone 
Cells. Biomed Res Int 2015, 421746, doi:10.1155/2015/421746 (2015). 
19 Chen, X. et al. Osteoblast-osteoclast interactions. Connect Tissue Res 59, 99-107, 
doi:10.1080/03008207.2017.1290085 (2018). 
 
191 | P a g e  
 
20 Lieben, L. Bone: Direct contact between mature osteoblasts and osteoclasts. Nat 
Rev Rheumatol, doi:10.1038/nrrheum.2018.16 (2018). 
21 Goldring, S. R. The osteocyte: key player in regulating bone turnover. RMD Open 
1, e000049, doi:10.1136/rmdopen-2015-000049 (2015). 
22 Long, C. L. & Humphrey, M. B. Osteoimmunology: the expanding role of 
immunoreceptors in osteoclasts and bone remodeling. Bonekey Rep 1, 
doi:10.1038/bonekey.2012.59 (2012). 
23 Numan, M. S., Amiable, N., Brown, J. P. & Michou, L. Paget's disease of bone: 
an osteoimmunological disorder? Drug Des Devel Ther 9, 4695-4707, 
doi:10.2147/DDDT.S88845 (2015). 
24 Bar-Shavit, Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-
resorbing osteoimmune cell. J Cell Biochem 102, 1130-1139, 
doi:10.1002/jcb.21553 (2007). 
25 Xiao, Y. et al. Identification of the Common Origins of Osteoclasts, 
Macrophages, and Dendritic Cells in Human Hematopoiesis. Stem Cell Reports 4, 
984-994, doi:10.1016/j.stemcr.2015.04.012 (2015). 
26 Ross, F. P. M-CSF, c-Fms, and signaling in osteoclasts and their precursors. Ann 
N Y Acad Sci 1068, 110-116, doi:10.1196/annals.1346.014 (2006). 
27 Kim, J. H. & Kim, N. Signaling Pathways in Osteoclast Differentiation. Chonnam 
Med J 52, 12-17, doi:10.4068/cmj.2016.52.1.12 (2016). 
28 Soltanoff, C. S., Yang, S., Chen, W. & Li, Y. P. Signaling networks that control 
the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene 
Expr 19, 1-46 (2009). 
29 Yongwon Choi, R. F., Steven L. Teitelbaum, Hiroshi Takayanagi. in 
Osteoimmunology (Second edition) -Interactions of the Immune and Skeletal 
Systems   (ed Mark Horowitz oseph Lorenzo, Yongwon Choi, Hiroshi Takayanagi 
and Georg Schett ) Ch. 4, 41-70 (2016). 
30 Weilbaecher, K. N. et al. Linkage of M-CSF signaling to Mitf, TFE3, and the 
osteoclast defect in Mitf(mi/mi) mice. Mol Cell 8, 749-758 (2001). 
31 Kikuta, J. & Ishii, M. Osteoclast migration, differentiation and function: novel 
therapeutic targets for rheumatic diseases. Rheumatology (Oxford) 52, 226-234, 
doi:10.1093/rheumatology/kes259 (2013). 
32 Taeko Ishii, J. K., Atsuko Kubo & Masaru Ishii. Control of osteoclast precursor 
migration: A novel point of control for osteoclastogenesis and bone homeostasis. 
BMS BONEKEY 7 (2010). 
33 Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and 
activation. Nature 423, 337, doi:10.1038/nature01658 (2003). 
34 Ikeda, K. & Takeshita, S. The role of osteoclast differentiation and function in 
skeletal homeostasis. J Biochem 159, 1-8, doi:10.1093/jb/mvv112 (2016). 
35 Boyce, B. F. et al. Roles for NF-kappaB and c-Fos in osteoclasts. J Bone Miner 
Metab 23 Suppl, 11-15 (2005). 
36 Novack, D. V. & Teitelbaum, S. L. The osteoclast: friend or foe? Annu Rev 
Pathol 3, 457-484, doi:10.1146/annurev.pathmechdis.3.121806.151431 (2008). 
37 Kim, J. H. & Kim, N. Regulation of NFATc1 in Osteoclast Differentiation. J 
Bone Metab 21, 233-241, doi:10.11005/jbm.2014.21.4.233 (2014). 
 
192 | P a g e  
 
38 Park, J. H., Lee, N. K. & Lee, S. Y. Current Understanding of RANK Signaling in 
Osteoclast Differentiation and Maturation. Mol Cells 40, 706-713, 
doi:10.14348/molcells.2017.0225 (2017). 
39 Arai, A. et al. Fos plays an essential role in the upregulation of RANK expression 
in osteoclast precursors within the bone microenvironment. J Cell Sci 125, 2910-
2917, doi:10.1242/jcs.099986 (2012). 
40 Chiu, Y. H. & Ritchlin, C. T. DC-STAMP: A Key Regulator in Osteoclast 
Differentiation. J Cell Physiol 231, 2402-2407, doi:10.1002/jcp.25389 (2016). 
41 Yagi, M. et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and 
foreign body giant cells. J Exp Med 202, 345-351, doi:10.1084/jem.20050645 
(2005). 
42 Miyamoto, T. The dendritic cell-specific transmembrane protein DC-STAMP is 
essential for osteoclast fusion and osteoclast bone-resorbing activity. Mod 
Rheumatol 16, 341-342, doi:10.1007/s10165-006-0524-0 (2006). 
43 Witwicka, H. et al. Studies of OC-STAMP in Osteoclast Fusion: A New 
Knockout Mouse Model, Rescue of Cell Fusion, and Transmembrane Topology. 
PLoS One 10, e0128275, doi:10.1371/journal.pone.0128275 (2015). 
44 Levaot, N. et al. Osteoclast fusion is initiated by a small subset of RANKL-
stimulated monocyte progenitors, which can fuse to RANKL-unstimulated 
progenitors. Bone 79, 21-28, doi:10.1016/j.bone.2015.05.021 (2015). 
45 Kuroda, Y. & Matsuo, K. Molecular mechanisms of triggering, amplifying and 
targeting RANK signaling in osteoclasts. World J Orthop 3, 167-174, 
doi:10.5312/wjo.v3.i11.167 (2012). 
46 Charles, J. F. et al. The collection of NFATc1-dependent transcripts in the 
osteoclast includes numerous genes non-essential to physiologic bone resorption. 
Bone 51, 902-912, doi:10.1016/j.bone.2012.08.113 (2012). 
47 Takahashi, N., Udagawa, N. & Suda, T. Vitamin D endocrine system and 
osteoclasts. BoneKEy Rep 3, doi:10.1038/bonekey.2013.229 (2014). 
48 Takahashi, N., Ejiri, S., Yanagisawa, S. & Ozawa, H. Regulation of osteoclast 
polarization. Odontology 95, 1-9, doi:10.1007/s10266-007-0071-y (2007). 
49 Georgess, D., Machuca-Gayet, I., Blangy, A. & Jurdic, P. Podosome organization 
drives osteoclast-mediated bone resorption. Cell Adh Migr 8, 191-204 (2014). 
50 Itzstein, C., Coxon, F. P. & Rogers, M. J. The regulation of osteoclast function 
and bone resorption by small GTPases. Small GTPases 2, 117-130, 
doi:10.4161/sgtp.2.3.16453 (2011). 
51 Szewczyk, K. A., Fuller, K. & Chambers, T. J. Distinctive subdomains in the 
resorbing surface of osteoclasts. PLoS One 8, e60285, 
doi:10.1371/journal.pone.0060285 (2013). 
52 Baron, R. Molecular mechanisms of bone resorption. An update. Acta Orthop 
Scand Suppl 266, 66-70 (1995). 
53 Lacombe, J., Karsenty, G. & Ferron, M. Regulation of lysosome biogenesis and 
functions in osteoclasts. Cell Cycle 12, 2744-2752, doi:10.4161/cc.25825 (2013). 
54 Zhao, H. Membrane trafficking in osteoblasts and osteoclasts: new avenues for 
understanding and treating skeletal diseases. Traffic 13, 1307-1314, 
doi:10.1111/j.1600-0854.2012.01395.x (2012). 
 
193 | P a g e  
 
55 Aiken, A. & Khokha, R. Unraveling metalloproteinase function in skeletal 
biology and disease using genetically altered mice. Biochim Biophys Acta 1803, 
121-132, doi:10.1016/j.bbamcr.2009.07.002 (2010). 
56 Little, C. B. et al. Matrix metalloproteinase 13-deficient mice are resistant to 
osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte 
development. Arthritis Rheum 60, 3723-3733, doi:10.1002/art.25002 (2009). 
57 Zhao, H., Laitala-Leinonen, T., Parikka, V. & Vaananen, H. K. Downregulation 
of small GTPase Rab7 impairs osteoclast polarization and bone resorption. J Biol 
Chem 276, 39295-39302, doi:10.1074/jbc.M010999200 (2001). 
58 Pavlos, N. J. et al. Rab3D regulates a novel vesicular trafficking pathway that is 
required for osteoclastic bone resorption. Mol Cell Biol 25, 5253-5269, 
doi:10.1128/MCB.25.12.5253-5269.2005 (2005). 
59 Oikawa, T., Kuroda, Y. & Matsuo, K. Regulation of osteoclasts by membrane-
derived lipid mediators. Cell Mol Life Sci 70, 3341-3353, doi:10.1007/s00018-
012-1238-4 (2013). 
60 Stenbeck, G. & Horton, M. A. Endocytic trafficking in actively resorbing 
osteoclasts. J Cell Sci 117, 827-836, doi:10.1242/jcs.00935 (2004). 
61 Stenbeck, G., Lawrence, K. M. & Albert, A. P. Hormone-stimulated modulation 
of endocytic trafficking in osteoclasts. Front Endocrinol (Lausanne) 3, 103, 
doi:10.3389/fendo.2012.00103 (2012). 
62 Wang, L. et al. Osteoblast-induced osteoclast apoptosis by fas ligand/FAS 
pathway is required for maintenance of bone mass. Cell Death Differ 22, 1654-
1664, doi:10.1038/cdd.2015.14 (2015). 
63 Szymczyk, K. H., Freeman, T. A., Adams, C. S., Srinivas, V. & Steinbeck, M. J. 
Active caspase-3 is required for osteoclast differentiation. J Cell Physiol 209, 
836-844, doi:10.1002/jcp.20770 (2006). 
64 Iwasawa, M. et al. The antiapoptotic protein Bcl-xL negatively regulates the 
bone-resorbing activity of osteoclasts in mice. J Clin Invest 119, 3149-3159, 
doi:10.1172/JCI39819 (2009). 
65 Tanaka, S. et al. Regulation of osteoclast apoptosis by Bcl-2 family protein Bim 
and Caspase-3. Adv Exp Med Biol 658, 111-116, doi:10.1007/978-1-4419-1050-
9_12 (2010). 
66 Akiyama, T. et al. Regulation of osteoclast apoptosis by ubiquitylation of 
proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 22, 6653-6664, 
doi:10.1093/emboj/cdg635 (2003). 
67 Croucher, P. I., McDonald, M. M. & Martin, T. J. Bone metastasis: the 
importance of the neighbourhood. Nat Rev Cancer 16, 373-386, 
doi:10.1038/nrc.2016.44 (2016). 
68 Macedo, F. et al. Bone Metastases: An Overview. Oncol Rev 11, 321, 
doi:10.4081/oncol.2017.321 (2017). 
69 Bienz, M. & Saad, F. Management of bone metastases in prostate cancer: a 
review. Curr Opin Support Palliat Care 9, 261-267, 
doi:10.1097/SPC.0000000000000157 (2015). 
70 Shiozawa, Y. et al. Human prostate cancer metastases target the hematopoietic 
stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121, 
1298-1312, doi:10.1172/JCI43414 (2011). 
 
194 | P a g e  
 
71 Shiozawa, Y., Pienta, K. J. & Taichman, R. S. Hematopoietic stem cell niche is a 
potential therapeutic target for bone metastatic tumors. Clin Cancer Res 17, 5553-
5558, doi:10.1158/1078-0432.CCR-10-2505 (2011). 
72 Sturge, J., Caley, M. P. & Waxman, J. Bone metastasis in prostate cancer: 
emerging therapeutic strategies. Nat Rev Clin Oncol 8, 357-368, 
doi:10.1038/nrclinonc.2011.67 (2011). 
73 Merseburger, A. S. et al. Perspectives on treatment of metastatic castration-
resistant prostate cancer. Oncologist 18, 558-567, 
doi:10.1634/theoncologist.2012-0478 (2013). 
74 Garcia, J. A. Sipuleucel-T in patients with metastatic castration-resistant prostate 
cancer: an insight for oncologists. Ther Adv Med Oncol 3, 101-108, 
doi:10.1177/1758834010397692 (2011). 
75 Israeli, R. S. Managing bone loss and bone metastases in prostate cancer patients: 
a focus on bisphosphonate therapy. Rev Urol 10, 99-110 (2008). 
76 Paller, C. J., Carducci, M. A. & Philips, G. K. Management of bone metastases in 
refractory prostate cancer--role of denosumab. Clin Interv Aging 7, 363-372, 
doi:10.2147/CIA.S27930 (2012). 
77 Manolagas, S. C. Role of cytokines in bone resorption. Bone 17, 63S-67S (1995). 
78 Lu, X. & Kang, Y. Epidermal growth factor signalling and bone metastasis. Br J 
Cancer 102, 457-461, doi:10.1038/sj.bjc.6605490 (2010). 
79 Roberts, E., Cossigny, D. A. & Quan, G. M. The role of vascular endothelial 
growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer 2013, 
418340, doi:10.1155/2013/418340 (2013). 
80 Logothetis, C. J. & Lin, S. H. Osteoblasts in prostate cancer metastasis to bone. 
Nat Rev Cancer 5, 21-28, doi:10.1038/nrc1528 (2005). 
81 Roy, S. et al. Multifaceted Role of Neuropilins in the Immune System: Potential 
Targets for Immunotherapy. Frontiers in Immunology 8, 
doi:10.3389/fimmu.2017.01228 (2017). 
82 Guo, H. F. & Vander Kooi, C. W. Neuropilin Functions as an Essential Cell 
Surface Receptor. J Biol Chem 290, 29120-29126, doi:10.1074/jbc.R115.687327 
(2015). 
83 Hayashi, M. et al. Osteoprotection by semaphorin 3A. Nature 485, 69-74, 
doi:10.1038/nature11000 (2012). 
84 Saad, S. et al. Semaphorin-3a, neuropilin-1 and plexin-A1 in prosthetic-particle 
induced bone loss. Acta Biomater 30, 311-318, doi:10.1016/j.actbio.2015.11.025 
(2016). 
85 Verlinden, L. et al. Nrp2 deficiency leads to trabecular bone loss and is 
accompanied by enhanced osteoclast and reduced osteoblast numbers. Bone 55, 
465-475, doi:10.1016/j.bone.2013.03.023 (2013). 
86 Parker, M. W. et al. Structural basis for VEGF-C binding to neuropilin-2 and 
sequestration by a soluble splice form. Structure 23, 677-687, 
doi:10.1016/j.str.2015.01.018 (2015). 
87 Yasuoka, H. et al. Neuropilin-2 expression in breast cancer: correlation with 
lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. 
BMC Cancer 9, 220, doi:10.1186/1471-2407-9-220 (2009). 
 
195 | P a g e  
 
88 Ji, T. et al. Neuropilin-2 expression is inhibited by secreted Wnt antagonists and 
its down-regulation is associated with reduced tumor growth and metastasis in 
osteosarcoma. Mol Cancer 14, 86, doi:10.1186/s12943-015-0359-4 (2015). 
89 Dutta, S. et al. NRP2 transcriptionally regulates its downstream effector WDFY1. 
Sci Rep 6, 23588, doi:10.1038/srep23588 (2016). 
 
